Covered_Recipient_Type,Teaching_Hospital_ID,Teaching_Hospital_Name,Physician_Profile_ID,Physician_First_Name,Physician_Middle_Name,Physician_Last_Name,Recipient_Primary_Business_Street_Address_Line1,Recipient_Primary_Business_Street_Address_Line2,Recipient_City,Recipient_Zip_Code,Physician_Primary_Type,Physician_Specialty,Submitting_Applicable_Manufacturer_or_Applicable_GPO_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
Covered Recipient Physician,,,55556,CLIFFORD,KENT,BOESE,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503-4619,Medical Doctor,Allopathic & Osteopathic Physicians/ Orthopaedic Surgery,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,800.00,04/01/2014,Cash or cash equivalent,120278745,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,1125.00,12/05/2014,In-kind items and services,120244693,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,1062.50,01/23/2014,In-kind items and services,120244689,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,500.00,02/24/2014,In-kind items and services,120244691,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,625.00,09/16/2014,In-kind items and services,120244699,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,1300.00,09/16/2014,In-kind items and services,120244695,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,1706.25,09/16/2014,In-kind items and services,120244697,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1200.00,05/19/2014,Cash or cash equivalent,131474344,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1100.00,07/03/2014,Cash or cash equivalent,131464522,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1671.61,04/04/2014,Cash or cash equivalent,131464526,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3500.00,01/06/2014,Cash or cash equivalent,131474664,,,ION US COA,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2650.00,01/06/2014,Cash or cash equivalent,131474662,,,ION US COA,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,390.00,12/15/2014,Cash or cash equivalent,131474666,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,11/17/2014,Cash or cash equivalent,131474310,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3000.00,01/03/2014,Cash or cash equivalent,131474368,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2471.61,01/31/2014,Cash or cash equivalent,131464530,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,915.00,09/12/2014,Cash or cash equivalent,131474326,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1185.00,04/21/2014,Cash or cash equivalent,131474348,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,550.00,12/15/2014,Cash or cash equivalent,131464514,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2250.00,01/03/2014,Cash or cash equivalent,131474366,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,330.00,01/03/2014,Cash or cash equivalent,131474370,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,31328.75,07/07/2014,Cash or cash equivalent,131463774,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA  PAS2,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Drive,,Iowa City,52242,,,"Dexcom, Inc.",100000010478,"Dexcom, Inc.",CA,23812.51,05/16/2014,Cash or cash equivalent,153798922,,,Spritz Peds Pre Piv,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Drive,,Iowa City,52242,,,"Dexcom, Inc.",100000010478,"Dexcom, Inc.",CA,58723.58,11/06/2014,Cash or cash equivalent,153798926,,,Spritz Peds Pivotal,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,870.00,02/18/2014,Cash or cash equivalent,131474356,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,550.00,09/12/2014,Cash or cash equivalent,131464518,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,525.00,08/18/2014,Cash or cash equivalent,131464520,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,656.25,01/03/2014,Cash or cash equivalent,131472482,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1095.00,10/03/2014,Cash or cash equivalent,131474324,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,225.00,03/03/2014,Cash or cash equivalent,131464528,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4425.00,11/17/2014,Cash or cash equivalent,131474312,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,585.00,07/03/2014,Cash or cash equivalent,131474338,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,500.00,04/04/2014,Cash or cash equivalent,131472476,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1075.00,06/02/2014,Cash or cash equivalent,131464524,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,360.00,06/16/2014,Cash or cash equivalent,131474660,,,ION US COA,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1625.00,01/31/2014,Cash or cash equivalent,131472480,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2281.25,11/10/2014,Cash or cash equivalent,155697282,Xarelto,,"A  Randomized, Double blind, Event driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,5174.00,11/06/2014,Cash or cash equivalent,155697284,Xarelto,,"A  Randomized, Double blind, Event driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,69031.25,01/30/2014,Cash or cash equivalent,144327574,,,AZ Funnel Study,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,40.56,03/31/2014,In-kind items and services,144343972,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,37310.00,01/22/2014,Cash or cash equivalent,144332108,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,591.76,01/21/2014,Cash or cash equivalent,144334328,,,Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaDLBCL,,
Covered Recipient Teaching Hospital,1629,TRINITY BETTENDORF,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,29740.00,01/22/2014,Cash or cash equivalent,144332034,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,1629,TRINITY BETTENDORF,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,34.03,03/31/2014,In-kind items and services,144343864,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3.41,03/31/2014,In-kind items and services,144343980,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,4110.60,09/23/2014,Cash or cash equivalent,144329016,,,Effect of Vandetanib Therapy on Markers of Proliferation and Apoptosis in Primary Human Breast Cancer,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3408.00,01/22/2014,Cash or cash equivalent,144332124,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2402.86,12/18/2014,Cash or cash equivalent,144338936,BRILINTA,,A Randomised Double Blind Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin ASA in Patients with Acute Ischaemic Stroke or TIA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,171.90,01/09/2014,In-kind items and services,155697294,,,A Long Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy  A Harmonized Protocol Across Sponsors,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,16400.00,10/10/2014,Cash or cash equivalent,155697288,Daratumumab,,"54767414 MMY 3003  Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone  DRd  vs Lenalidomide and Dexamethasone  Rd  in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7404.00,11/26/2014,Cash or cash equivalent,155697292,Daratumumab,,"54767414 MMY 3003  Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone  DRd  vs Lenalidomide and Dexamethasone  Rd  in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2680.00,10/24/2014,Cash or cash equivalent,155697286,Daratumumab,,"54767414 MMY 3003  Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone  DRd  vs Lenalidomide and Dexamethasone  Rd  in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,171.90,01/09/2014,In-kind items and services,155697296,,,A Long Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy  A Harmonized Protocol Across Sponsors,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3801.00,11/13/2014,Cash or cash equivalent,155697290,Daratumumab,,"54767414 MMY 3003  Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone  DRd  vs Lenalidomide and Dexamethasone  Rd  in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1775.00,07/16/2014,Cash or cash equivalent,164071650,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4629.79,12/18/2014,Cash or cash equivalent,164071682,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,01/01/2014,Cash or cash equivalent,164071576,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,03/01/2014,Cash or cash equivalent,164071586,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,973.75,04/15/2014,Cash or cash equivalent,164071598,,,"An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,08/01/2014,Cash or cash equivalent,164071652,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,12/01/2014,Cash or cash equivalent,164071680,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,04/01/2014,Cash or cash equivalent,164071590,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5.40,06/09/2014,Cash or cash equivalent,164071610,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,09/01/2014,Cash or cash equivalent,164071656,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1775.00,11/24/2014,Cash or cash equivalent,164071678,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,35.80,04/09/2014,Cash or cash equivalent,164071594,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5.40,06/09/2014,Cash or cash equivalent,164071612,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,26.85,06/09/2014,Cash or cash equivalent,164071636,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,95.00,09/01/2014,Cash or cash equivalent,164071658,,,"A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,95.00,08/01/2014,Cash or cash equivalent,164071654,,,"A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4935.37,04/04/2014,Cash or cash equivalent,164071592,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,06/09/2014,Cash or cash equivalent,164071624,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,16.20,06/09/2014,Cash or cash equivalent,164071630,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,16.20,06/09/2014,Cash or cash equivalent,164071634,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.01,06/09/2014,Cash or cash equivalent,164071616,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,204.60,02/04/2014,Cash or cash equivalent,164071582,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,07/01/2014,Cash or cash equivalent,164071648,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5.00,10/28/2014,Cash or cash equivalent,164071668,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,02/01/2014,Cash or cash equivalent,164071580,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,26.85,03/04/2014,Cash or cash equivalent,164071588,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.95,06/09/2014,Cash or cash equivalent,164071608,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,16.20,06/09/2014,Cash or cash equivalent,164071632,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,13821.30,06/26/2014,Cash or cash equivalent,164071644,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,12464.11,10/02/2014,Cash or cash equivalent,164071662,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,63150.49,09/25/2014,Cash or cash equivalent,164071660,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,The amount of this record is associated with the value of study drug provided to the site for clinical trial research purposes.
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,16.74,04/24/2014,Cash or cash equivalent,164071600,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,05/01/2014,Cash or cash equivalent,164071602,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5.40,06/09/2014,Cash or cash equivalent,164071614,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,06/09/2014,Cash or cash equivalent,164071620,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,06/09/2014,Cash or cash equivalent,164071622,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,26.85,06/09/2014,Cash or cash equivalent,164071628,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,420.00,02/10/2014,Cash or cash equivalent,164071584,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1706.25,06/23/2014,Cash or cash equivalent,164071642,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,95.00,07/01/2014,Cash or cash equivalent,164071646,,,"A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,50.20,01/08/2014,Cash or cash equivalent,164071578,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1375.00,10/23/2014,Cash or cash equivalent,164071664,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5.00,10/28/2014,Cash or cash equivalent,164071666,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.37,10/28/2014,Cash or cash equivalent,164071670,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,06/01/2014,Cash or cash equivalent,164071604,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.95,06/09/2014,Cash or cash equivalent,164071606,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,06/09/2014,Cash or cash equivalent,164071626,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Shire North American Group Inc,100000061292,Shire North American Group Inc,DE,1500.00,04/30/2014,Cash or cash equivalent,136101688,,,"A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome Mucopolysaccharidosis II",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,690.63,06/17/2014,Cash or cash equivalent,164071638,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,700.00,06/23/2014,Cash or cash equivalent,164071640,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.37,10/28/2014,Cash or cash equivalent,164071672,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,95.00,11/01/2014,Cash or cash equivalent,164071674,,,"A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,11/01/2014,Cash or cash equivalent,164071676,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,973.75,04/15/2014,Cash or cash equivalent,164071596,,,"An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,06/09/2014,Cash or cash equivalent,164071618,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR  2561 JCP PSC,,PEDSLOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,7909.00,04/24/2014,Cash or cash equivalent,138448366,Letairis,,"AMBITION A RANDOMISED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",,GS-US-300-0140
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,400.00,11/18/2014,Cash or cash equivalent,138430227,Ranexa,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF RANOLAZINE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH A HISTORY OF CHRONIC ANGINA WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION WITH INCOMPLETE REVASCULARIZATION",,GS-US-259-0116
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR  2561 JCP PSC,,PEDSLOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,3097.50,01/28/2014,Cash or cash equivalent,138448370,Letairis,,"AMBITION A RANDOMISED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",,GS-US-300-0140
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,583.00,11/20/2014,Cash or cash equivalent,138429948,Ranexa,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF RANOLAZINE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH A HISTORY OF CHRONIC ANGINA WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION WITH INCOMPLETE REVASCULARIZATION",,GS-US-259-0116
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR  2561 JCP PSC,,PEDSLOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,13401.30,02/06/2014,Cash or cash equivalent,138448360,Letairis,,"AMBITION A RANDOMISED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",,GS-US-300-0140
Covered Recipient Physician,,,311760,DONALD,,WENDER,230 NEBRASKA ST,,SIOUX CITY,51101,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Hematology & Oncology,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,525.00,08/27/2014,Cash or cash equivalent,152805308,Injectafer,,VI32204304,,
Covered Recipient Physician,,,311760,DONALD,,WENDER,230 NEBRASKA ST,,SIOUX CITY,51101,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Hematology & Oncology,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,6763.00,04/02/2014,Cash or cash equivalent,152805714,Injectafer,,VI32204301,,
Covered Recipient Physician,,,311760,DONALD,,WENDER,230 NEBRASKA ST,,SIOUX CITY,51101,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Hematology & Oncology,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,1263.00,06/20/2014,Cash or cash equivalent,152805504,Injectafer,,VI32204302,,
Covered Recipient Physician,,,311760,DONALD,,WENDER,230 NEBRASKA ST,,SIOUX CITY,51101,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Hematology & Oncology,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,350.00,07/23/2014,Cash or cash equivalent,152805438,Injectafer,,VI32204303,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR  2561 JCP PSC,,PEDSLOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,2066.75,05/22/2014,Cash or cash equivalent,138448372,Letairis,,"AMBITION A RANDOMISED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",,GS-US-300-0140
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVE,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2212.11,01/07/2014,Cash or cash equivalent,144076992,EFFIENT,,A PROSPECTIVE MULTI CENTER RANDOMIZED DOUBLE BLIND TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF 12 VERSUS 30 MONTHS OF DUAL ANTIPLATELET THERAPY -DAPT- IN SUBJECTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION -PCI-WITH EITHER DRUG ELUTING STENT -DES- OR BARE METAL STENT -BMS- PLACEMENT FOR THE TREATMENT OF CORONARY ARTERY LESIONS,,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1152.87,01/24/2014,Cash or cash equivalent,163590776,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,5100.00,04/28/2014,Cash or cash equivalent,163591088,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1576.50,10/20/2014,Cash or cash equivalent,163590858,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1623.93,10/23/2014,Cash or cash equivalent,163590912,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,9875.00,07/28/2014,Cash or cash equivalent,163591324,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1628.78,10/21/2014,Cash or cash equivalent,163590860,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1683.09,01/21/2014,Cash or cash equivalent,163590908,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,17625.00,04/28/2014,Cash or cash equivalent,163590986,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,8800.00,01/23/2014,Cash or cash equivalent,163591298,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,13825.00,01/23/2014,Cash or cash equivalent,163591344,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,2250.00,11/12/2014,Cash or cash equivalent,163590770,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,8575.00,07/28/2014,Cash or cash equivalent,163591332,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,10164.00,06/03/2014,Cash or cash equivalent,144066464,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,http://clinicaltrials.gov/ct2/show/NCT01602224,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,2200.00,11/12/2014,Cash or cash equivalent,163590740,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,2352.00,05/28/2014,Cash or cash equivalent,138430234,Ranexa,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF RANOLAZINE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH A HISTORY OF CHRONIC ANGINA WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION WITH INCOMPLETE REVASCULARIZATION",,GS-US-259-0116
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR  2561 JCP PSC,,PEDSLOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,3306.25,03/20/2014,Cash or cash equivalent,138448362,Letairis,,"AMBITION A RANDOMISED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",,GS-US-300-0140
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,3050.00,02/18/2014,Cash or cash equivalent,138430222,Ranexa,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF RANOLAZINE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH A HISTORY OF CHRONIC ANGINA WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION WITH INCOMPLETE REVASCULARIZATION",,GS-US-259-0116
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,1712.00,08/21/2014,Cash or cash equivalent,138430230,Ranexa,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF RANOLAZINE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH A HISTORY OF CHRONIC ANGINA WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION WITH INCOMPLETE REVASCULARIZATION",,GS-US-259-0116
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,181.30,04/15/2014,In-kind items and services,144089688,,,A RANDOMIZED OPEN LABEL PHASE 2 STUDY EVALUATING LY2875358 PLUS ERLOTINIB AND LY2875358 MONOTHERAPY IN MET DIAGNOSTIC POSITIVE NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO ERLOTINIB,http://clinicaltrials.gov/ct2/show/NCT01900652,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1748,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,504.27,01/07/2014,Cash or cash equivalent,144083364,,,A PROSPECTIVE MULTI CENTER RANDOMIZED DOUBLE BLIND TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF 12 VERSUS 30 MONTHS OF DUAL ANTIPLATELET THERAPY -DAPT- IN SUBJECTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION -PCI-WITH EITHER DRUG ELUTING STENT -DES- OR BARE METAL STENT -BMS- PLACEMENT FOR THE TREATMENT OF CORONARY ARTERY LESIONS,,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Physician,,,125678,MICHAEL,STEVEN,BROOKS,202 10TH ST SE,,CEDAR RAPIDS,52403,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Rheumatology,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1522.48,10/01/2014,In-kind items and services,144086310,,,A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED 24-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS,https://clinicaltrials.gov/ct2/show/NCT02349295,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,9775.00,01/14/2014,Cash or cash equivalent,144084990,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,http://clinicaltrials.gov/ct2/show/NCT01602224,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,14531.00,06/02/2014,Cash or cash equivalent,144089684,,,A RANDOMIZED OPEN LABEL PHASE 2 STUDY EVALUATING LY2875358 PLUS ERLOTINIB AND LY2875358 MONOTHERAPY IN MET DIAGNOSTIC POSITIVE NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO ERLOTINIB,http://clinicaltrials.gov/ct2/show/NCT01900652,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,248.70,10/28/2014,In-kind items and services,144082454,,,ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY,http://clinicaltrials.gov/ct2/show/NCT02008357,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,540.00,01/01/2014,In-kind items and services,144066696,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,http://clinicaltrials.gov/ct2/show/NCT01602224,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,21019.00,03/18/2014,Cash or cash equivalent,144070691,,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY,http://clinicaltrials.gov/ct2/show/NCT01865084,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,90688.05,01/21/2014,Cash or cash equivalent,144089830,,,A PHASE 2 EFFICACY AND SAFETY DOSE RANGING STUDY OF LY3015014 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,https://clinicaltrials.gov/ct2/show/NCT01890967,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1049.25,01/01/2014,In-kind items and services,144080054,,,A PHASE 2 EFFICACY AND SAFETY DOSE RANGING STUDY OF LY3015014 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,https://clinicaltrials.gov/ct2/show/NCT01890967,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1180.60,02/13/2014,In-kind items and services,144070988,,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY,http://clinicaltrials.gov/ct2/show/NCT01865084,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,15600.00,10/20/2014,Cash or cash equivalent,144081842,,,ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY,http://clinicaltrials.gov/ct2/show/NCT02008357,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Physician,,,538515,SUSAN,K,SCHULTZ,2 MEADE DR,,IOWA CITY,52241,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Psychiatry,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1175.00,01/01/2014,In-kind items and services,144081846,,,ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY,http://clinicaltrials.gov/ct2/show/NCT02008357,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Physician,,,537419,JAMES,R,LAMORGESE,4885 Lakewood Dr,,Cedar Rapids,52411,Medical Doctor,Allopathic & Osteopathic Physicians/ Neurological Surgery,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,10912.50,07/14/2014,Cash or cash equivalent,120685083,,,PRESTIGE,,
Covered Recipient Physician,,,537419,JAMES,R,LAMORGESE,4885 Lakewood Dr,,Cedar Rapids,52411,Medical Doctor,Allopathic & Osteopathic Physicians/ Neurological Surgery,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,4612.50,09/30/2014,Cash or cash equivalent,120684701,,,PRESTIGE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,14375.00,11/24/2014,Cash or cash equivalent,120685247,,,Investigator Sponsored Research,,
Covered Recipient Physician,,,537419,JAMES,R,LAMORGESE,4885 Lakewood Dr,,Cedar Rapids,52411,Medical Doctor,Allopathic & Osteopathic Physicians/ Neurological Surgery,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,8460.00,06/16/2014,Cash or cash equivalent,120684985,,,PRESTIGE,,
Covered Recipient Physician,,,537419,JAMES,R,LAMORGESE,4885 Lakewood Dr,,Cedar Rapids,52411,Medical Doctor,Allopathic & Osteopathic Physicians/ Neurological Surgery,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,4837.50,01/15/2014,Cash or cash equivalent,120684715,,,P04 12 Prestige LP 2,,
Covered Recipient Physician,,,537419,JAMES,R,LAMORGESE,4885 Lakewood Dr,,Cedar Rapids,52411,Medical Doctor,Allopathic & Osteopathic Physicians/ Neurological Surgery,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,225.00,09/24/2014,Cash or cash equivalent,120682557,,,PRESTIGE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,900.00,03/04/2014,Cash or cash equivalent,144067354,HUMATROPE,,THE GENETICS AND NEUROENDOCRINOLOGY OF SHORT STATURE INTERNATIONAL STUDY -GENESIS,http://clinicaltrials.gov/ct2/show/NCT01088412,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1629,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE RD,,BETTENDORF,52722,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,800.00,03/03/2014,Cash or cash equivalent,144061846,EFFIENT,,THE TRANSLATE ACS STUDY - TREATMENT WITH ADP RECEPTOR INHIBITORS -  LONGITUDINAL ASSESSMENT OF TREATMENT PATTERNS AND EVENTS AFTER ACUTE CORONARY SYNDROME,http://clinicaltrials.gov/ct2/show/NCT01088503,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1000.00,03/26/2014,Cash or cash equivalent,120605067,,,Resolute US,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1430.00,07/16/2014,Cash or cash equivalent,120606269,,,ENDURANT,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1550.00,02/24/2014,Cash or cash equivalent,120598229,,,ECG Feedback for CRT,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1540.00,02/20/2014,Cash or cash equivalent,120606605,,,ENDURANT,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1500.00,02/24/2014,Cash or cash equivalent,120598227,,,ECG Feedback for CRT,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1210.00,10/09/2014,Cash or cash equivalent,120605727,,,ENDURANT,,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,310.00,03/25/2014,In-kind items and services,130054035,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,1758,COVENANT MEDICAL CENTER,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,40.00,01/23/2014,In-kind items and services,130054079,Neulasta,,Bone Pain Management US NOLAN study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1718.75,04/28/2014,Cash or cash equivalent,130055735,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,36894.80,06/12/2014,Cash or cash equivalent,175617568,,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1532.88,08/06/2014,Cash or cash equivalent,175617550,,,Alisertib MLN8237 or Investigators Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,214.80,02/03/2014,Cash or cash equivalent,175617532,,,Alisertib MLN8237 or Investigators Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,28702.67,01/14/2014,In-kind items and services,130055533,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,12864.00,03/06/2014,In-kind items and services,130054959,Aranesp,,NSCLC,,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8844.90,03/24/2014,Cash or cash equivalent,130054033,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,30494.59,02/07/2014,Cash or cash equivalent,130055523,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,16883.92,10/06/2014,In-kind items and services,130055531,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6858.57,07/14/2014,In-kind items and services,130055525,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,639.58,07/28/2014,In-kind items and services,130054145,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1401.00,04/08/2014,Cash or cash equivalent,130054957,Aranesp,,NSCLC,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,22873.20,04/16/2014,Cash or cash equivalent,130055737,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35853.12,07/17/2014,In-kind items and services,130055741,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35853.12,04/24/2014,In-kind items and services,130055743,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,299.58,06/25/2014,In-kind items and services,130055817,Nplate,,Pediatric Long Term Treatment Study,,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,320.46,01/31/2014,In-kind items and services,130054031,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8336.96,07/14/2014,In-kind items and services,130055521,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,654.71,05/27/2014,In-kind items and services,130055529,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,89.82,01/28/2014,In-kind items and services,130055527,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,725.88,09/01/2014,In-kind items and services,130054149,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6250.00,09/11/2014,Cash or cash equivalent,130054151,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,305.47,01/28/2014,In-kind items and services,130055739,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,1758,COVENANT MEDICAL CENTER,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6612.00,01/09/2014,Cash or cash equivalent,130054081,Neulasta,,Bone Pain Management US NOLAN study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1190.74,10/15/2014,In-kind items and services,130054147,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,67.00,07/01/2014,Cash or cash equivalent,185970204,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,121719.50,10/10/2014,Cash or cash equivalent,185970224,,,PDPA The University of Iowa,,Preferred Development Partner Agreement including   - Staffing  - Clinical Studies  - Basic Research  - Clinical Documentation Projects  - Training & Education Programs
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,12000.00,12/24/2014,Cash or cash equivalent,185970264,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,2975.00,12/20/2014,Cash or cash equivalent,185970266,,,YA-OSS-0003,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,2400.00,12/17/2014,Cash or cash equivalent,185970268,,,YA-SHO-0001,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,5000.00,11/23/2014,Cash or cash equivalent,185970228,,,D-2012-036,,
Covered Recipient Teaching Hospital,1753,Iowa Methodist Medical Center,,,,,1415 WOODLAND AVE STE 218,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3242.50,07/30/2014,Cash or cash equivalent,164131876,,,ADVANCE CRT REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,1964.00,02/20/2014,Cash or cash equivalent,185970152,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,4669.00,06/03/2014,Cash or cash equivalent,185970188,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,60071.00,06/27/2014,Cash or cash equivalent,185970194,,,D-2013-051,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,8708.00,10/30/2014,Cash or cash equivalent,185970226,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,10488.00,11/07/2014,Cash or cash equivalent,185970236,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,35033.00,12/17/2014,Cash or cash equivalent,185970262,,,PDPA The University of Iowa,,Preferred Development Partner Agreement including   - Staffing  - Clinical Studies  - Basic Research  - Clinical Documentation Projects  - Training & Education Programs
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,2108.00,01/10/2014,Cash or cash equivalent,185970148,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,1312.00,06/17/2014,Cash or cash equivalent,185970190,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,6105.00,08/07/2014,Cash or cash equivalent,185970214,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,1751.00,01/07/2014,Cash or cash equivalent,185970146,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,2075.00,03/03/2014,Cash or cash equivalent,185970158,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,12000.00,06/23/2014,Cash or cash equivalent,185970178,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,460.00,10/26/2014,Cash or cash equivalent,185970220,,,D-2009-043,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,138339.50,01/31/2014,Cash or cash equivalent,185970126,,,PDPA The University of Iowa,,Preferred Development Partner Agreement including   - Staffing  - Clinical Studies  - Basic Research  - Clinical Documentation Projects  - Training & Education Programs
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,3755.00,01/02/2014,Cash or cash equivalent,185970144,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,13599.00,02/07/2014,Cash or cash equivalent,185970150,,,D-2009-051,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,402.00,09/30/2014,Cash or cash equivalent,185970218,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,800.00,06/23/2014,Cash or cash equivalent,185970180,,,YA-SHO-0001,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,1964.00,04/30/2014,Cash or cash equivalent,185970164,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,3675.00,06/23/2014,Cash or cash equivalent,185970182,,,YA-OSS-0003,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,4306.00,04/17/2014,Cash or cash equivalent,185970162,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,67.00,06/18/2014,Cash or cash equivalent,185970192,,,D-2012-036,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1905.94,02/24/2014,In-kind items and services,175617566,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,286.40,02/03/2014,In-kind items and services,175617534,,,Alisertib MLN8237 or Investigators Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,578.98,07/23/2014,Cash or cash equivalent,175617562,,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,299.62,02/14/2014,In-kind items and services,175617526,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,3115.00,10/24/2014,Cash or cash equivalent,175617528,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,3500.00,11/12/2014,Cash or cash equivalent,179150051,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1753,Iowa Methodist Medical Center,,,,,1415 WOODLAND AVE STE 218,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,643.50,03/05/2014,Cash or cash equivalent,164131868,,,CARE NON RESPONDER,,
Covered Recipient Teaching Hospital,1753,Iowa Methodist Medical Center,,,,,1415 WOODLAND AVE STE 218,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2025.00,11/12/2014,Cash or cash equivalent,164131884,,,ADVANCE CRT REGISTRY,,
Covered Recipient Teaching Hospital,1751,Mercy Medical Center-Des Moines,,,,,1111 6TH AVE,,DES MOINES,50314,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,1300.00,02/19/2014,Cash or cash equivalent,164126784,,,QUICKFLEX 1258T PAS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,12/30/2014,Cash or cash equivalent,179150400,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,12/30/2014,Cash or cash equivalent,179150390,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,12/30/2014,Cash or cash equivalent,179150394,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,12/30/2014,Cash or cash equivalent,179150404,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,12/30/2014,Cash or cash equivalent,179150071,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,12/30/2014,Cash or cash equivalent,179150247,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,12/30/2014,Cash or cash equivalent,179150214,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,12/30/2014,Cash or cash equivalent,179150064,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,12/30/2014,Cash or cash equivalent,179150254,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,500.00,12/30/2014,Cash or cash equivalent,179150232,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,12/30/2014,Cash or cash equivalent,179150220,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,12/30/2014,Cash or cash equivalent,179150226,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,500.00,12/30/2014,Cash or cash equivalent,179150240,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,1998.75,09/12/2014,Cash or cash equivalent,191537974,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,75.00,07/18/2014,Cash or cash equivalent,191537984,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,6071.25,08/06/2014,Cash or cash equivalent,191537980,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,2073.75,05/19/2014,Cash or cash equivalent,191537996,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,21332.19,06/20/2014,Cash or cash equivalent,191538000,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,5205.28,10/10/2014,Cash or cash equivalent,191537970,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,400.00,07/25/2014,Cash or cash equivalent,191537990,,,BBIOCRCT002 MarrowStim PAD Kit for Treatment of CLI in Subjects with Severe PAD,,
Covered Recipient Physician,,,304617,KENNETH,,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians/ Pain Medicine/ Pain Medicine,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,668.70,02/28/2014,Cash or cash equivalent,178507540,,,HYD3003,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,200.00,08/26/2014,Cash or cash equivalent,179277013,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma",,
Covered Recipient Physician,,,304617,KENNETH,,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians/ Pain Medicine/ Pain Medicine,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,1242.01,02/28/2014,Cash or cash equivalent,178507538,,,HYD3003,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1000.00,06/05/2014,Cash or cash equivalent,179429018,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,12/30/2014,Cash or cash equivalent,179150056,Belviq,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ Lorcaserin HCl on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,6199.18,01/15/2014,Cash or cash equivalent,174382726,ZOMETA,,A PROSPECTIVE RANDOMIZED DOUBLE BLIND MULTI CENTER COMPARATIVE 3 ARM TRIAL EFFICACY AND SAFETY OF ZOLEDRONIC ACID 4MG MONTHLY VS 3 MONTHLY VS PLACEBO AFTER UP TO 12 MONTHS OF TREATMENT WITH ZOLEDRONIC ACID IN PATIENTS WITH BONE LESIONS FROM MULTIPLE MYELOMA OR BREAST CANCER,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,8500.00,12/19/2014,Cash or cash equivalent,174378362,XOLAIR,,LONG TERM NATURAL HISTORY OF PATIENTS WITH SEVERE OR DIFFICULT TO TREAT ASTHMA FROM THE TENOR OBSERVATIONAL STUDY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,321943.48,04/17/2014,Cash or cash equivalent,174350289,TASIGNA,,A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,20805.00,02/14/2014,Cash or cash equivalent,174366220,TASIGNA,,PHASE II STUDY OF MMR RATES FOLLOWING NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR FOUR AND A HALF FOR 1 VERSUS 2 YEARS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,1016.50,06/05/2014,Cash or cash equivalent,182060456,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,1235.00,12/24/2014,Cash or cash equivalent,182060476,TUDORZA,,"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,2660.00,01/29/2014,Cash or cash equivalent,182060462,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,1526.22,07/28/2014,In-kind items and services,182060460,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,21000.00,08/29/2014,Cash or cash equivalent,182060466,LINZESS,,"AN OPEN-LABEL, MULTIPLE-DOSE, MILK-ONLY LACTATIONSTUDY IN LACTATING WOMEN RECEIVING LINACLOTIDE THERAPEUTICALLY",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,1106.50,04/10/2014,In-kind items and services,182060474,TUDORZA,,"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,5320.00,10/29/2014,Cash or cash equivalent,182060478,TUDORZA,,"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,73250.68,06/06/2014,Cash or cash equivalent,174355458,TOBI PODHALER,,A 24 WEEK OPEN LABEL PARALLEL GROUP INTERVENTIONAL PHASE IV STUDY COMPARING TOBRAMYCIN INHALATION POWDER TIP ADMINISTERED ONCE DAILY CONTINUOUSLY VERSUS TIP ADMINISTERED BID IN 28 DAY ON AND OR 28 DAY OFF CYCLES FOR THE TREATMENT OF PULMONARY PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,1425.00,08/06/2014,Cash or cash equivalent,182060458,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,5365.37,01/27/2014,In-kind items and services,182060464,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,7131.50,11/20/2014,Cash or cash equivalent,195455608,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,420.00,03/26/2014,Cash or cash equivalent,195455580,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,2225.00,04/30/2014,Cash or cash equivalent,195455584,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,1365.00,06/19/2014,Cash or cash equivalent,195455586,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,19002.50,08/12/2014,Cash or cash equivalent,195455600,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,0.00,10/26/2014,Cash or cash equivalent,187138802,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,325.00,12/30/2014,Cash or cash equivalent,187138786,,,,,
Covered Recipient Physician,,,451716,DANIEL,,DIEKEMA,200 HAWKINS DR,C60664,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Infectious Disease,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,1555.63,01/15/2014,In-kind items and services,173819882,Mycamine,,Prospective Antifungal Therapy PATH Registry,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,655.00,12/30/2014,Cash or cash equivalent,187138790,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,60.00,07/22/2014,Cash or cash equivalent,187138806,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1350.00,08/08/2014,Cash or cash equivalent,187138828,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,0.00,11/25/2014,Cash or cash equivalent,187138784,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,1887.00,01/16/2014,Cash or cash equivalent,173818061,Vesicare,,A Randomized Double Blind Parallel Placebo Controlled Phase 4 Multicenter Study to Assess Efficacy and Safety of VESIcare Solifenacin Succinate to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,09/19/2014,Cash or cash equivalent,187138794,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,10/26/2014,Cash or cash equivalent,187138800,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,75.00,07/22/2014,Cash or cash equivalent,187138808,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,405.00,08/08/2014,Cash or cash equivalent,187138812,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,975.00,07/22/2014,Cash or cash equivalent,187138820,,,H030014 Phase III Primary Prevention,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,LIMITED TO OFFICIAL STATE DUTIES ONLY,UNIV.OF IA. SW34  GENERAL HOSP,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Infectious Disease,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,450.30,10/21/2014,In-kind items and services,182050620,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,0.00,12/30/2014,Cash or cash equivalent,187138792,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,3000.00,08/09/2014,Cash or cash equivalent,187138834,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,50.00,07/22/2014,Cash or cash equivalent,187138804,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1125.00,08/08/2014,Cash or cash equivalent,187138824,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1350.00,07/22/2014,Cash or cash equivalent,187138830,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,12/30/2014,Cash or cash equivalent,187138788,,,,,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians/ Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,2015.33,09/24/2014,In-kind items and services,182047028,,,Fluzone,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,0.00,09/19/2014,Cash or cash equivalent,187138796,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,200.00,08/12/2014,Cash or cash equivalent,187138810,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,07/22/2014,Cash or cash equivalent,187138818,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,450.00,11/25/2014,Cash or cash equivalent,187138782,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1000.00,08/12/2014,Cash or cash equivalent,187138822,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,10/26/2014,Cash or cash equivalent,187138798,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,08/08/2014,Cash or cash equivalent,187138814,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,07/22/2014,Cash or cash equivalent,187138816,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1125.00,07/22/2014,Cash or cash equivalent,187138826,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1625.00,07/22/2014,Cash or cash equivalent,187138832,,,H030014 Phase III Primary Prevention,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,ATN  GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1350.00,11/25/2014,Cash or cash equivalent,187138778,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,460.00,07/30/2014,Cash or cash equivalent,195455590,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,460.00,09/24/2014,Cash or cash equivalent,195455592,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,460.00,12/17/2014,Cash or cash equivalent,195455596,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,420.00,01/22/2014,Cash or cash equivalent,195455582,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,2400.19,08/07/2014,Cash or cash equivalent,195455598,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,2100.00,11/12/2014,Cash or cash equivalent,195455574,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,460.00,07/02/2014,Cash or cash equivalent,195455588,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,460.00,12/17/2014,Cash or cash equivalent,195455594,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,9073.75,10/07/2014,Cash or cash equivalent,195455604,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,12874.31,08/19/2014,Cash or cash equivalent,195455602,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,02115,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,350.00,07/02/2014,Cash or cash equivalent,195455576,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,02115,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,13075.00,03/05/2014,Cash or cash equivalent,195455578,COMETRIQ,,"A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib -XL184- Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,8750.75,10/30/2014,Cash or cash equivalent,195455606,COMETRIQ,,"A Phase 3, Randomized, Controlled Study of Cabozantinib -XL184- vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy",,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians/ Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,100.00,03/11/2014,Cash or cash equivalent,182054310,,,Safety and Immunogenicity Among Adults of Fluzone Quadrivalent  Fluzone Intradermal  and Fluzone High-Dose Influenza Virus Vaccines  2014 2015 Formulations,,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians/ Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,690.76,09/24/2014,In-kind items and services,182047026,,,Fluzone,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,LIMITED TO OFFICIAL STATE DUTIES ONLY,UNIV.OF IA. SW34  GENERAL HOSP,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Infectious Disease,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,702.34,01/27/2014,In-kind items and services,182044596,,,H030014 Phase III Primary Prevention Study Cdiff,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,165.86,09/29/2014,In-kind items and services,187863368,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,UNIVERSITY OF IOWA,GRANT ACCOUNTING B5 JESSUP HALL,IOWA CITY	,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1320.00,09/22/2014,Cash or cash equivalent,187863382,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR 100 CMAB,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2707.00,08/05/2014,Cash or cash equivalent,187863396,,,Eliglustat ENCORE GZGD02607,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR 100 CMAB,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,54975.75,06/19/2014,Cash or cash equivalent,187863410,,,A PHASE 3  RANDOMIZED  MULTI-CENTER  MULTI-NATIONAL  OPEN-LABEL  ACTIVE COMPARATOR STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GENZ-112638 IN PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO HAVE REACHED THE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.91,09/29/2014,In-kind items and services,187863350,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,UNIVERSITY OF IOWA,GRANT ACCOUNTING B5 JESSUP HALL,IOWA CITY	,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,522.00,06/30/2014,Cash or cash equivalent,187863372,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1500.00,09/24/2014,Cash or cash equivalent,187863386,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5000.00,11/24/2014,Cash or cash equivalent,187863408,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8150.00,01/07/2014,Cash or cash equivalent,188271376,,,Eff-IV-NSTEMI with PCI,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12974.00,07/24/2014,In-kind items and services,187862584,,,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.07,09/29/2014,In-kind items and services,187863357,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11498.58,06/25/2014,In-kind items and services,187863416,,,Epidemiology of Diabetes Interventions and Complications,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2603.60,02/25/2014,In-kind items and services,187862574,CLOLAR,,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,81.38,09/10/2014,In-kind items and services,187863361,,,Open-Label Extension Study of EFC12492  R727-CL-1112  EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,UNIVERSITY OF IOWA,GRANT ACCOUNTING B5 JESSUP HALL,IOWA CITY	,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1320.00,04/09/2014,Cash or cash equivalent,187863376,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3500.00,03/06/2014,Cash or cash equivalent,187862580,CLOLAR,,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4500.00,04/22/2014,Cash or cash equivalent,187863406,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2700.00,10/20/2014,Cash or cash equivalent,187863390,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2900.00,12/18/2014,Cash or cash equivalent,187863400,,,Open-Label Extension Study of EFC12492  R727-CL-1112  EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,01/07/2014,Cash or cash equivalent,188271374,,,Eff-IV-NSTEMI with PCI,,
Covered Recipient Physician,,,1163055,Thomas,,Carter,201 Hawkins Drive,,Iowa City,52240,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Hematology & Oncology,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1333.00,01/17/2014,Cash or cash equivalent,192133094,,,,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1917.00,02/11/2014,Cash or cash equivalent,188230148,,,CAMMS Extension study3,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,1000.00,01/16/2014,Cash or cash equivalent,189082686,,,"A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727 SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins",,"This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study of alirocumab REGN727 SAR236553 in patients with primary hypercholesterolemia and moderate, high, or very high CV risk, who are intolerant to statins."
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,4790.25,06/16/2014,Cash or cash equivalent,189093162,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia",,The purpose of this study is to assess the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,6945.75,09/23/2014,Cash or cash equivalent,189093164,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia",,The purpose of this study is to assess the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,2500.00,07/02/2014,Cash or cash equivalent,189093166,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia",,The purpose of this study is to assess the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,1000.00,07/02/2014,Cash or cash equivalent,189093168,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia",,The purpose of this study is to assess the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,698.94,10/25/2014,In-kind items and services,187573386,,,DS5565 Fibromyalgia Alday Program,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,44.00,12/18/2014,In-kind items and services,187572716,,,DS5565 Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,381.94,12/18/2014,In-kind items and services,187572714,,,DS5565 Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,102.69,12/18/2014,In-kind items and services,187572636,,,DS5565 Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,629.56,12/18/2014,In-kind items and services,187572712,,,DS5565 Fibromyalgia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,6620.63,07/09/2014,Cash or cash equivalent,189093170,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia",,The purpose of this study is to assess the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia
Covered Recipient Teaching Hospital,1750,MERCY HOSPITAL IOWA CITY,,,,,500 E MARKET ST,,IOWA CITY,52245,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,4000.00,05/01/2014,Cash or cash equivalent,192365706,,,ORTHOGHK3 SOW4 Arcos Revision Stem,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Reliance Medical Products, Inc.",100000000321,"Reliance Medical Products, Inc.",OH,7053.00,08/21/2014,Cash or cash equivalent,196809590,,,Muscle Activity and Posture During Clinical Ophthalmologic Practice,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Haag-Streit USA, Inc.",100000010377,"Haag-Streit USA, Inc.",OH,7053.00,08/21/2014,Cash or cash equivalent,196811202,,,Muscle Activity and Posture During Clinical Ophthalmologic Practice,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,07/14/2014,Cash or cash equivalent,163701422,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,256.86,04/23/2014,Cash or cash equivalent,163695012,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,176.86,05/21/2014,Cash or cash equivalent,163696730,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,06/05/2014,Cash or cash equivalent,163697385,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/23/2014,Cash or cash equivalent,163700502,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,08/20/2014,Cash or cash equivalent,163703686,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,170.00,08/11/2014,Cash or cash equivalent,163704602,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,09/25/2014,Cash or cash equivalent,163707702,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,06/26/2014,Cash or cash equivalent,163699794,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,12/02/2014,Cash or cash equivalent,163705540,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3474.40,01/24/2014,Cash or cash equivalent,163803302,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2712.50,10/10/2014,Cash or cash equivalent,163803340,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,10188.00,11/11/2014,Cash or cash equivalent,163708158,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,180.00,04/21/2014,Cash or cash equivalent,163694034,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,09/03/2014,Cash or cash equivalent,163702418,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/04/2014,Cash or cash equivalent,163704112,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/21/2014,Cash or cash equivalent,163704184,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,110.00,04/25/2014,Cash or cash equivalent,163695762,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,03/24/2014,Cash or cash equivalent,163694862,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/16/2014,Cash or cash equivalent,163710372,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,196.86,06/19/2014,Cash or cash equivalent,163699614,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,32.32,11/24/2014,Cash or cash equivalent,163706840,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,05/30/2014,Cash or cash equivalent,163698476,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,7.90,01/20/2014,Cash or cash equivalent,163802894,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,06/02/2014,Cash or cash equivalent,163698706,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,86.16,10/24/2014,Cash or cash equivalent,163706998,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1776.00,07/10/2014,Cash or cash equivalent,163803330,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,04/28/2014,Cash or cash equivalent,163694046,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,04/02/2014,Cash or cash equivalent,163693140,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,130.00,05/01/2014,Cash or cash equivalent,163698128,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,925.34,03/03/2014,Cash or cash equivalent,163691592,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,04/08/2014,Cash or cash equivalent,163693386,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3664.94,04/07/2014,Cash or cash equivalent,163803326,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,9.90,04/15/2014,Cash or cash equivalent,163803328,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,70.00,08/28/2014,Cash or cash equivalent,163703944,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,146.86,07/08/2014,Cash or cash equivalent,163700026,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,303.72,05/13/2014,Cash or cash equivalent,163696118,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,05/02/2014,Cash or cash equivalent,163698710,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,04/10/2014,Cash or cash equivalent,163695513,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,202.80,05/12/2014,Cash or cash equivalent,163697786,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,03/18/2014,Cash or cash equivalent,163692234,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,120.00,12/08/2014,Cash or cash equivalent,163710028,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,07/01/2014,Cash or cash equivalent,163701150,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.08,08/07/2014,Cash or cash equivalent,163725024,Victoza,,NN2211-3659,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/29/2014,Cash or cash equivalent,163710998,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/22/2014,Cash or cash equivalent,163709081,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4778.85,12/23/2014,Cash or cash equivalent,163709110,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,34154.40,08/18/2014,Cash or cash equivalent,163702896,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3510.79,09/23/2014,Cash or cash equivalent,163707070,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,07/10/2014,Cash or cash equivalent,163701040,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,800.00,08/18/2014,Cash or cash equivalent,131474332,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2500.00,03/03/2014,Cash or cash equivalent,131474352,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Physician,,,163314,TYSON,KING,COBB,3385 DEXTER CT STE 300,,DAVENPORT,52807,Medical Doctor,Allopathic & Osteopathic Physicians/ Orthopaedic Surgery/ Hand Surgery,Integra LifeSciences Corporation,100000010950,Integra LifeSciences Corporation,NJ,10000.00,02/03/2014,Cash or cash equivalent,201924442,,,"A multi-center, randomized, prospective study with endoscopic cubital tunnel release",,"Retrospective, long-term follow up to assess resolution of symptoms, satisfaction, recurrence rates, complication rate, return to work"
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3000.00,03/03/2014,Cash or cash equivalent,131474354,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2355.00,02/18/2014,Cash or cash equivalent,131474358,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3000.00,09/02/2014,Cash or cash equivalent,131474330,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,07/17/2014,Cash or cash equivalent,163699520,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/25/2014,Cash or cash equivalent,163705100,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,07/03/2014,Cash or cash equivalent,131474340,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,527.44,06/17/2014,Cash or cash equivalent,163701317,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,06/12/2014,Cash or cash equivalent,163699142,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,9235.00,11/17/2014,Cash or cash equivalent,131474314,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,09/10/2014,Cash or cash equivalent,163704898,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,5636.00,10/20/2014,Cash or cash equivalent,131474318,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4813.00,07/03/2014,Cash or cash equivalent,131474342,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,70.00,05/16/2014,Cash or cash equivalent,163697674,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,06/18/2014,Cash or cash equivalent,163701700,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,08/19/2014,Cash or cash equivalent,163703484,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,140.00,12/15/2014,Cash or cash equivalent,131474672,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,09/02/2014,Cash or cash equivalent,131474328,,,CAP2   PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Physician,,,163314,TYSON,KING,COBB,3385 DEXTER CT STE 300,,DAVENPORT,52807,Medical Doctor,Allopathic & Osteopathic Physicians/ Orthopaedic Surgery/ Hand Surgery,Integra LifeSciences Corporation,100000010950,Integra LifeSciences Corporation,NJ,23250.00,05/14/2014,Cash or cash equivalent,201924458,,,Multi-Center prospective study with Endoscopic Cubital Tunnel Release,,Multi-Center prospective study with Endoscopic Cubital Tunnel Release
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3.30,05/20/2014,Cash or cash equivalent,163698632,Victoza,,NN9211-3919,,
Covered Recipient Physician,,,33805,Bruce,,Gantz,200 HAWKINS DR,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Otolaryngology,Cochlear Ltd,100000005734,Cochlear Americas,CO,174.85,02/22/2014,Cash or cash equivalent,174047960,,,Nucleus Hybrid L24 Implant System New Enrollment Post Approval Study,,Travel related to Investigator Meeting
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1000.00,01/10/2014,Cash or cash equivalent,174047402,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System- IDE Supplement Investigation of Nucleus 6 Sound Processor Signal Processing Algorithms,,IRB related expense
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1002.50,05/20/2014,Cash or cash equivalent,174047412,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System- IDE Supplement Investigation of Nucleus 6 Sound Processor Signal Processing Algorithms,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1438.00,03/19/2014,Cash or cash equivalent,174047404,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1365.00,08/21/2014,Cash or cash equivalent,174047420,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System,,IRB related expense
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,05/29/2014,Cash or cash equivalent,198253288,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,12/12/2014,Cash or cash equivalent,198253304,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1365.00,06/03/2014,Cash or cash equivalent,174047428,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System,,IRB related expense
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,275.00,07/07/2014,Cash or cash equivalent,174047416,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,3906.00,03/12/2014,In-kind items and services,174048204,,,Feasibility test of surgery and tethering system,,In kind research support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1365.00,09/25/2014,Cash or cash equivalent,174047424,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,IRB related expense
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,673.00,09/05/2014,Cash or cash equivalent,174047422,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,2640.00,05/19/2014,Cash or cash equivalent,174047410,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,147.00,06/16/2014,Cash or cash equivalent,174047414,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,Study support
Covered Recipient Physician,,,33805,Bruce,,Gantz,200 HAWKINS DR,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Otolaryngology,Cochlear Ltd,100000005734,Cochlear Americas,CO,89.04,02/22/2014,Cash or cash equivalent,174048000,,,Nucleus Hybrid L24 Implant System New Enrollment Post Approval Study,,Food expense associated with business interaction
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,275.00,07/24/2014,Cash or cash equivalent,174047418,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System,,Study support
Covered Recipient Physician,,,33805,Bruce,,Gantz,200 HAWKINS DR,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Otolaryngology,Cochlear Ltd,100000005734,Cochlear Americas,CO,268.96,02/22/2014,Cash or cash equivalent,174047958,,,Nucleus Hybrid L24 Implant System New Enrollment Post Approval Study,,Travel related to Investigator Meeting
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,428.75,10/27/2014,Cash or cash equivalent,174047426,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System- IDE Supplement Investigation of Nucleus 6 Sound Processor Signal Processing Algorithms,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1473.00,05/07/2014,Cash or cash equivalent,174047408,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,339.00,01/27/2014,In-kind items and services,174047430,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System- IDE Supplement Investigation of Nucleus 6 Sound Processor Signal Processing Algorithms,,In kind research support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1259.00,04/09/2014,Cash or cash equivalent,174047406,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System- IDE Supplement Investigation of Nucleus 6 Sound Processor Signal Processing Algorithms,,Study support
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,110.00,05/08/2014,Cash or cash equivalent,163697240,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4813.00,03/27/2014,Cash or cash equivalent,163690924,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,70.00,04/09/2014,Cash or cash equivalent,163693974,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,09/29/2014,Cash or cash equivalent,163705360,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2500.00,06/11/2014,Cash or cash equivalent,163701620,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,06/04/2014,Cash or cash equivalent,163701844,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,236.86,05/14/2014,Cash or cash equivalent,163697084,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1000.00,04/07/2014,Cash or cash equivalent,163695270,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,266.86,05/22/2014,Cash or cash equivalent,163696908,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,07/11/2014,Cash or cash equivalent,163700234,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,08/21/2014,Cash or cash equivalent,163703882,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,206.86,05/15/2014,Cash or cash equivalent,163697468,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,04/04/2014,Cash or cash equivalent,163695102,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3375.00,03/27/2014,Cash or cash equivalent,163693116,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,110.00,04/14/2014,Cash or cash equivalent,163694752,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,202.04,04/29/2014,Cash or cash equivalent,163694090,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,431.25,11/19/2014,Cash or cash equivalent,163803300,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3479.20,11/25/2014,Cash or cash equivalent,163803348,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1706.25,10/29/2014,Cash or cash equivalent,163803346,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,12/10/2014,Cash or cash equivalent,163708424,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,06/11/2014,Cash or cash equivalent,163700338,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,176.86,06/06/2014,Cash or cash equivalent,163702028,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,501.60,07/24/2014,Cash or cash equivalent,163703806,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,130.00,05/29/2014,Cash or cash equivalent,163698109,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,39.95,10/28/2014,Cash or cash equivalent,163803298,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/18/2014,Cash or cash equivalent,163710402,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,39.03,05/27/2014,Cash or cash equivalent,163696340,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,6.96,11/04/2014,Cash or cash equivalent,163707802,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/26/2014,Cash or cash equivalent,163707872,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/09/2014,Cash or cash equivalent,163707880,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,07/03/2014,Cash or cash equivalent,163702124,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,413.00,10/06/2014,Cash or cash equivalent,163706366,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/30/2014,Cash or cash equivalent,163711348,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,04/11/2014,Cash or cash equivalent,163693556,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4569.80,06/04/2014,Cash or cash equivalent,163696772,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,216.86,05/09/2014,Cash or cash equivalent,163697592,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,384.60,11/10/2014,Cash or cash equivalent,163708370,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,75.00,12/23/2014,Cash or cash equivalent,163710604,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,05/07/2014,Cash or cash equivalent,163696862,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,05/28/2014,Cash or cash equivalent,163697710,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,04/30/2014,Cash or cash equivalent,163697782,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3245.60,07/18/2014,Cash or cash equivalent,163724982,Victoza,,NN2211-3659,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,6273.30,04/22/2014,Cash or cash equivalent,163693266,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,08/12/2014,Cash or cash equivalent,163702318,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,06/03/2014,Cash or cash equivalent,163699056,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,120.00,09/15/2014,Cash or cash equivalent,163708446,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,109.85,07/15/2014,Cash or cash equivalent,163803334,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4371.20,09/01/2014,Cash or cash equivalent,163803336,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,15.80,10/17/2014,Cash or cash equivalent,163803342,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,04/24/2014,Cash or cash equivalent,163693308,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,09/19/2014,Cash or cash equivalent,163703614,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,06/23/2014,Cash or cash equivalent,163700186,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1830.00,12/12/2014,Cash or cash equivalent,198253294,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1350.00,12/01/2014,Cash or cash equivalent,198253316,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,3050.00,04/04/2014,Cash or cash equivalent,198253336,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Covered Recipient Physician,,,1155351,TODD,J,JANUS,1221 PLEASANT ST,,DES MOINES,50309-1423,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Neurology,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,172.00,01/31/2014,Cash or cash equivalent,198232946,,,Long Term Safety and Efficacy Extension Study of Oral BG00012 Monotherapy in Relapsing Remitting Multiple Sclerosis,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,05/29/2014,Cash or cash equivalent,198253278,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,05/29/2014,Cash or cash equivalent,198253254,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,570.00,06/06/2014,Cash or cash equivalent,198253346,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,05/29/2014,Cash or cash equivalent,198253249,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1914.00,12/19/2014,Cash or cash equivalent,198253325,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,48062.30,09/09/2014,Cash or cash equivalent,192757426,,,Video laryngoscope comparison,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,499.37,10/14/2014,Cash or cash equivalent,192757486,,,Video laryngoscope comparison,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,05/29/2014,Cash or cash equivalent,198253258,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,54020.00,09/11/2014,Cash or cash equivalent,192757406,,,Video laryngoscope comparison,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,33273.90,03/06/2014,Cash or cash equivalent,192757440,,,Video laryngoscope comparison,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,61685.00,03/06/2014,Cash or cash equivalent,192757444,,,Video laryngoscope comparison,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,33273.90,09/04/2014,Cash or cash equivalent,192757412,,,Video laryngoscope comparison,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,427.96,05/08/2014,Cash or cash equivalent,198253171,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,05/29/2014,Cash or cash equivalent,198253262,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1327.50,05/29/2014,Cash or cash equivalent,198253246,ELOCTATE,,Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,2744.00,10/02/2014,Cash or cash equivalent,198253311,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Amarin Pharma Inc.,100000010379,Amarin Pharma Inc.,NJ,37995.00,12/02/2014,Cash or cash equivalent,208760102,AMR101,,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,05/07/2014,Cash or cash equivalent,207721572,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1598.75,01/29/2014,Cash or cash equivalent,207553350,RAPAMUNE,,Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,700.00,04/16/2014,Cash or cash equivalent,207514032,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,03/06/2014,Cash or cash equivalent,207542492,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,02/01/2014,In-kind items and services,207550914,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1085.00,06/04/2014,Cash or cash equivalent,207730734,,,AN OPEN LABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA  ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1725.00,06/18/2014,Cash or cash equivalent,207740450,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1375.00,04/16/2014,Cash or cash equivalent,207541046,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,05/07/2014,Cash or cash equivalent,207728990,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,04/01/2014,In-kind items and services,207732548,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,07/01/2014,In-kind items and services,207866748,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/29/2014,Cash or cash equivalent,207942108,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,9331.25,11/13/2014,Cash or cash equivalent,207972564,SUTENT,,An OpenLabel Sunitinib Malate SU011248 Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1800.00,12/01/2014,Cash or cash equivalent,207987424,CELEBREX,,Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy A Random,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,07/16/2014,Cash or cash equivalent,207773654,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,01/29/2014,Cash or cash equivalent,207558372,RAPAMUNE,,Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,08/27/2014,Cash or cash equivalent,207888770,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1542.56,07/16/2014,Cash or cash equivalent,207795766,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6089.50,07/16/2014,Cash or cash equivalent,207779068,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,05/07/2014,Cash or cash equivalent,207710762,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,05/07/2014,Cash or cash equivalent,207745976,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1155.44,07/16/2014,Cash or cash equivalent,207791961,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,946.44,09/24/2014,Cash or cash equivalent,207866790,,,A Study Of Inotuzumab Ozogamicin Versus Investigator s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,09/01/2014,In-kind items and services,207866850,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1200 PLEASANT STREET,,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3442.50,12/29/2014,In-kind items and services,208055328,TYGACIL,ZYVOX,LEADER program,,Study Drug
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,08/01/2014,In-kind items and services,207884412,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/03/2014,Cash or cash equivalent,208021272,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/10/2014,Cash or cash equivalent,208017338,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,12/10/2014,Cash or cash equivalent,208024118,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1778.88,10/29/2014,Cash or cash equivalent,207953350,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/03/2014,Cash or cash equivalent,208025294,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4513.00,03/06/2014,Cash or cash equivalent,207923202,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/03/2014,Cash or cash equivalent,208055478,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/10/2014,Cash or cash equivalent,208017336,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3750.00,11/12/2014,Cash or cash equivalent,207990914,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2949.00,06/04/2014,Cash or cash equivalent,207721148,,,AN OPEN LABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA  ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1250.00,04/16/2014,Cash or cash equivalent,207800282,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,05/07/2014,Cash or cash equivalent,207715418,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,06/18/2014,Cash or cash equivalent,207745384,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,04/30/2014,Cash or cash equivalent,207825658,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,05/07/2014,Cash or cash equivalent,207716414,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,05/07/2014,Cash or cash equivalent,207740510,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,05/07/2014,Cash or cash equivalent,207746412,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,08/30/2014,Cash or cash equivalent,207860948,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/10/2014,Cash or cash equivalent,208053116,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1065.19,09/24/2014,Cash or cash equivalent,207866864,,,A Study Of Inotuzumab Ozogamicin Versus Investigator s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,12/03/2014,Cash or cash equivalent,208044704,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,938.13,08/20/2014,Cash or cash equivalent,207891108,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/03/2014,Cash or cash equivalent,208030674,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,708.94,10/29/2014,Cash or cash equivalent,207965238,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,05/21/2014,Cash or cash equivalent,207712990,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,03/01/2014,In-kind items and services,207584376,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,06/01/2014,In-kind items and services,207706928,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,05/01/2014,In-kind items and services,207712410,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,01/01/2014,In-kind items and services,207579468,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,315.00,05/07/2014,Cash or cash equivalent,207731260,,,PHASE 3 S  I YOUNG ADULTS 1825 YR,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,875.00,01/29/2014,Cash or cash equivalent,207638008,RAPAMUNE,,Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,10300.00,04/16/2014,Cash or cash equivalent,207648672,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1864.38,07/16/2014,Cash or cash equivalent,207755542,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,10/29/2014,Cash or cash equivalent,207951042,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,11/12/2014,Cash or cash equivalent,207995100,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/10/2014,Cash or cash equivalent,208017368,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/29/2014,Cash or cash equivalent,207933306,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,983.25,10/29/2014,Cash or cash equivalent,207933004,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,983.25,10/29/2014,Cash or cash equivalent,207933022,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,12/10/2014,Cash or cash equivalent,208017388,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/03/2014,Cash or cash equivalent,208024124,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,708.94,10/29/2014,Cash or cash equivalent,207953340,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1065.19,07/16/2014,Cash or cash equivalent,207777130,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,05/07/2014,Cash or cash equivalent,207735438,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,850.00,01/08/2014,Cash or cash equivalent,204136367,,,Magna Mitral 2006 05,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,7609.49,02/21/2014,Cash or cash equivalent,204136702,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010 12,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,500.00,06/04/2014,Cash or cash equivalent,204137408,,,Magna Mitral 2006 05,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,23113.75,10/17/2014,Cash or cash equivalent,204138168,,,Magna Mitral 2006 05,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,67580.14,07/23/2014,Cash or cash equivalent,204137646,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010 12,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,99.00,08/22/2014,Cash or cash equivalent,204137870,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010 12,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,6300.00,10/17/2014,Cash or cash equivalent,204138176,,,Magna Mitral 2006 05,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,"Cardica, Inc.",100000005621,"Cardica, Inc.",CA,24640.00,07/17/2014,Cash or cash equivalent,195528886,,,MAGIC,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,"Cardica, Inc.",100000005621,"Cardica, Inc.",CA,500.00,08/27/2014,Cash or cash equivalent,195532238,,,MAGIC,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Drive 1353 JCP,,Iowa City,52242,,,Musculoskeletal Transplant Foundation Inc.,100000000081,Musculoskeletal Transplant Foundation Inc.,NJ,27136.50,03/20/2014,Cash or cash equivalent,171831742,,,Automated Shape-matching of Custom Bone Allograft Implants,,
Covered Recipient Physician,,,170831,Craig,,Mahoney,"450 Laurel Street, Suite A",,Des Moines,50314,Medical Doctor,Allopathic & Osteopathic Physicians/ Orthopaedic Surgery,Liventa Biosciences Inc.,100000010588,Liventa Biosciences Inc.,PA,1000.00,09/16/2014,Cash or cash equivalent,194827532,AmnioClear LCT,,LCT Knee Registry Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Stryker Corporation,100000010503,Stryker Corporation,MI,1300.00,03/27/2014,Cash or cash equivalent,208877665,,,MAPS,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Drive 1353 JCP,,Iowa City,52242,,,Musculoskeletal Transplant Foundation Inc.,100000000081,Musculoskeletal Transplant Foundation Inc.,NJ,10000.00,01/09/2014,Cash or cash equivalent,171917012,,,Automated Shape-matching of Custom Bone Allograft Implants,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000010364,Roche Products Limited,,9567.00,12/24/2014,Cash or cash equivalent,207444970,NonCovered Product,,SUB-OPTIMALLY CONTROLLED PTS WITH SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,10800.74,04/03/2014,Cash or cash equivalent,211770426,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000061306,"Intermune, Inc.",CA,17584.00,12/01/2014,Cash or cash equivalent,207445396,NonCovered Product,,PIPF-031,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,750.00,02/14/2014,Cash or cash equivalent,211771078,BioTherapeutics - GAMMAGARD-KIOVIG,,NCT01736579 THE UNIVERSITY OF IOWA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,3000.00,02/14/2014,Cash or cash equivalent,211771080,BioTherapeutics - GAMMAGARD-KIOVIG,,NCT01736579 THE UNIVERSITY OF IOWA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,452.81,01/03/2014,Cash or cash equivalent,211770430,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,2157.98,12/24/2014,Cash or cash equivalent,211770436,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,6163.43,09/10/2014,Cash or cash equivalent,211770434,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,12349.74,05/16/2014,Cash or cash equivalent,204137296,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010 12,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,800.00,10/17/2014,Cash or cash equivalent,204138132,,,Magna Mitral 2006 05,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,85374.64,10/31/2014,Cash or cash equivalent,204138240,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010 12,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Medivation Inc.,100000010858,Medivation Inc.,CA,250.00,01/28/2014,Cash or cash equivalent,212113010,XTANDI,,Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000010364,Roche Products Limited,,699.80,05/28/2014,Cash or cash equivalent,207418294,NonCovered Product,,SAFETY STUDY IN PEDIATRIC FXS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Medivation Inc.,100000010858,Medivation Inc.,CA,1072.00,02/18/2014,Cash or cash equivalent,212112982,XTANDI,,Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000010364,Roche Products Limited,,13792.00,11/25/2014,Cash or cash equivalent,207444582,NonCovered Product,,PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000010364,Roche Products Limited,,2128.30,08/22/2014,Cash or cash equivalent,207440476,NonCovered Product,,12-WEEK EFFICACY STUDY IN FXS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"ARIAD Pharmaceuticals, Inc.",100000010550,"ARIAD Pharmaceuticals, Inc.",MA,11417.00,02/03/2014,Cash or cash equivalent,212009452,Iclusig,,EPIC,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,132.19,12/10/2014,Cash or cash equivalent,211771510,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,138.52,05/01/2014,Cash or cash equivalent,211771524,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,3000.00,02/14/2014,Cash or cash equivalent,211772692,BioTherapeutics - GAMMAGARD-KIOVIG,,NCT01736579 THE UNIVERSITY OF IOWA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,10800.74,04/03/2014,Cash or cash equivalent,211771514,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,6163.43,09/10/2014,Cash or cash equivalent,211771528,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,516.55,01/02/2014,Cash or cash equivalent,211771518,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,2157.98,12/24/2014,Cash or cash equivalent,211771534,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,750.00,02/14/2014,Cash or cash equivalent,211772688,BioTherapeutics - GAMMAGARD-KIOVIG,,NCT01736579 THE UNIVERSITY OF IOWA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,452.81,01/03/2014,Cash or cash equivalent,211771520,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,516.55,01/02/2014,Cash or cash equivalent,211770428,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,132.19,12/10/2014,Cash or cash equivalent,211770424,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,138.52,05/01/2014,Cash or cash equivalent,211770432,BioTherapeutics - GAMMAGARD-KIOVIG,,University of Iowa,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,4100.00,02/19/2014,Cash or cash equivalent,196522920,Tiotropium-bromide,,Hospital discharge study 2,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,Vertex Pharmaceuticals Incorporated,MA,8010.70,01/21/2014,Cash or cash equivalent,201641164,KALYDECO,,STUDY OF IVACAFTOR IN SUBJECTS WITH CYSTIC FIBROSIS WHO HAVE THE R117HCFTR MUTATION,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,Vertex Pharmaceuticals Incorporated,MA,90428.85,03/14/2014,Cash or cash equivalent,201643862,KALYDECO,,A PHASE 3 ROLLOVER STUDY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS 12 YEARS AND OLDER WITH CYSTIC FIBROSIS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,Vertex Pharmaceuticals Incorporated,MA,67002.70,01/01/2014,Cash or cash equivalent,201643504,KALYDECO,,A STUDY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN CYSTIC FIBROSIS SUBJECTS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DELCFTR MUTATION TRANSPORT,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,Vertex Pharmaceuticals Incorporated,MA,85.00,07/29/2014,Cash or cash equivalent,201644902,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,Vertex Pharmaceuticals Incorporated,MA,74036.92,01/01/2014,Cash or cash equivalent,201639854,KALYDECO,,STUDY OF VX809 ALONE AND IN COMBINATION WITH VX770 IN CYSTIC FIBROSIS CF PATIENTS HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DELCFTR MUTATION,,
Covered Recipient Teaching Hospital,1758,COVENANT MEDICAL CENTER,,,,,3421 W 9th St,,Waterloo,50702,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,8250.00,01/29/2014,Cash or cash equivalent,189684832,Revlimid,,Celgene - Connect CLL,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,13775.00,01/30/2014,Cash or cash equivalent,189685958,Pomalyst,,CC-4047-MM-007,,
Covered Recipient Physician,,,571099,DELWYN,D,MILLER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Psychiatry,"Genentech, Inc.",100000000166,"Roche TCRC, Inc.",NY,185.63,07/15/2014,Cash or cash equivalent,207427612,NonCovered Product,,PDE10 INHIB. IN SCHIZOPHRENIA,,
Covered Recipient Physician,,,571099,DELWYN,D,MILLER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Psychiatry,"Genentech, Inc.",100000000166,"Roche TCRC, Inc.",NY,3000.00,07/28/2014,Cash or cash equivalent,207418022,NonCovered Product,,PDE10 INHIB. IN SCHIZOPHRENIA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,18562.50,10/02/2014,Cash or cash equivalent,207427862,Xeloda,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,435.00,09/17/2014,Cash or cash equivalent,207437720,NonCovered Product,,MOSAIC,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4725.00,08/05/2014,Cash or cash equivalent,207429658,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,22960.00,06/26/2014,Cash or cash equivalent,207427192,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3175.00,01/27/2014,Cash or cash equivalent,207423712,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,657.01,07/24/2014,Cash or cash equivalent,207434262,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,628.88,11/06/2014,Cash or cash equivalent,207443450,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,19800.00,04/03/2014,Cash or cash equivalent,207427472,Avastin,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3218.76,10/20/2014,Cash or cash equivalent,207428040,NonCovered Product,,IPF PHASE II STUDY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,342.57,11/06/2014,Cash or cash equivalent,207443560,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,700.00,11/21/2014,Cash or cash equivalent,207440824,Perjeta,,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1750.00,08/08/2014,Cash or cash equivalent,207434726,NonCovered Product,,NLCS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1200.00,03/25/2014,Cash or cash equivalent,207427468,Perjeta,Herceptin,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4922.00,04/29/2014,Cash or cash equivalent,207425940,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,19800.00,07/01/2014,Cash or cash equivalent,207427672,Avastin,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,850.00,01/16/2014,Cash or cash equivalent,207427332,Avastin,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1820.00,01/23/2014,Cash or cash equivalent,207427726,Perjeta,Herceptin,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6187.25,02/03/2014,Cash or cash equivalent,207427738,Perjeta,Herceptin,CHEMOTRASTUZUMAB VS CHEMOTRASTUZUMAB&PERTUZUMAB,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,700.00,04/23/2014,Cash or cash equivalent,207427758,Perjeta,Herceptin,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,7163.75,05/06/2014,Cash or cash equivalent,207427762,Perjeta,Herceptin,CHEMOTRASTUZUMAB VS CHEMOTRASTUZUMAB&PERTUZUMAB,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6250.00,01/09/2014,Cash or cash equivalent,207417800,NonCovered Product,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3712.50,10/29/2014,Cash or cash equivalent,207436046,Xeloda,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,14850.00,04/21/2014,Cash or cash equivalent,212351286,NonCovered Product,,The PRROTECT Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,3746.00,11/12/2014,Cash or cash equivalent,194977804,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,7456.00,04/23/2014,Cash or cash equivalent,194977784,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,805.00,09/10/2014,Cash or cash equivalent,194977795,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,15956.00,07/24/2014,Cash or cash equivalent,194977790,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,4613.90,09/18/2014,Cash or cash equivalent,194977800,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1950.00,02/25/2014,Cash or cash equivalent,194977810,VELETRI EPOPROSTENOL,,PROSPECT - AC-066A501 USA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6383.25,01/29/2014,Cash or cash equivalent,207430708,NonCovered Product,,SFTY & EFFC OF MPSK3169A IN PTS WTH CORON HRT DIS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,508031.13,09/24/2014,Cash or cash equivalent,207437874,NonCovered Product,,MOSAIC,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1365.00,06/09/2014,Cash or cash equivalent,194977788,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,971.45,05/01/2014,Cash or cash equivalent,207419962,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5540.00,04/01/2014,Cash or cash equivalent,207424900,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,510.64,02/03/2014,Cash or cash equivalent,207414510,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3064.50,08/07/2014,Cash or cash equivalent,207421832,Perjeta,,CHEMOTRASTUZUMAB VS CHEMOTRASTUZUMAB&PERTUZUMAB,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3696.43,07/15/2014,Cash or cash equivalent,207436088,NonCovered Product,,IPF PHASE II STUDY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,11500.00,05/27/2014,Cash or cash equivalent,207421002,NonCovered Product,,NLCS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4950.00,07/03/2014,Cash or cash equivalent,207427678,Avastin,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1863.00,12/01/2014,Cash or cash equivalent,207444644,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4995.00,07/25/2014,Cash or cash equivalent,207417742,Perjeta,,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5000.00,01/28/2014,Cash or cash equivalent,207427340,NonCovered Product,,IPF PHASE II STUDY,,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,314.44,05/01/2014,Cash or cash equivalent,207419836,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,898.21,02/03/2014,Cash or cash equivalent,207414612,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,483.00,06/18/2014,Cash or cash equivalent,207422220,Perjeta,Herceptin,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,22275.00,07/16/2014,Cash or cash equivalent,207427630,NonCovered Product,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,29700.00,10/03/2014,Cash or cash equivalent,207427854,Xeloda,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6235.78,04/08/2014,Cash or cash equivalent,207427484,NonCovered Product,,IPF PHASE II STUDY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1037.50,10/24/2014,Cash or cash equivalent,207428250,Perjeta,,CHEMOTRASTUZUMAB VS CHEMOTRASTUZUMAB&PERTUZUMAB,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3155.00,10/29/2014,Cash or cash equivalent,207437200,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,2925.00,07/21/2014,Cash or cash equivalent,194973760,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1521,MERCY MEDICAL CENTER - NORTH IOWA,,,,,1000 4th St SW,SUITE IOPT,Mason City,50401,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,4750.00,02/27/2014,Cash or cash equivalent,185190147,SPRYCEL,,Studying Interventions for Managing Patients With Chronic Myeloid Leukemia  CML  in Chronic Phase  The 5 Year Prospective Cohort Study  SIMPLICITY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,16091.30,01/16/2014,Cash or cash equivalent,185194282,,,Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed  Previously Untreated Multiple Myeloma  ELOQUENT   1,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,1817.74,08/13/2014,Cash or cash equivalent,185198300,ELIQUIS,,Phase III VTE Prev in Children w Cent Ven Cath,,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,700 E University Ave,,Des Moines,50316,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,24150.00,02/03/2014,Cash or cash equivalent,185196430,NULOJIX,,Evaluating Nulojix  Belatacept  Long Term Safety in Transplant  ENLIST,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,3850.00,03/19/2014,Cash or cash equivalent,194973740,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1925.00,06/11/2014,Cash or cash equivalent,194973746,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1365.00,08/13/2014,In-kind items and services,194973782,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,4390.00,12/17/2014,Cash or cash equivalent,194973796,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1300.00,01/16/2014,In-kind items and services,194973735,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,251.19,07/24/2014,Cash or cash equivalent,194973778,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,9250.00,01/27/2014,Cash or cash equivalent,207414402,NonCovered Product,,NLCS,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1365.00,06/26/2014,In-kind items and services,194973756,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,2000.00,07/24/2014,Cash or cash equivalent,194973772,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,673.50,12/31/2014,In-kind items and services,194973812,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010476,"Actelion Pharmaceuticals, Ltd",CA,5125.00,07/01/2014,Cash or cash equivalent,194979386,TRACLEER BOSENTAN,,COMPASS 2 - AC-052-414 USA,http://clinicaltrials.gov/ct2/show/NCT00303459?term=actelion+compass+2&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010476,"Actelion Pharmaceuticals, Ltd",CA,6625.00,02/13/2014,Cash or cash equivalent,194979384,TRACLEER BOSENTAN,,COMPASS 2 - AC-052-414 USA,http://clinicaltrials.gov/ct2/show/NCT00303459?term=actelion+compass+2&rank=1,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1058.00,10/23/2014,Cash or cash equivalent,207428160,Perjeta,,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,352.00,01/24/2014,Cash or cash equivalent,207427728,Perjeta,Herceptin,PERTUZUMAB  HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,355.69,08/14/2014,In-kind items and services,212928026,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Teaching Hospital,1752,IOWA LUTHTERAN HOSPITAL,,,,,700 EAST UNIVERSITY,,DES MOINES,50316,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1900.00,08/28/2014,Cash or cash equivalent,212936284,INVANZ,,Study For Monitoring Antimicrobial Resistance Trends,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,4703.04,08/14/2014,In-kind items and services,212938860,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Physician,,,708876,TIMOTHY,,STAUDTE,5409 AVENUE O,,FORT MADISON,52627-9601,Medical Doctor,Allopathic & Osteopathic Physicians/ Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,50.00,12/11/2014,Cash or cash equivalent,212909994,IMPLANON,,Nexplanon Observational Risk Assessment Study NORA,,
Covered Recipient Physician,,,163901,KAREN,J,KROGSTAD,1610 WEST TOWNLINE,STE 100,CRESTON,50801,Medical Doctor,Allopathic & Osteopathic Physicians/ Family Medicine,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,50.00,11/06/2014,Cash or cash equivalent,212918828,IMPLANON,,Nexplanon Observational Risk Assessment Study NORA,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,130.29,01/15/2014,In-kind items and services,212939028,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,705.63,05/09/2014,Cash or cash equivalent,185199256,YERVOY,,PhIII Prostate 2nd line CRPC - Ipi RT vs RT,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,17240.00,12/19/2014,Cash or cash equivalent,185188046,SPRYCEL,,An Open Label  Randomized  2 1  Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,21289.28,05/09/2014,Cash or cash equivalent,185187192,,,Phase IB Rituxan combination,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,2835.96,01/21/2014,Cash or cash equivalent,185200438,BYDUREON,,Medullary Thyroid Cancer Surveillance Study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,3875.00,07/03/2014,Cash or cash equivalent,185179838,NULOJIX,,Factors Associated with Conversion from CNI-Based Immunosuprresion in Kidney Transpltation,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,850.00,07/16/2014,Cash or cash equivalent,185175078,,,Not Applicable,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,62736.89,03/29/2014,Cash or cash equivalent,185199260,OPDIVO,,Phase III RCC Monotherapy vs. everolimus  ONO 4538-03,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2393.76,10/20/2014,In-kind items and services,212914610,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,727.00,02/26/2014,In-kind items and services,212906226,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Physician,,,708876,TIMOTHY,,STAUDTE,5409 AVENUE O,,FORT MADISON,52627-9601,Medical Doctor,Allopathic & Osteopathic Physicians/ Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,200.00,01/10/2014,Cash or cash equivalent,212922440,IMPLANON,,Post authorization safety study IMPLANON NXT observational cohort study,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,201.36,05/16/2014,In-kind items and services,212900932,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,136.78,04/01/2014,In-kind items and services,212918426,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,311.38,07/24/2014,Cash or cash equivalent,174125360,Creon,,P12 792,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,388.80,04/11/2014,In-kind items and services,212920508,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,5045.68,04/23/2014,In-kind items and services,212910982,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,983.91,01/15/2014,In-kind items and services,212913716,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,4366.80,05/20/2014,Cash or cash equivalent,215346500,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,6226.88,04/01/2014,Cash or cash equivalent,215346462,Proleukin,,PROCLAIM Registry,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1204.20,05/28/2014,Cash or cash equivalent,215346482,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,350.00,08/19/2014,Cash or cash equivalent,215346484,Proleukin,,"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,3162.60,05/20/2014,Cash or cash equivalent,215346472,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,675.00,08/19/2014,Cash or cash equivalent,215346490,Proleukin,,"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1000.00,11/25/2014,Cash or cash equivalent,215346498,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,448.85,01/09/2014,Cash or cash equivalent,174125362,Creon,,P12 792,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Varian Medical Systems, Inc.",100000010850,"Varian Medical Systems, Inc.",CA,57865.00,09/22/2014,Cash or cash equivalent,186195860,,,A Portable Real-time HDR Applicator Monitoring System for Intracavitary Brachtherapy,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Varian Medical Systems, Inc.",100000010850,"Varian Medical Systems, Inc.",CA,57865.00,04/07/2014,Cash or cash equivalent,186195856,,,A Portable Real-time HDR Applicator Monitoring System for Intracavitary Brachtherapy,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1225.00,10/07/2014,Cash or cash equivalent,215346480,Proleukin,,PROCLAIM Registry,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,5570.10,08/19/2014,Cash or cash equivalent,215346488,Proleukin,,"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Physician,,,126578,Jerry,,Rozeboom,855 A AVE NE,,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians/ Obstetrics & Gynecology,"Intuitive Surgical, Inc.",100000010533,"Intuitive Surgical Operations, Inc.",CA,31800.00,01/14/2014,Cash or cash equivalent,215965686,,,Multicenter Evaluation of Robotic Hysterectomy Outcomes,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1806.30,05/20/2014,Cash or cash equivalent,215346466,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1350.00,06/24/2014,Cash or cash equivalent,215346474,Proleukin,,PROCLAIM Registry,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1225.00,10/07/2014,Cash or cash equivalent,215346476,Proleukin,,PROCLAIM Registry,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,75.00,11/25/2014,Cash or cash equivalent,215346494,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,998.00,09/29/2014,Cash or cash equivalent,215886210,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161286,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1323.00,09/29/2014,Cash or cash equivalent,215886374,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,5046.00,02/21/2014,Cash or cash equivalent,214164548,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161310,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,750.00,03/10/2014,Cash or cash equivalent,214161328,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161332,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161342,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,164.00,07/17/2014,Cash or cash equivalent,215886200,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,101.60,09/29/2014,Cash or cash equivalent,215886212,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,163.00,08/15/2014,Cash or cash equivalent,214164560,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161358,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161360,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161374,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1323.00,09/29/2014,Cash or cash equivalent,215886208,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1720.00,09/29/2014,Cash or cash equivalent,215886202,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161200,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161236,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161242,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161246,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161256,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161288,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161290,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,938.60,07/17/2014,Cash or cash equivalent,215886198,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161298,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161316,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161274,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161280,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161346,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161250,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161260,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161270,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161364,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161368,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1690.00,09/29/2014,Cash or cash equivalent,215886204,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Physician,,,35650,JENNIFER,,ROBINSON,621 HIGHLAND PARK AVE,,CORALVILLE,52241,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1.08,05/28/2014,Cash or cash equivalent,208680862,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,552.75,12/26/2014,In-kind items and services,211670192,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1625.00,01/13/2014,Cash or cash equivalent,211668642,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1100.00,12/23/2014,Cash or cash equivalent,215886414,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,20.20,03/26/2014,In-kind items and services,211670160,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,27806.61,05/15/2014,Cash or cash equivalent,211668524,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,505.00,12/26/2014,In-kind items and services,211670188,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,13396.18,07/18/2014,Cash or cash equivalent,211668482,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,327.50,12/26/2014,In-kind items and services,211670206,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,575.00,06/27/2014,Cash or cash equivalent,211668662,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1519.22,08/20/2014,Cash or cash equivalent,211668574,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1819.00,07/17/2014,Cash or cash equivalent,215886196,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,393.75,06/27/2014,Cash or cash equivalent,211668658,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,11.80,07/28/2014,In-kind items and services,211670178,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,118.00,10/28/2014,In-kind items and services,211670214,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,10000.00,06/27/2014,Cash or cash equivalent,211668676,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,295.00,12/26/2014,In-kind items and services,211670328,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,24354.99,10/15/2014,Cash or cash equivalent,211668502,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1000.00,01/13/2014,Cash or cash equivalent,211668646,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,525.00,01/13/2014,Cash or cash equivalent,211668648,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,13500.00,01/13/2014,Cash or cash equivalent,211668652,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,11.80,03/26/2014,In-kind items and services,211670170,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,13312.97,06/27/2014,Cash or cash equivalent,211668528,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,63514.44,08/20/2014,Cash or cash equivalent,211668512,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,13.10,07/28/2014,In-kind items and services,211670183,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,196.50,12/26/2014,In-kind items and services,211670196,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,9994.24,06/27/2014,Cash or cash equivalent,211668670,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,31006.60,07/18/2014,Cash or cash equivalent,211668476,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1006.25,09/26/2014,Cash or cash equivalent,211668506,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,221.10,10/28/2014,In-kind items and services,211670264,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,862.50,07/18/2014,Cash or cash equivalent,211668631,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,393.75,06/27/2014,Cash or cash equivalent,211668654,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,36.85,03/26/2014,In-kind items and services,211670220,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Physician,,,944296,LAURIE,,GUTMANN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Psychiatry & Neurology/ Clinical Neurophysiology,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1420.00,09/29/2014,Cash or cash equivalent,215886206,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,881.25,06/27/2014,Cash or cash equivalent,211668666,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1098.28,11/19/2014,Cash or cash equivalent,211668486,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,20.20,07/28/2014,In-kind items and services,211670126,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,131.00,10/28/2014,In-kind items and services,211670130,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Physician,,,35650,JENNIFER,,ROBINSON,621 HIGHLAND PARK AVE,,CORALVILLE,52241,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,92.20,05/28/2014,Cash or cash equivalent,208680858,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,Musculoskeletal Transplant Foundation Inc.,100000000081,Musculoskeletal Transplant Foundation Inc.,NJ,27136.50,09/25/2014,Cash or cash equivalent,159845544,,,,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,13000.68,12/22/2014,Cash or cash equivalent,216054734,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,14681.25,12/22/2014,Cash or cash equivalent,216054736,Gilenya,,CFTY720D2319,,
Covered Recipient Physician,,,88578,BRIAN,,OLSHANSKY,4344 MAIER AVE SW,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,"On-x Life Technologies, Inc",100000011215,"On-x Life Technologies, Inc",TX,1250.00,12/15/2014,Cash or cash equivalent,217193430,,,Clinical Trial of the On X Valve Using Low Dose Anticoagulation,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,4581.72,02/20/2014,Cash or cash equivalent,216054744,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,16366.50,05/06/2014,Cash or cash equivalent,216054746,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,49114.80,07/01/2014,Cash or cash equivalent,216054748,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,285.00,07/14/2014,Cash or cash equivalent,216054752,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,9348.57,09/04/2014,Cash or cash equivalent,216054754,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,Musculoskeletal Transplant Foundation Inc.,100000000081,Musculoskeletal Transplant Foundation Inc.,NJ,27136.50,05/21/2014,Cash or cash equivalent,159845396,,,,,
Covered Recipient Physician,,,35175,JEFFERY,,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Infectious Disease,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,231.62,07/08/2014,Cash or cash equivalent,208658904,,,"A phase IIIb, randomized, open label study of the safety, efficacy and tolerability of switching to a fixed dose combination of dolutegravir abacavir lamivudine from current antiretroviral regimen compared to continuation of the current antiretroviral reg",,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,bioMerieux,100000000114,bioMerieux,NC,10000.00,09/10/2014,Cash or cash equivalent,215590258,,,VITEK 2,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,1405.00,02/11/2014,Cash or cash equivalent,216054738,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,7793.55,02/20/2014,Cash or cash equivalent,216054740,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,550.00,07/14/2014,Cash or cash equivalent,216054750,Gilenya,,CFTY720D2319,,
Covered Recipient Physician,,,604519,STEPHEN,,RINDERKNECHT,40 E HICKMAN RD,,WAUKEE,50263,Doctor of Osteopathy,Physician Assistants & Advanced Practice Nursing Providers/ Clinical Nurse Specialist/ Pediatrics,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,633.04,12/22/2014,Cash or cash equivalent,208664322,NIMENRIX,,MenACWY TT 057 PRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,3035.16,02/20/2014,Cash or cash equivalent,216054742,Gilenya,,CFTY720D2319,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/08/2014,Cash or cash equivalent,221352424,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/08/2014,Cash or cash equivalent,221352452,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352472,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,05/13/2014,Cash or cash equivalent,221358288,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,05/13/2014,Cash or cash equivalent,221358292,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,05/13/2014,Cash or cash equivalent,221358306,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221364994,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365004,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365016,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386818,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386826,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,11/12/2014,Cash or cash equivalent,221386828,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386836,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,11/12/2014,Cash or cash equivalent,221386838,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/07/2014,Cash or cash equivalent,221349298,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,07/08/2014,Cash or cash equivalent,221368340,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,07/08/2014,Cash or cash equivalent,221368346,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/09/2014,Cash or cash equivalent,221377252,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,09/09/2014,Cash or cash equivalent,221377262,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/08/2014,Cash or cash equivalent,221352176,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/08/2014,Cash or cash equivalent,221352180,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365036,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,06/10/2014,Cash or cash equivalent,221365044,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365068,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/09/2014,Cash or cash equivalent,221392178,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,12/09/2014,Cash or cash equivalent,221392180,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/09/2014,Cash or cash equivalent,221392182,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,08/12/2014,Cash or cash equivalent,221373642,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,08/12/2014,Cash or cash equivalent,221373650,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/08/2014,Cash or cash equivalent,221352422,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,04/08/2014,Cash or cash equivalent,221352440,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/08/2014,Cash or cash equivalent,221352450,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/08/2014,Cash or cash equivalent,221352460,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/08/2014,Cash or cash equivalent,221352468,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,09/09/2014,Cash or cash equivalent,221377278,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,06/10/2014,Cash or cash equivalent,221365092,,,ProMRI,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,04/23/2014,Cash or cash equivalent,195431914,,,CANOPY,,AV AV 10669432 20140528 0089 AV 10669432 20140528 0089 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,07/21/2014,Cash or cash equivalent,195430784,,,CANOPY,,AV AV 10743241 20140806 0213 AV 10743241 20140806 0213 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,8150.00,12/09/2014,Cash or cash equivalent,195428996,,,CANOPY,,AV AV 10743241 20150113 0443 AV 10743241 20150113 0443 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,06/10/2014,Cash or cash equivalent,221365002,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365006,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,06/10/2014,Cash or cash equivalent,221365028,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386786,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386792,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Retrophin, Inc.",100000061305,"Retrophin, Inc.",NY,6850.00,11/01/2014,Cash or cash equivalent,221065296,,,Duet Clinical Trial,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,02/18/2014,Cash or cash equivalent,195432322,,,COAPT,,AV AV 10201280 20140320 0030 AV 10201280 20140320 0030 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,08/12/2014,Cash or cash equivalent,221372198,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372200,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,08/12/2014,Cash or cash equivalent,221372206,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372214,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352374,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352380,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/08/2014,Cash or cash equivalent,221352418,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,12/09/2014,Cash or cash equivalent,221389942,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,12/09/2014,Cash or cash equivalent,221389950,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,12/09/2014,Cash or cash equivalent,221389966,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341790,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,02/11/2014,Cash or cash equivalent,221341812,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,02/11/2014,Cash or cash equivalent,221341822,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,02/11/2014,Cash or cash equivalent,221341836,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,02/11/2014,Cash or cash equivalent,221341844,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365032,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386810,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386816,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,11/12/2014,Cash or cash equivalent,221386840,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386844,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391102,,,SIELLO,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,02/18/2014,Cash or cash equivalent,195432320,,,COAPT,,AV AV 10201280 20140320 0028 AV 10201280 20140320 0028 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,02/18/2014,Cash or cash equivalent,195428322,,,COAPT,,AV AV 10201280 20140320 0027 AV 10201280 20140320 0027 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,02/18/2014,Cash or cash equivalent,195435406,,,COAPT,,AV AV 10201280 20140320 0029 AV 10201280 20140320 0029 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372218,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372222,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,08/12/2014,Cash or cash equivalent,221372226,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383594,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376188,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376196,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,06/10/2014,Cash or cash equivalent,221365050,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,06/10/2014,Cash or cash equivalent,221365056,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1000.00,11/18/2014,Cash or cash equivalent,221388670,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,2000.00,05/08/2014,Cash or cash equivalent,214972238,,,ACE An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1400.00,12/04/2014,Cash or cash equivalent,195430298,,,CANOPY,,AV AV 10380625 20150106 0619 AV 10380625 20150106 0619 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,12/03/2014,Cash or cash equivalent,195430302,,,COAPT,,AV AV 10380625 20150106 0628 AV 10380625 20150106 0628 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,10/15/2014,Cash or cash equivalent,221383602,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,10/15/2014,Cash or cash equivalent,221383614,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383618,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372208,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352384,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/08/2014,Cash or cash equivalent,221352386,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352396,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,12/09/2014,Cash or cash equivalent,221389938,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,12/09/2014,Cash or cash equivalent,221389954,,,ProMRI,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,4800.00,02/18/2014,Cash or cash equivalent,195432324,,,COAPT,,AV AV 10201280 20140320 0032 AV 10201280 20140320 0032 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,10/15/2014,Cash or cash equivalent,221383646,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,376.85,10/15/2014,Cash or cash equivalent,221383652,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1079.08,04/08/2014,Cash or cash equivalent,221352400,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352402,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/08/2014,Cash or cash equivalent,221352412,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383586,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,01/07/2014,Cash or cash equivalent,221339720,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386846,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386856,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,11/12/2014,Cash or cash equivalent,221386870,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,50309,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,8250.00,02/27/2014,Cash or cash equivalent,220589522,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,2250.00,02/18/2014,Cash or cash equivalent,195435408,,,COAPT,,AV AV 10201280 20140320 0031 AV 10201280 20140320 0031 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,10/21/2014,Cash or cash equivalent,195428756,,,COAPT,,AV AV 10380625 20141106 0300 AV 10380625 20141106 0300 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369406,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/08/2014,Cash or cash equivalent,221369410,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386878,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366204,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,06/10/2014,Cash or cash equivalent,221366206,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383598,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,54.41,10/15/2014,Cash or cash equivalent,221383610,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,10/15/2014,Cash or cash equivalent,221383638,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/08/2014,Cash or cash equivalent,221369402,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369416,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/08/2014,Cash or cash equivalent,221369432,,,SIELLO,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,2375.00,09/30/2014,Cash or cash equivalent,195427720,,,COAPT,,AV AV 10743241 20141015 0010 AV 10743241 20141015 0010 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1800.00,12/08/2014,Cash or cash equivalent,195430286,,,CANOPY,,AV AV 10380625 20150106 0510 AV 10380625 20150106 0510 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,05/13/2014,Cash or cash equivalent,221358290,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366168,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366194,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,06/10/2014,Cash or cash equivalent,221366198,,,SIELLO,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1415 Woodland Avenue,Suite 218,Des Moines,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,6650.00,09/25/2014,Cash or cash equivalent,220589638,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,1751,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,3725.00,12/22/2014,Cash or cash equivalent,195429148,,,COAPT,,AV AV 10186723 20150112 0060 AV 10186723 20150112 0060 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,05/13/2014,Cash or cash equivalent,221358294,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,05/13/2014,Cash or cash equivalent,221358304,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,05/13/2014,Cash or cash equivalent,221358324,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369436,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,06/10/2014,Cash or cash equivalent,221365082,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365090,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,06/10/2014,Cash or cash equivalent,221365094,,,ProMRI,,
Covered Recipient Teaching Hospital,1759,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,04/15/2014,Cash or cash equivalent,195434936,,,CANOPY,,AV AV 10669432 20140528 0161 AV 10669432 20140528 0161 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161306,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161284,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161348,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161216,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161230,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161366,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161370,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161238,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161240,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161262,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161264,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161266,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2625.00,03/06/2014,Cash or cash equivalent,214164552,TYVASO,,AN OPEN LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT,http://clinicaltrials.gov/ct2/show/NCT01027949,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,956.00,08/15/2014,Cash or cash equivalent,214164562,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1620.00,08/15/2014,Cash or cash equivalent,214164564,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1253.00,09/05/2014,Cash or cash equivalent,214164570,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161190,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1065.00,08/08/2014,Cash or cash equivalent,214164558,ORENITRAM,,AN OPEN LABEL LONG TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION,http://clinicaltrials.gov/ct2/show/NCT01560637,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,3441.00,10/24/2014,Cash or cash equivalent,214164576,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161302,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161202,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161314,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161204,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161208,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161210,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161218,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161224,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161228,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161322,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161330,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161350,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161356,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161254,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,5212.00,08/15/2014,Cash or cash equivalent,214164566,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"SYNCARDIA SYSTEMS, INC",100000005570,"SynCardia Systems, Inc",AZ,5801.50,04/11/2014,Cash or cash equivalent,214991782,,,FREEDOM DRIVER SYSTEM STUDY,,
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,4706.00,09/05/2014,Cash or cash equivalent,214164572,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,6682.00,09/05/2014,Cash or cash equivalent,214164574,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,HZNP USA Inc.,100000005604,Horizon Pharma Ireland Limited,,22646.15,12/12/2014,Cash or cash equivalent,217544674,Actimmune,,,,Improving the host inate immune response to community associated CA MRSA
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,HZNP USA Inc.,100000005604,Horizon Pharma Ireland Limited,,6676.00,10/23/2014,Cash or cash equivalent,217544670,Actimmune,,,,Improving the host inate immune response to community associated CA MRSA
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,HZNP USA Inc.,100000005604,Horizon Pharma Ireland Limited,,1993.00,07/10/2014,Cash or cash equivalent,217544668,Actimmune,,,,Improving the host inate immune response to community associated CA MRSA
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"SYNCARDIA SYSTEMS, INC",100000005570,"SynCardia Systems, Inc",AZ,3339.50,01/10/2014,Cash or cash equivalent,214991776,,,FREEDOM DRIVER SYSTEM STUDY,,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161312,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161318,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161196,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161198,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,750.00,03/10/2014,Cash or cash equivalent,214161326,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161340,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161352,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,540.00,12/02/2014,Cash or cash equivalent,205830154,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,7206.08,09/12/2014,Cash or cash equivalent,205825184,,,Independent Study Support -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,2430.00,10/20/2014,Cash or cash equivalent,205819827,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,4860.00,04/09/2014,Cash or cash equivalent,205839118,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161372,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161212,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161220,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161226,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,405.00,12/02/2014,Cash or cash equivalent,205822566,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,17482.96,09/12/2014,Cash or cash equivalent,205825890,,,Independent Study Support -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,1350.00,04/09/2014,Cash or cash equivalent,205837296,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,810.00,12/02/2014,Cash or cash equivalent,205821796,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,1500.00,06/09/2014,Cash or cash equivalent,205828080,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,810.00,09/22/2014,Cash or cash equivalent,205830100,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,1080.00,09/22/2014,Cash or cash equivalent,205830884,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161252,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,711261,Daniel,Jonathan,Caplan,University of Iowa,337-1 Dental Science N,Iowa City,52242-1010,Doctor of Dentistry,Dental Providers/ Dentist/ General Practice,"Ivoclar Vivadent, Inc.",100000010562,"Ivoclar Vivadent, Inc.",NY,11448.00,06/25/2014,In-kind items and services,216751098,Cervitec Plus- 72 boxes,,Iowa Nursing Facility Oral Hygiene Intervention: A Pilot Study.,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Ivoclar Vivadent, Inc.",100000010562,"Ivoclar Vivadent, Inc.",NY,852.00,05/27/2014,In-kind items and services,214507390,,,examination of hybrid abutment crowns,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,2500.00,06/09/2014,Cash or cash equivalent,205839378,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,4050.00,04/09/2014,Cash or cash equivalent,205836988,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Physician,,,132783,NICOLAS,WAHIB,SHAMMAS,1236 E RUSHOLME ST,SUITE 300,DAVENPORT,52803,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Interventional Cardiology,Bayer HealthCare LLC,100000005409,Bayer HealthCare LLC,NJ,1890.00,09/22/2014,Cash or cash equivalent,205837042,,,6 Clinical Trial Pase IV -Post Marketing- -Bayer Product or TA-,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,90.00,11/12/2014,Cash or cash equivalent,219336212,Prolastin-C,,"A Multicenter, Randomized, Partial Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1Proteinase Inhibitor in Subjects With New Onset Type 1 Diabetes Mellitus",,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161272,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161276,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,6000.00,02/28/2014,Cash or cash equivalent,219334920,,,Observational Study of tissue Plasminogen Activator Used for Catheter Directed Thrombolysis in Patients with Acute Lower Extremity Native Artery or Bypass Graft Occlusion,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"SYNCARDIA SYSTEMS, INC",100000005570,"SynCardia Systems, Inc",AZ,5828.50,11/07/2014,Cash or cash equivalent,214991788,,,FREEDOM DRIVER SYSTEM STUDY,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,43000.00,10/01/2014,In-kind items and services,219336308,Prolastin-C,,"A Multicenter, Randomized, Partial Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1Proteinase Inhibitor in Subjects With New Onset Type 1 Diabetes Mellitus",,
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161248,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161304,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161308,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161320,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161338,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161354,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2875.00,01/01/2014,Cash or cash equivalent,214161194,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161206,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161214,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161234,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2625.00,03/06/2014,Cash or cash equivalent,214164550,TYVASO,,AN OPEN LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT,http://clinicaltrials.gov/ct2/show/NCT01027949,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2625.00,03/06/2014,Cash or cash equivalent,214164554,TYVASO,,AN OPEN LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT,http://clinicaltrials.gov/ct2/show/NCT01027949,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,5324.00,05/23/2014,Cash or cash equivalent,214164556,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7284.00,08/15/2014,Cash or cash equivalent,214164568,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161296,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161300,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161222,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161324,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161334,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161336,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161344,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161292,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7500.00,02/07/2014,Cash or cash equivalent,214161294,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161278,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161282,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161244,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161258,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161268,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,14950.00,01/01/2014,Cash or cash equivalent,214161232,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161362,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,802474,LINDA,MARIE,CADARET,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians/ Internal Medicine/ Cardiovascular Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,10125.00,07/04/2014,Cash or cash equivalent,214161376,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://clinicaltrials.gov/ct2/show/NCT01266265,NA
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PL,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,1250.00,03/18/2014,Cash or cash equivalent,120279501,,,DePuy Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PL,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,8575.00,03/18/2014,Cash or cash equivalent,120279503,,,Registry Outcomes,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,550.00,09/26/2014,Cash or cash equivalent,120279507,,,DePuy Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,6950.00,12/15/2014,Cash or cash equivalent,120279517,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVEROOM W278GH,,IOWA CITY,52242-1009,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,12250.00,06/12/2014,Cash or cash equivalent,120280115,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242-1302,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,12600.00,08/28/2014,Cash or cash equivalent,120280117,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242-1302,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,9350.00,12/18/2014,Cash or cash equivalent,120280119,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,2000.00,11/21/2014,Cash or cash equivalent,120279513,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,600.00,09/26/2014,Cash or cash equivalent,120279505,,,DePuy Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,2350.00,09/30/2014,Cash or cash equivalent,120279509,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,5950.00,09/26/2014,Cash or cash equivalent,120279511,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,8250.00,12/15/2014,Cash or cash equivalent,120279515,,,DePuy Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,8225.00,09/30/2014,Cash or cash equivalent,120279519,,,Registry Outcomes,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221364982,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365000,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,06/10/2014,Cash or cash equivalent,221366172,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,06/10/2014,Cash or cash equivalent,221366182,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,06/10/2014,Cash or cash equivalent,221366190,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341802,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365018,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365024,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,06/10/2014,Cash or cash equivalent,221365086,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/13/2014,Cash or cash equivalent,221358312,,,ProMRI,,
Covered Recipient Physician,,,404877,GERRY,F,FUNK,200 Hawkins Dr Suite 21266,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Otolaryngology,Covidien LP,100000000083,Covidien LP,MA,709.52,01/21/2014,Cash or cash equivalent,215233080,,,Orion R&D,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,02/11/2014,Cash or cash equivalent,221341820,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365052,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365074,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365076,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,06/10/2014,Cash or cash equivalent,221365078,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386820,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386834,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391094,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/07/2014,Cash or cash equivalent,221349290,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/07/2014,Cash or cash equivalent,221349292,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,07/08/2014,Cash or cash equivalent,221368338,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,07/08/2014,Cash or cash equivalent,221368344,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,09/09/2014,Cash or cash equivalent,221377264,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/07/2014,Cash or cash equivalent,221349296,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/12/2014,Cash or cash equivalent,221373640,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,08/12/2014,Cash or cash equivalent,221373644,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,08/12/2014,Cash or cash equivalent,221373646,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,08/12/2014,Cash or cash equivalent,221373648,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,08/12/2014,Cash or cash equivalent,221373656,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,12/09/2014,Cash or cash equivalent,221389956,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372204,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,08/12/2014,Cash or cash equivalent,221372212,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/07/2014,Cash or cash equivalent,221349304,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,12/09/2014,Cash or cash equivalent,221392192,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352428,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352470,,,ProMRI,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,5950 University Ave Suite 195,,West Des Moines,50266,Medical Doctor,Allopathic & Osteopathic Physicians/ Surgery/ Vascular Surgery,Covidien LP,100000000083,Covidien LP,MA,2500.00,03/19/2014,Cash or cash equivalent,215236919,,,ILLUMENATE Pivotal,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,10/15/2014,Cash or cash equivalent,221383580,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,12/09/2014,Cash or cash equivalent,221391106,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,02/11/2014,Cash or cash equivalent,221341784,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386804,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386842,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,12/09/2014,Cash or cash equivalent,221392188,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/09/2014,Cash or cash equivalent,221392190,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,579.05,10/15/2014,Cash or cash equivalent,221383606,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,27.57,10/15/2014,Cash or cash equivalent,221383624,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,05/13/2014,Cash or cash equivalent,221359602,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/08/2014,Cash or cash equivalent,221352382,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365022,,,ProMRI,,
Covered Recipient Physician,,,404877,GERRY,F,FUNK,200 Hawkins Dr Suite 21266,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Otolaryngology,Covidien LP,100000000083,Covidien LP,MA,105.03,01/23/2014,Cash or cash equivalent,215235280,,,Orion R&D,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,579.05,10/15/2014,Cash or cash equivalent,221383626,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,376.85,10/15/2014,Cash or cash equivalent,221383628,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,10/15/2014,Cash or cash equivalent,221383640,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383642,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352390,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352404,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352414,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,02/11/2014,Cash or cash equivalent,221341826,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/08/2014,Cash or cash equivalent,221352178,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341796,,,ProMRI,,
Covered Recipient Physician,,,571099,DELWYN,,MILLER,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,,"Otsuka America Pharmaceutical, Inc.",100000010725,"Otsuka Pharmaceutical Development & Commercialization, Inc.",NJ,300.00,03/21/2014,Cash or cash equivalent,216063236,,,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole OPC-14597 as Maintenance Treatment in Bipolar I Patients",https://www.clinicaltrials.gov/show/NCT01567527,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,12/09/2014,Cash or cash equivalent,221389946,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,12/09/2014,Cash or cash equivalent,221389948,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,12/09/2014,Cash or cash equivalent,221389960,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365060,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,06/10/2014,Cash or cash equivalent,221365070,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341798,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,02/11/2014,Cash or cash equivalent,221341828,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,02/11/2014,Cash or cash equivalent,221341834,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,02/11/2014,Cash or cash equivalent,221341840,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376194,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/08/2014,Cash or cash equivalent,221369400,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/08/2014,Cash or cash equivalent,221369430,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383590,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,04/07/2014,Cash or cash equivalent,221347190,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,04/07/2014,Cash or cash equivalent,221347192,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/08/2014,Cash or cash equivalent,221369434,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,12/09/2014,Cash or cash equivalent,221391110,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,12/09/2014,Cash or cash equivalent,221389944,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,12/09/2014,Cash or cash equivalent,221389958,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,06/10/2014,Cash or cash equivalent,221366388,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,82.72,10/15/2014,Cash or cash equivalent,221383644,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352364,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/08/2014,Cash or cash equivalent,221352368,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352370,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352420,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,10/15/2014,Cash or cash equivalent,221383588,,,BIOHELIX-I,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,5950 University Ave Suite 195,,West Des Moines,50266,Medical Doctor,Allopathic & Osteopathic Physicians/ Surgery/ Vascular Surgery,Covidien LP,100000000083,Covidien LP,MA,1000.00,03/19/2014,Cash or cash equivalent,215234096,,,ILLUMENATE Pivotal,,
Covered Recipient Physician,,,404877,GERRY,F,FUNK,200 Hawkins Dr Suite 21266,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians/ Otolaryngology,Covidien LP,100000000083,Covidien LP,MA,2800.00,01/23/2014,Cash or cash equivalent,215234216,,,Orion R&D,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,02/11/2014,Cash or cash equivalent,221343320,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386854,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386866,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,10/15/2014,Cash or cash equivalent,221383596,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,82.72,10/15/2014,Cash or cash equivalent,221383600,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,54.41,10/15/2014,Cash or cash equivalent,221383612,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,27.57,10/15/2014,Cash or cash equivalent,221383648,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,54.41,10/15/2014,Cash or cash equivalent,221383654,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,54.41,10/15/2014,Cash or cash equivalent,221383656,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/13/2014,Cash or cash equivalent,221359600,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365084,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/13/2014,Cash or cash equivalent,221358284,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,05/13/2014,Cash or cash equivalent,221358296,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/13/2014,Cash or cash equivalent,221358300,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,05/13/2014,Cash or cash equivalent,221358310,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366196,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,04/07/2014,Cash or cash equivalent,221347198,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,01/07/2014,Cash or cash equivalent,221339724,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369396,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369404,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/08/2014,Cash or cash equivalent,221369424,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,02/11/2014,Cash or cash equivalent,221343380,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,07/08/2014,Cash or cash equivalent,221368342,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369438,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,06/10/2014,Cash or cash equivalent,221366200,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,04/07/2014,Cash or cash equivalent,221347194,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/09/2014,Cash or cash equivalent,221392174,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,04/08/2014,Cash or cash equivalent,221352430,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352454,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,04/08/2014,Cash or cash equivalent,221352458,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386852,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,11/12/2014,Cash or cash equivalent,221386858,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,11/12/2014,Cash or cash equivalent,221386860,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/09/2014,Cash or cash equivalent,221392186,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/09/2014,Cash or cash equivalent,221392194,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,02/11/2014,Cash or cash equivalent,221341788,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/09/2014,Cash or cash equivalent,221377254,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,09/09/2014,Cash or cash equivalent,221377268,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,09/09/2014,Cash or cash equivalent,221377270,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,06/10/2014,Cash or cash equivalent,221366164,,,SIELLO,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,460.00,11/04/2014,Cash or cash equivalent,120565581,,,PSR,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,6100.00,09/26/2014,Cash or cash equivalent,120279521,,,Registry Outcomes,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,500.00,05/29/2014,Cash or cash equivalent,120565629,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,5543.00,01/23/2014,Cash or cash equivalent,120566711,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1336.00,05/20/2014,Cash or cash equivalent,120566039,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,560.00,10/30/2014,Cash or cash equivalent,120565713,,,PPP Fully Integrated,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Spectrum Pharmaceuticals Inc.,100000011115,Spectrum Pharmaceuticals Inc.,NV,2850.00,08/20/2014,Cash or cash equivalent,221784296,ZEST,,ZEST,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,1215 Pleasant St Suite 618,,DES MOINES,50309,Medical Doctor,Allopathic & Osteopathic Physicians/ Surgery/ Vascular Surgery,Covidien LP,100000000083,Covidien LP,MA,666.67,07/30/2014,Cash or cash equivalent,215233022,,,ILLUMENATE Pivotal,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Spectrum Pharmaceuticals Inc.,100000011115,Spectrum Pharmaceuticals Inc.,NV,20190.00,08/20/2014,Cash or cash equivalent,221784298,ZEST,,ZEST,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1347.00,01/16/2014,Cash or cash equivalent,120566045,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,863.00,11/12/2014,Cash or cash equivalent,120565837,,,PSR,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,365.00,11/12/2014,Cash or cash equivalent,120565511,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,4032.00,01/13/2014,Cash or cash equivalent,120566543,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,5523.00,03/27/2014,Cash or cash equivalent,120566709,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,2357.00,11/13/2014,Cash or cash equivalent,120566271,,,PSR,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,3715.00,09/04/2014,Cash or cash equivalent,120566513,,,PSR,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,3755.00,09/04/2014,Cash or cash equivalent,120566521,,,PSR,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,Covidien LP,100000000083,Covidien LP,MA,4150.00,03/19/2014,Cash or cash equivalent,215238953,,,DURABILITY PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,362.00,06/05/2014,Cash or cash equivalent,120565503,,,PPP Fully Integrated,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Spectrum Pharmaceuticals Inc.,100000011115,Spectrum Pharmaceuticals Inc.,NV,1335.00,06/20/2014,Cash or cash equivalent,221784290,ZEST,,ZEST,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Spectrum Pharmaceuticals Inc.,100000011115,Spectrum Pharmaceuticals Inc.,NV,1200.00,06/24/2014,Cash or cash equivalent,221784294,ZEST,,ZEST,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,2207.00,08/07/2014,Cash or cash equivalent,120566241,,,PPP Fully Integrated,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Spectrum Pharmaceuticals Inc.,100000011115,Spectrum Pharmaceuticals Inc.,NV,14840.00,10/15/2014,Cash or cash equivalent,221784292,ZEST,,ZEST,,
Covered Recipient Teaching Hospital,1753,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,Covidien LP,100000000083,Covidien LP,MA,4350.00,08/13/2014,Cash or cash equivalent,215232964,,,DURABILITY PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,2073.00,09/09/2014,Cash or cash equivalent,120566217,,,PSR,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,12/09/2014,Cash or cash equivalent,221391108,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,12/09/2014,Cash or cash equivalent,221389940,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,12/09/2014,Cash or cash equivalent,221389964,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,12/09/2014,Cash or cash equivalent,221391114,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,12/09/2014,Cash or cash equivalent,221391116,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,12/09/2014,Cash or cash equivalent,221391118,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,10/15/2014,Cash or cash equivalent,221383582,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,10/15/2014,Cash or cash equivalent,221383584,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,27.57,10/15/2014,Cash or cash equivalent,221383604,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,10/15/2014,Cash or cash equivalent,221383592,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/08/2014,Cash or cash equivalent,221352398,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352416,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,08/12/2014,Cash or cash equivalent,221373658,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,82.72,10/15/2014,Cash or cash equivalent,221383620,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,54.41,10/15/2014,Cash or cash equivalent,221383634,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,10/15/2014,Cash or cash equivalent,221383658,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,10/15/2014,Cash or cash equivalent,221383616,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,54.41,10/15/2014,Cash or cash equivalent,221383630,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,10/15/2014,Cash or cash equivalent,221383636,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,349.27,04/07/2014,Cash or cash equivalent,221347188,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,04/07/2014,Cash or cash equivalent,221347200,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,01/07/2014,Cash or cash equivalent,221339716,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,01/07/2014,Cash or cash equivalent,221339718,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/08/2014,Cash or cash equivalent,221369392,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,376.85,10/15/2014,Cash or cash equivalent,221383608,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,10/15/2014,Cash or cash equivalent,221383622,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,579.05,10/15/2014,Cash or cash equivalent,221383650,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,01/07/2014,Cash or cash equivalent,221339726,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/08/2014,Cash or cash equivalent,221369394,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/08/2014,Cash or cash equivalent,221369398,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369428,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,05/13/2014,Cash or cash equivalent,221358302,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,11/12/2014,Cash or cash equivalent,221386850,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386862,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386874,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,01/07/2014,Cash or cash equivalent,221339722,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/08/2014,Cash or cash equivalent,221369418,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369426,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,06/10/2014,Cash or cash equivalent,221366390,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,06/10/2014,Cash or cash equivalent,221366394,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,06/10/2014,Cash or cash equivalent,221366396,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/08/2014,Cash or cash equivalent,221369412,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/08/2014,Cash or cash equivalent,221369414,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/08/2014,Cash or cash equivalent,221369422,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/07/2014,Cash or cash equivalent,221349300,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,11/12/2014,Cash or cash equivalent,221386868,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386872,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,11/12/2014,Cash or cash equivalent,221386848,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,04/07/2014,Cash or cash equivalent,221347202,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,06/10/2014,Cash or cash equivalent,221366392,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,12/09/2014,Cash or cash equivalent,221392184,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/08/2014,Cash or cash equivalent,221352438,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352448,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352456,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/08/2014,Cash or cash equivalent,221352476,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366184,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,06/10/2014,Cash or cash equivalent,221366192,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2014,Cash or cash equivalent,221366160,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366166,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366186,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,06/10/2014,Cash or cash equivalent,221366162,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,06/10/2014,Cash or cash equivalent,221366170,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2014,Cash or cash equivalent,221366176,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,06/10/2014,Cash or cash equivalent,221366188,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386864,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,02/11/2014,Cash or cash equivalent,221343322,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,08/12/2014,Cash or cash equivalent,221373652,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/13/2014,Cash or cash equivalent,221358280,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,08/12/2014,Cash or cash equivalent,221373654,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/13/2014,Cash or cash equivalent,221358282,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,05/13/2014,Cash or cash equivalent,221358298,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,05/13/2014,Cash or cash equivalent,221358318,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,02/11/2014,Cash or cash equivalent,221341792,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341794,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,02/11/2014,Cash or cash equivalent,221341800,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,02/11/2014,Cash or cash equivalent,221341810,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,02/11/2014,Cash or cash equivalent,221341814,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,02/11/2014,Cash or cash equivalent,221341824,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,02/11/2014,Cash or cash equivalent,221341842,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,05/13/2014,Cash or cash equivalent,221358286,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,05/13/2014,Cash or cash equivalent,221358308,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,05/13/2014,Cash or cash equivalent,221358316,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,05/13/2014,Cash or cash equivalent,221358322,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/08/2014,Cash or cash equivalent,221369440,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/09/2014,Cash or cash equivalent,221377256,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,09/09/2014,Cash or cash equivalent,221377260,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/12/2014,Cash or cash equivalent,221373638,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,06/10/2014,Cash or cash equivalent,221366174,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,06/10/2014,Cash or cash equivalent,221366178,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,06/10/2014,Cash or cash equivalent,221366180,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,06/10/2014,Cash or cash equivalent,221366202,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221364986,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365008,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365012,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,09/09/2014,Cash or cash equivalent,221377266,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352426,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/08/2014,Cash or cash equivalent,221352436,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352444,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/08/2014,Cash or cash equivalent,221352446,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365088,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,05/13/2014,Cash or cash equivalent,221358314,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,05/13/2014,Cash or cash equivalent,221358320,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/07/2014,Cash or cash equivalent,221349294,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/07/2014,Cash or cash equivalent,221349302,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352434,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/08/2014,Cash or cash equivalent,221352442,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,04/08/2014,Cash or cash equivalent,221352462,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/08/2014,Cash or cash equivalent,221352464,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,02/11/2014,Cash or cash equivalent,221343378,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,06/10/2014,Cash or cash equivalent,221365034,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,06/10/2014,Cash or cash equivalent,221365038,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,06/10/2014,Cash or cash equivalent,221365042,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365046,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,05/13/2014,Cash or cash equivalent,221360198,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376192,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221364984,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221364998,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365014,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386784,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,04/08/2014,Cash or cash equivalent,221352432,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,04/08/2014,Cash or cash equivalent,221352466,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,04/08/2014,Cash or cash equivalent,221352474,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/09/2014,Cash or cash equivalent,221377258,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,09/09/2014,Cash or cash equivalent,221377272,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,09/09/2014,Cash or cash equivalent,221377274,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,09/09/2014,Cash or cash equivalent,221377276,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,08/12/2014,Cash or cash equivalent,221372202,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,08/12/2014,Cash or cash equivalent,221372216,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386794,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391092,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,05/13/2014,Cash or cash equivalent,221360200,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376190,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376198,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376200,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221364988,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221364992,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,06/10/2014,Cash or cash equivalent,221364996,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365020,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386780,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386796,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386800,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386806,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386822,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386824,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,11/12/2014,Cash or cash equivalent,221386830,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391098,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,12/09/2014,Cash or cash equivalent,221392176,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341774,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365026,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/08/2014,Cash or cash equivalent,221352182,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386790,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386802,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386814,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391090,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391096,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,12/09/2014,Cash or cash equivalent,221392172,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,02/11/2014,Cash or cash equivalent,221341776,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341778,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,02/11/2014,Cash or cash equivalent,221341780,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341782,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,09/09/2014,Cash or cash equivalent,221376186,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,12/09/2014,Cash or cash equivalent,221391112,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/08/2014,Cash or cash equivalent,221352184,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365048,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,06/10/2014,Cash or cash equivalent,221365058,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/09/2014,Cash or cash equivalent,221391100,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,02/11/2014,Cash or cash equivalent,221341786,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2014,Cash or cash equivalent,221365030,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365040,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365054,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,06/10/2014,Cash or cash equivalent,221365062,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,06/10/2014,Cash or cash equivalent,221365064,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,06/10/2014,Cash or cash equivalent,221364990,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386782,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/12/2014,Cash or cash equivalent,221386788,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,11/12/2014,Cash or cash equivalent,221386808,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,02/11/2014,Cash or cash equivalent,221341804,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,02/11/2014,Cash or cash equivalent,221341808,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,02/11/2014,Cash or cash equivalent,221341832,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,02/11/2014,Cash or cash equivalent,221341806,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372224,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,06/10/2014,Cash or cash equivalent,221365066,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,06/10/2014,Cash or cash equivalent,221365072,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,11/12/2014,Cash or cash equivalent,221386812,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,11/12/2014,Cash or cash equivalent,221386832,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372194,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372196,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,08/12/2014,Cash or cash equivalent,221372210,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,12/09/2014,Cash or cash equivalent,221391104,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,12/09/2014,Cash or cash equivalent,221389936,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,02/11/2014,Cash or cash equivalent,221341816,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,02/11/2014,Cash or cash equivalent,221341818,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,02/11/2014,Cash or cash equivalent,221341830,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,02/11/2014,Cash or cash equivalent,221341838,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,02/11/2014,Cash or cash equivalent,221341846,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,06/10/2014,Cash or cash equivalent,221366398,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,01/07/2014,Cash or cash equivalent,221339714,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/08/2014,Cash or cash equivalent,221369408,,,SIELLO,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352372,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/08/2014,Cash or cash equivalent,221352376,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352392,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,04/08/2014,Cash or cash equivalent,221352408,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,12/09/2014,Cash or cash equivalent,221389952,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/08/2014,Cash or cash equivalent,221352366,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/08/2014,Cash or cash equivalent,221352388,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/08/2014,Cash or cash equivalent,221352394,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/08/2014,Cash or cash equivalent,221352406,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/08/2014,Cash or cash equivalent,221352410,,,ProMRI,,
Covered Recipient Teaching Hospital,1761,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,12/09/2014,Cash or cash equivalent,221389962,,,ProMRI,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1845.00,11/21/2014,Cash or cash equivalent,155719118,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1975.00,11/21/2014,Cash or cash equivalent,155719120,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2408.00,01/17/2014,Cash or cash equivalent,155719128,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,15851.00,10/27/2014,Cash or cash equivalent,155719026,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEOFFICE B5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,14719.00,08/29/2014,Cash or cash equivalent,155719036,,,A Multicenter Longitudinal Study for the Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,154.54,06/13/2014,Cash or cash equivalent,155719048,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,600 7Th St Se,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,51.00,01/24/2014,In-kind items and services,155712578,SIRUKUMAB,,"A Multicenter, Randomized, Double blind, Placebo controlled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti TNF Therapy",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,715.00,10/27/2014,Cash or cash equivalent,155719070,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,800.00,11/10/2014,Cash or cash equivalent,155719080,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7824.00,09/15/2014,Cash or cash equivalent,155719088,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,550.00,11/21/2014,Cash or cash equivalent,155719098,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,825.00,11/21/2014,Cash or cash equivalent,155719106,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,196.00,03/06/2014,In-kind items and services,155712560,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6663.00,12/05/2014,Cash or cash equivalent,155719010,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50324,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3627.00,12/08/2014,In-kind items and services,155706482,Stelara,,"A Phase 3, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6896.00,11/26/2014,Cash or cash equivalent,155719028,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,154.54,04/24/2014,Cash or cash equivalent,155719046,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,100.00,10/03/2014,Cash or cash equivalent,155719068,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,168.00,11/10/2014,Cash or cash equivalent,155719078,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,--,Des Moines,50314-3017,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,24380.99,09/18/2014,Cash or cash equivalent,144326736,BRILINTA,,A Multinational  Randomised  Double Blind  Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death  Myocardial Infarction or Stroke in Patients with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,207 CROCKER ST,STE 300,DES MOINES,50309-1318,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3975.00,10/20/2014,Cash or cash equivalent,131463154,,,PLATINUM,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,21983.95,01/14/2014,Cash or cash equivalent,144336914,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,Po Box 3014,Ames,50010-3014,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,7.50,09/30/2014,In-kind items and services,144339870,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,Po Box 3014,Ames,50010-3014,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2500.00,09/16/2014,Cash or cash equivalent,144327002,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3497.00,01/08/2014,Cash or cash equivalent,144340226,,,An Observational Study to Assess Respiratory Syncytial Virus RSV-associated Illness in Adults With Chronic Obstructive Pulmonary Disease COPD andor Congestive Heart Failure CHF,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,67.15,03/31/2014,In-kind items and services,144346430,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,7222.50,08/18/2014,Cash or cash equivalent,131465460,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3500.00,02/28/2014,Cash or cash equivalent,155714558,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6300.00,05/23/2014,Cash or cash equivalent,155714560,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,220.00,10/31/2014,Cash or cash equivalent,155710122,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,440.00,12/26/2014,Cash or cash equivalent,155710126,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,409.15,03/31/2014,In-kind items and services,144346426,,,An Observational Study to Assess Respiratory Syncytial Virus RSV-associated Illness in Adults With Chronic Obstructive Pulmonary Disease COPD andor Congestive Heart Failure CHF,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1470.00,03/07/2014,In-kind items and services,155712568,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52759,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,333.00,02/14/2014,Cash or cash equivalent,155708996,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,13095.00,11/25/2014,Cash or cash equivalent,144327864,,,A Phase III Randomised Double blind Placebo controlled Multi centre International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced Unresectable Non Small Cell Lung Cancer Stage III Who Have Not Progressed Following Definitive  Platinum based Concurrent Chemoradiation Therapy PACIFIC,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2854.71,12/31/2014,In-kind items and services,144342572,,,A Phase III Randomised Double blind Placebo controlled Multi centre International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced Unresectable Non Small Cell Lung Cancer Stage III Who Have Not Progressed Following Definitive  Platinum based Concurrent Chemoradiation Therapy PACIFIC,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Suite West 4,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,9875.64,09/23/2014,Cash or cash equivalent,144330078,BRILINTA,,A Randomised Double Blind Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin ASA in Patients with Acute Ischaemic Stroke or TIA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4050.00,02/18/2014,Cash or cash equivalent,131465380,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,207 CROCKER ST,STE 300,DES MOINES,50309-1318,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1750.00,01/21/2014,Cash or cash equivalent,131463156,,,PLATINUM,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,675.00,11/17/2014,Cash or cash equivalent,131465454,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3307.50,09/12/2014,Cash or cash equivalent,131465458,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,675.00,07/03/2014,Cash or cash equivalent,131465462,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2610.00,05/19/2014,Cash or cash equivalent,131465464,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1282.50,01/03/2014,Cash or cash equivalent,131465378,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1462.50,03/18/2014,Cash or cash equivalent,131465468,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1260.00,04/21/2014,Cash or cash equivalent,131465466,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1102.50,10/03/2014,Cash or cash equivalent,131465456,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4 SITE,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3350.00,02/14/2014,Cash or cash equivalent,155714556,Imbruvica,,"A Phase 2, Multicenter, Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Brutons Tyrosine Kinase  BTK  Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,800.00,03/31/2014,Cash or cash equivalent,155710108,,,Outcomes Registry of Better Quality of Care In the Treatment  ORBIT  Atrial Fibrillation Registry.,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1760.00,03/03/2014,Cash or cash equivalent,155710110,,,Outcomes Registry of Better Quality of Care In the Treatment  ORBIT  Atrial Fibrillation Registry.,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4326.00,10/27/2014,Cash or cash equivalent,155719004,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3636.00,12/05/2014,Cash or cash equivalent,155719008,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1600.00,07/25/2014,Cash or cash equivalent,155719016,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2430.12,01/13/2014,Cash or cash equivalent,155719130,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,517.00,03/27/2014,In-kind items and services,155712574,SIRUKUMAB,,"A Multicenter, Randomized, Double blind, Placebo controlled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti TNF Therapy",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7856.40,12/19/2014,Cash or cash equivalent,155719030,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEOFFICE B5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7499.00,07/25/2014,Cash or cash equivalent,155719034,,,A Multicenter Longitudinal Study for the Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,537.00,05/30/2014,Cash or cash equivalent,155719050,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,8355.00,04/28/2014,Cash or cash equivalent,155719058,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,99909.00,05/23/2014,Cash or cash equivalent,155719064,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,966.00,08/13/2014,Cash or cash equivalent,155719066,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52759,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,853.00,09/05/2014,Cash or cash equivalent,155708990,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,489.00,09/15/2014,Cash or cash equivalent,155719084,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50301,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2513.00,11/17/2014,In-kind items and services,155706974,,,28431754DIA2004,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,Ste 3262,Des Moines,50301,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2250.00,11/17/2014,In-kind items and services,155706978,,,28431754DIA2004,,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52759,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,999.00,10/31/2014,Cash or cash equivalent,155708992,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52759,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,666.00,01/31/2014,Cash or cash equivalent,155708998,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,940.00,07/28/2014,Cash or cash equivalent,155710118,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,12011.00,01/30/2014,Cash or cash equivalent,155719134,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50324,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,191.80,11/21/2014,In-kind items and services,155706478,Stelara,,"A Phase 3, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,220.00,10/16/2014,Cash or cash equivalent,155710120,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,660.00,11/26/2014,Cash or cash equivalent,155710124,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1440.00,06/27/2014,Cash or cash equivalent,155710128,,,Outcomes Registry of Better Quality of Care In the Treatment  ORBIT  Atrial Fibrillation Registry.,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3040.00,05/02/2014,Cash or cash equivalent,155710130,,,Outcomes Registry of Better Quality of Care In the Treatment  ORBIT  Atrial Fibrillation Registry.,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52759,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,374.00,06/27/2014,Cash or cash equivalent,155709000,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,500.00,07/25/2014,Cash or cash equivalent,155719012,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,9000.00,07/25/2014,Cash or cash equivalent,155719020,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEOFFICE B5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6100.00,11/26/2014,Cash or cash equivalent,155719040,,,A Multicenter Longitudinal Study for the Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1074.00,06/27/2014,Cash or cash equivalent,155719054,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3756.00,10/16/2014,Cash or cash equivalent,155719074,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,510.00,11/21/2014,Cash or cash equivalent,155719092,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,615.00,11/21/2014,Cash or cash equivalent,155719100,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,680.00,11/21/2014,Cash or cash equivalent,155719102,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,DIVISION OF SPONSORED PROGRAMS2 GILMORE HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3549.00,06/13/2014,Cash or cash equivalent,155718994,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1911.00,08/22/2014,Cash or cash equivalent,155719000,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,21578.79,10/09/2014,Cash or cash equivalent,155719006,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2330.00,07/25/2014,Cash or cash equivalent,155719018,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,16407.00,12/26/2014,Cash or cash equivalent,155719032,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,746.00,04/24/2014,Cash or cash equivalent,155719052,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1639.25,10/03/2014,Cash or cash equivalent,155719072,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,350.00,10/14/2014,In-kind items and services,155715828,Imbruvica,,PCI 32765MCL4001,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,955.00,11/21/2014,Cash or cash equivalent,155719110,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1805.00,11/21/2014,Cash or cash equivalent,155719116,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,ACCOUNTS PAYABLE230 NEBRASKA STREET,,SIOUX CITY,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,300.00,07/03/2014,Cash or cash equivalent,155714562,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50301,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1000.00,12/22/2014,In-kind items and services,155706976,,,28431754DIA2004,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2160.00,02/28/2014,Cash or cash equivalent,155719126,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,DIVISION OF SPONSORED PROGRAMS2 GILMORE HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6801.84,06/02/2014,Cash or cash equivalent,155718998,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,5982.99,07/03/2014,Cash or cash equivalent,155719002,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTINGOFFICE 5B JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,53643.75,01/06/2014,Cash or cash equivalent,155719042,,,Effects of Paliperidone Palmitate vs Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients   A Randomized Clinical Trial,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50324,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,9838.00,02/03/2014,In-kind items and services,155706476,Remicade,,"Prospective, Multicenter, Randomized, Double Blind, Placebo Controlled Trial Comparing REMICADE  infliximab  and Placebo in the Prevention of Relapse in Crohns Disease Patients Undergoing Surgical Resection",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1911.00,06/30/2014,Cash or cash equivalent,155719060,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,66031.00,05/16/2014,Cash or cash equivalent,155719062,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,275.00,09/15/2014,Cash or cash equivalent,155719082,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50324,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1000.00,11/24/2014,In-kind items and services,155706480,Stelara,,"A Phase 3, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,445.00,11/21/2014,Cash or cash equivalent,155719090,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,825.00,11/21/2014,Cash or cash equivalent,155719104,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1570.00,11/21/2014,Cash or cash equivalent,155719112,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1470.00,03/13/2014,In-kind items and services,155712564,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,517.00,03/27/2014,In-kind items and services,155712572,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,31610.00,12/18/2014,In-kind items and services,155712576,SIRUKUMAB,,"A Multicenter, Randomized, Double blind, Placebo controlled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti TNF Therapy",,
Non-covered Recipient Entity,,,,,,,600 7Th St Se,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,9082.00,02/03/2014,In-kind items and services,155712580,SIRUKUMAB,,"A Multicenter, Randomized, Double blind, Placebo controlled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti TNF Therapy",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,560.10,12/04/2014,In-kind items and services,155715826,Imbruvica,,PCI 32765MCL4001,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1470.00,03/07/2014,In-kind items and services,155712562,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1470.00,03/13/2014,In-kind items and services,155712570,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52759,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,561.00,12/29/2014,Cash or cash equivalent,155708994,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,193.16,01/13/2014,Cash or cash equivalent,155719122,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEOFFICE B5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4343.75,11/26/2014,Cash or cash equivalent,155719038,,,A Multicenter Longitudinal Study for the Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1746.00,06/13/2014,Cash or cash equivalent,155719056,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3822.00,10/03/2014,Cash or cash equivalent,155719076,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7772.00,02/06/2014,In-kind items and services,155712558,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,720.00,01/31/2014,Cash or cash equivalent,155710106,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,580.00,06/27/2014,Cash or cash equivalent,155710112,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1800.00,05/02/2014,Cash or cash equivalent,155710116,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52401,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,196.00,03/06/2014,In-kind items and services,155712566,SIRUKUMAB,,"Vaccine Response Substudy of  A Multicenter, Randomized, Double blind, Placebocontrolled, Parallel Group Study of CNTO 136  sirukumab , a Human Anti IL 6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50701,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,720.00,06/02/2014,Cash or cash equivalent,155710114,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II  Orbit AF II,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4425.00,05/22/2014,In-kind items and services,165671282,,,OPEN STUDY,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,43701-2868,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671294,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,65201-8023,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671306,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,72211-3714,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671308,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,92123-4233,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671316,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669244,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669288,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673858,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673866,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673878,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669332,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669344,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673890,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673896,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27610-1231,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,01/13/2014,In-kind items and services,165669388,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,37404-2600,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165669394,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,43214-3467,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,02/14/2014,In-kind items and services,165669404,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669426,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669428,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669450,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669476,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672470,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673920,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,23298-5051,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671256,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,31602-2512,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671268,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,53233,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671304,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,75605-2411,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671310,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673938,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,98104-1132,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,01/13/2014,In-kind items and services,165673952,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669258,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,23452-5765,,,Cordis Corporation,100000005411,Cordis Corporation,CA,2500.00,01/22/2014,In-kind items and services,165669262,,,OPEN STUDY,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669270,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669294,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669296,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669416,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669300,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669366,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672486,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672496,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672526,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672530,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669452,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669478,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,85224-5680,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669506,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669372,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37934-1979,,,Cordis Corporation,100000005411,Cordis Corporation,CA,800.00,03/21/2014,In-kind items and services,165672512,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672520,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,23454-3064,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671258,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672554,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,17043-1034,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671242,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673854,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673870,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673906,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673908,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672556,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-3000,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672560,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,18901-3525,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671248,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,29204-1018,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673924,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,35630-5767,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,03/21/2014,In-kind items and services,165673926,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,44195-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,01/13/2014,In-kind items and services,165673934,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673948,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673954,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,12208-3412,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165669238,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669274,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669280,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669306,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669312,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669256,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669266,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669268,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669278,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669382,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673942,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669286,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669292,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,43214-3467,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,02/14/2014,In-kind items and services,165669402,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669422,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669432,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669454,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669482,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669314,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669338,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669340,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669342,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669316,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669318,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672458,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672460,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669484,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669496,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,85224-5680,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669502,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669360,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669368,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669370,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,29615-3557,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,01/13/2014,In-kind items and services,165669392,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669412,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669414,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669434,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669464,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669468,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669470,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669486,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,19610-3338,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4900.00,07/30/2014,In-kind items and services,165671252,,,OPEN STUDY,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,28204-3260,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671262,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,28204-3260,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671264,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672462,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672464,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,43210-1240,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671286,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,43214-3467,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671290,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,46290-1028,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671302,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,77030-3000,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671312,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,97210-3057,,,Cordis Corporation,100000005411,Cordis Corporation,CA,500.00,04/18/2014,In-kind items and services,165671320,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,20010-2976,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671254,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,27609,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671260,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,29607-5261,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671266,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,33176-2118,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671272,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,33176-2118,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671274,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,05/15/2014,In-kind items and services,165671280,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,43210-1240,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671288,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,45219-2906,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671300,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672478,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673844,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,98004-4623,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671326,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,800.00,04/18/2014,In-kind items and services,165672506,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672524,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672476,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672490,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672494,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37934-1979,,,Cordis Corporation,100000005411,Cordis Corporation,CA,800.00,03/21/2014,In-kind items and services,165672514,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672522,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672538,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672542,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673852,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673874,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673886,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673888,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673912,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672544,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672550,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673876,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673880,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673892,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673914,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,19610-3338,,,Cordis Corporation,100000005411,Cordis Corporation,CA,500.00,07/30/2014,In-kind items and services,165671250,,,OPEN STUDY,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,10021,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671234,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672548,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672558,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,27529-4685,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165673922,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,35630-5767,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,03/21/2014,In-kind items and services,165673930,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673936,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669430,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,12208-3412,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165669240,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669458,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669494,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,2500.00,01/31/2014,In-kind items and services,165669498,,,INSPIRATION,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,85224-5680,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669500,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,85224-5680,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669504,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669264,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669298,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669302,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669310,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669322,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669328,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669336,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669350,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669354,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669356,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672472,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,97477-8800,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671324,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673846,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672482,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672488,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,38138-1727,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672516,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672518,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672540,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672492,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,800.00,04/18/2014,In-kind items and services,165672502,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,05/15/2014,In-kind items and services,165672508,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37934-1979,,,Cordis Corporation,100000005411,Cordis Corporation,CA,1250.00,02/25/2014,In-kind items and services,165672510,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673862,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673864,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673872,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673898,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673902,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673868,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,500.00,05/27/2014,Cash or cash equivalent,164811346,Menveo,,Immunogenicity   Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673860,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673910,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,17043-1034,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671244,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672474,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,35211-1310,,,Cordis Corporation,100000005411,Cordis Corporation,CA,1200.00,01/15/2014,In-kind items and services,165672498,,,ELITE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37404-2600,,,Cordis Corporation,100000005411,Cordis Corporation,CA,800.00,04/18/2014,In-kind items and services,165672500,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672528,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672532,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672534,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669384,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27610-1231,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,01/13/2014,In-kind items and services,165669390,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,37404-2600,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165669396,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669420,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669242,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,92868-3201,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,01/13/2014,In-kind items and services,165673950,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669436,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669446,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669448,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669248,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669260,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669282,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669284,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,20168.63,03/05/2014,Cash or cash equivalent,164809792,Menveo,,Immunogenicity   Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672546,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669472,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669474,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669492,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669326,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669334,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669348,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669364,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669378,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,--,Iowa City,52242-1009,,,AstraZeneca Pharmaceuticals LP,100000000169,"MedImmune, LLC",MD,3351.38,12/31/2014,In-kind items and services,144338982,,,"A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia CLL",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,246.77,01/17/2014,Cash or cash equivalent,155719124,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR5970Z JPP,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2697.00,03/28/2014,Cash or cash equivalent,155719132,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,Ste E321gh,Iowa City,52242-1009,,,AstraZeneca Pharmaceuticals LP,100000000169,"MedImmune, LLC",MD,14991.20,03/10/2014,Cash or cash equivalent,144327142,,,"A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis",,
Non-covered Recipient Entity,,,,,,,DIVISION OF SPONSORED PROGRAMS2 GILMORE HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4326.00,03/20/2014,Cash or cash equivalent,155718992,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,DIVISION OF SPONSORED PROGRAMS2 GILMORE HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4945.00,06/13/2014,Cash or cash equivalent,155718996,Imbruvica,,"Randomized, Double blind, Placebo controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase  BTK  Inhibitor, in Combination with Bendamustine and Rituximab  BR  in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1100.00,07/25/2014,Cash or cash equivalent,155719014,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,10800.00,09/10/2014,Cash or cash equivalent,164812274,Menveo,,A Phase 4   Placebo-Controlled   Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,43214-3467,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671292,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,44035-6400,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671296,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,44094-4656,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671298,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1610.00,10/06/2014,Cash or cash equivalent,155719022,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,12312.00,10/10/2014,Cash or cash equivalent,155719024,,,"ESKETIN SUI 2001  A double blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTINGOFFICE 5B JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,164917.28,01/06/2014,In-kind items and services,155719044,,,Effects of Paliperidone Palmitate vs Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients   A Randomized Clinical Trial,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672468,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673848,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673850,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,700.00,09/15/2014,Cash or cash equivalent,155719086,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,510.00,11/21/2014,Cash or cash equivalent,155719094,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,510.00,11/21/2014,Cash or cash equivalent,155719096,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,825.00,11/21/2014,Cash or cash equivalent,155719108,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1700.00,11/21/2014,Cash or cash equivalent,155719114,,,A Randomized Controlled Study of YONDELIS  trabectedin  or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,90.08,01/07/2014,In-kind items and services,164811853,Menveo,,Immunogenicity   Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age,,
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,111.55,12/05/2014,Cash or cash equivalent,164083770,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,49.05,10/10/2014,Cash or cash equivalent,164079538,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,50.26,10/11/2014,Cash or cash equivalent,164079548,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,46.14,10/11/2014,Cash or cash equivalent,164079550,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079606,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/17/2014,Cash or cash equivalent,164079566,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,37.95,11/17/2014,Cash or cash equivalent,164079570,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079574,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080660,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,63.25,11/15/2014,Cash or cash equivalent,164080670,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/15/2014,Cash or cash equivalent,164080674,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,63.25,11/17/2014,Cash or cash equivalent,164079572,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079602,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,641.28,12/05/2014,Cash or cash equivalent,164083772,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,2500.00,10/16/2014,Cash or cash equivalent,164080654,,,"A Randomized, Double-Blind, Phase 2 Study of JAK Inhibitor or Placebo in Combination With Capecitabine in Subjects With Previously Treated Advanced or Metastatic HER2-negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1000.00,10/16/2014,Cash or cash equivalent,164080656,,,"A Randomized, Double-Blind, Phase 2 Study of JAK Inhibitor or Placebo in Combination With Capecitabine in Subjects With Previously Treated Advanced or Metastatic HER2-negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,22.27,10/10/2014,Cash or cash equivalent,164079536,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,180.55,10/10/2014,Cash or cash equivalent,164079542,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,15.69,10/11/2014,Cash or cash equivalent,164079552,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079598,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,12/16/2014,Cash or cash equivalent,164079608,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079580,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/15/2014,Cash or cash equivalent,164080662,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/15/2014,Cash or cash equivalent,164080658,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080664,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080666,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079588,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,12/16/2014,Cash or cash equivalent,164079590,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,11.60,12/05/2014,Cash or cash equivalent,164083766,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,234.68,12/05/2014,Cash or cash equivalent,164083768,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,111.55,12/05/2014,Cash or cash equivalent,164083774,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,660312.74,10/14/2014,Cash or cash equivalent,164080652,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,The amount of this record is associated with the value of study drug provided to the site for clinical trial research purposes.
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,40536-0093,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673932,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,37934-1979,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,02/14/2014,In-kind items and services,165669400,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,35630-5767,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,03/21/2014,In-kind items and services,165673928,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673940,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673944,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673946,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669246,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669254,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669304,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669440,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669444,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669250,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,19464-3224,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669252,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669272,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669276,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27610-1231,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,01/13/2014,In-kind items and services,165669386,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,05/15/2014,In-kind items and services,165669398,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,48602-6912,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4000.00,02/10/2014,In-kind items and services,165669406,,,INSPIRATION,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669352,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669362,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669460,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669466,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669480,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669290,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669308,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669320,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669324,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,52803-2473,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,03/21/2014,In-kind items and services,165669408,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669410,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669418,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669424,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669438,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669442,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669380,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,11/25/2014,In-kind items and services,165669330,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669346,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669358,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669374,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,27609-7300,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669376,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669456,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669462,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669488,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,70121-2429,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,11/25/2014,In-kind items and services,165669490,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672466,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,35233-2110,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671276,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,05/15/2014,In-kind items and services,165671278,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,32216-4331,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671270,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,37920-2244,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671284,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,92868-4228,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671318,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,97302-6222,,,Cordis Corporation,100000005411,Cordis Corporation,CA,500.00,01/22/2014,In-kind items and services,165671322,,,OPEN STUDY,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,78758-5386,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671314,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672480,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,32610-3003,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672484,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,37660-7332,,,Cordis Corporation,100000005411,Cordis Corporation,CA,800.00,04/18/2014,In-kind items and services,165672504,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,55905-0001,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672536,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673882,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673894,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673900,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673904,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673916,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,13501-5930,,,Cordis Corporation,100000005411,Cordis Corporation,CA,400.00,04/18/2014,In-kind items and services,165671236,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,14215-1145,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671240,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,18901-3525,,,Cordis Corporation,100000005411,Cordis Corporation,CA,700.00,04/18/2014,In-kind items and services,165671246,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673856,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673884,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,02114-3117,,,Cordis Corporation,100000005411,Cordis Corporation,CA,200.00,10/24/2014,In-kind items and services,165673918,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,77030-2312,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,10/24/2014,In-kind items and services,165672552,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/15/2014,Cash or cash equivalent,164080682,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080676,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079586,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,12/16/2014,Cash or cash equivalent,164079592,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,11.60,12/05/2014,Cash or cash equivalent,164083762,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,180.55,10/10/2014,Cash or cash equivalent,164079544,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,578.20,10/10/2014,Cash or cash equivalent,164079546,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/17/2014,Cash or cash equivalent,164079558,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,37.95,12/16/2014,Cash or cash equivalent,164079594,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,63.25,12/16/2014,Cash or cash equivalent,164079596,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080672,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,114.27,10/10/2014,Cash or cash equivalent,164079540,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079600,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4500.00,12/11/2014,Cash or cash equivalent,164087150,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,37.95,11/15/2014,Cash or cash equivalent,164080678,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079562,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079564,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080680,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,234.68,12/05/2014,Cash or cash equivalent,164083764,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,12/16/2014,Cash or cash equivalent,164079604,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,440208.29,12/15/2014,Cash or cash equivalent,164079582,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,The amount of this record is associated with the value of study drug provided to the site for clinical trial research purposes.
Non-covered Recipient Entity,,,,,,,202 10th St Se,,Cedar Rapids,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,617.44,12/05/2014,Cash or cash equivalent,164083776,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,269.66,10/10/2014,Cash or cash equivalent,164079534,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,660303.13,10/14/2014,Cash or cash equivalent,164079554,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,The amount of this record is associated with the value of study drug provided to the site for clinical trial research purposes.
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079556,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/17/2014,Cash or cash equivalent,164079560,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,11/17/2014,Cash or cash equivalent,164079568,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079576,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/17/2014,Cash or cash equivalent,164079578,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E Locust St,,Des Moines,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,39.48,12/16/2014,Cash or cash equivalent,164079584,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,23.80,11/15/2014,Cash or cash equivalent,164080668,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to clinical trial research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,90745.29,05/19/2014,Cash or cash equivalent,144075872,,,COMPARISON OF THE OXYNTOMODULIN ANALOG LY2944876 TO ONCE WEEKLY EXENATIDE AND TO PLACEBO IN PATIENTS WITH TYPE 2 DIABETES,https://clinicaltrials.gov/ct2/show/NCT02119819,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE STE 285,,CEDAR RAPIDS,52403,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,540.00,01/01/2014,In-kind items and services,144088134,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,http://clinicaltrials.gov/ct2/show/NCT01602224,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,88694.00,01/07/2014,Cash or cash equivalent,144076754,,,A COMPARISON OF LY2605541 ONCE DAILY AT A FIXED TIME WITH LY2605541 VARIABLE TIME OF DOSING IN PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS - AN OPEN LABEL RANDOMIZED CROSSOVER STUDY,http://clinicaltrials.gov/ct2/show/NCT01792284,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,998.04,01/22/2014,In-kind items and services,144088440,,,ASSESSMENT OF CLINICAL EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION WITH EVACETRAPIB IN PATIENTS AT A HIGH RISK FOR VASCULAR OUTCOMES,http://clinicaltrials.gov/ct2/show/NCT01687998,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,145968.94,01/14/2014,Cash or cash equivalent,144088528,AXIRON,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL STUDY WITH AN OPEN LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE SEX DRIVE AND ENERGY IN HYPOGONADAL MEN,http://clinicaltrials.gov/ct2/show/NCT01816295,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1113.00,01/27/2014,Cash or cash equivalent,144075810,,,THE IMPACT OF LY2605541 VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS ADVANCED TO MULTIPLE INJECTION BOLUS INSULIN WITH INSULIN LISPRO - A DOUBLE BLIND RANDOMIZED 26-WEEK STUDY - THE IMAGINE 4 STUDY,http://clinicaltrials.gov/ct2/show/NCT01468987,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,224.00,02/27/2014,Cash or cash equivalent,167811682,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,224.00,02/06/2014,Cash or cash equivalent,167811658,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,577.00,02/06/2014,Cash or cash equivalent,167811662,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,577.00,03/06/2014,Cash or cash equivalent,167811690,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,951.00,02/06/2014,Cash or cash equivalent,167811654,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,224.00,01/30/2014,Cash or cash equivalent,167811649,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,577.00,02/20/2014,Cash or cash equivalent,167811672,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,224.00,02/06/2014,Cash or cash equivalent,167811666,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,951.00,02/20/2014,Cash or cash equivalent,167811676,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,DBA JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,577.00,02/27/2014,Cash or cash equivalent,167811686,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,601758.75,03/03/2014,Cash or cash equivalent,144080752,,,A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD,http://clinicaltrials.gov/ct2/show/NCT01646177,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,25337.00,01/14/2014,Cash or cash equivalent,144076748,HUMULIN,,TWO TREATMENT APPROACHES FOR HUMAN REGULAR U500 INSULIN - THRICE DAILY VERSUS TWICE DAILY - IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS - A RANDOMIZED OPEN LABEL PARALLEL CLINICAL TRIAL,http://clinicaltrials.gov/ct2/show/NCT01774968,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1215 DUFF,,AMES,50010,,,"Onyx Pharmaceuticals, Inc., an Amgen subsidiary",100000000276,"Onyx Pharmaceuticals, Inc., an Amgen subsidiary",CA,83088.00,09/29/2014,In-kind items and services,132194992,Kyprolis,,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,810.00,01/01/2014,In-kind items and services,144069488,,,A MULTICENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED 24 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB - LY2439821- IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS,http://clinicaltrials.gov/ct2/show/NCT01695239,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,26.01,01/17/2014,In-kind items and services,144076000,HUMULIN,,TWO TREATMENT APPROACHES FOR HUMAN REGULAR U500 INSULIN - THRICE DAILY VERSUS TWICE DAILY - IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS - A RANDOMIZED OPEN LABEL PARALLEL CLINICAL TRIAL,http://clinicaltrials.gov/ct2/show/NCT01774968,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 341,,WEST DES MOINES,50266,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,917.00,08/05/2014,Cash or cash equivalent,144088088,,,A COMPARISON OF LY2605541 VERSUS INSULIN GLARGINE AS BASAL INSULIN TREATMENT IN COMBINATION WITH ORAL ANTI HYPERGLYCEMIA MEDICATIONS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS - A DOUBLE BLIND RANDOMIZED STUDY,http://clinicaltrials.gov/ct2/show/NCT01435616,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,3725.00,02/03/2014,Cash or cash equivalent,144076744,,,THE IMPACT OF LY2605541 VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH PREPRANDIAL INSULIN LISPRO - A DOUBLE BLIND RANDOMIZED 52 WEEK STUDY,http://clinicaltrials.gov/ct2/show/NCT01454284,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,225.50,10/28/2014,In-kind items and services,144088534,AXIRON,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL STUDY WITH AN OPEN LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE SEX DRIVE AND ENERGY IN HYPOGONADAL MEN,http://clinicaltrials.gov/ct2/show/NCT01816295,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1605.32,01/07/2014,Cash or cash equivalent,144062366,,,A PROSPECTIVE MULTI CENTER RANDOMIZED DOUBLE BLIND TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF 12 VERSUS 30 MONTHS OF DUAL ANTIPLATELET THERAPY -DAPT- IN SUBJECTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION -PCI-WITH EITHER DRUG ELUTING STENT -DES- OR BARE METAL STENT -BMS- PLACEMENT FOR THE TREATMENT OF CORONARY ARTERY LESIONS,,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2500.00,03/24/2014,Cash or cash equivalent,144069588,,,A MULTICENTER RANDOMIZED DOUBLE-BLIND ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS,http://clinicaltrials.gov/ct2/show/NCT01870284,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2710.95,02/13/2014,In-kind items and services,144080748,,,A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD,http://clinicaltrials.gov/ct2/show/NCT01646177,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1036.12,03/24/2014,In-kind items and services,144075806,,,A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY2409021 COMPARED TO SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS,http://clinicaltrials.gov/ct2/show/NCT02111096,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,45030.93,04/14/2014,Cash or cash equivalent,144075868,,,A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY2409021 COMPARED TO SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS,http://clinicaltrials.gov/ct2/show/NCT02111096,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE STE 285,,CEDAR RAPIDS,52403,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,12733.00,01/21/2014,Cash or cash equivalent,144074760,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,http://clinicaltrials.gov/ct2/show/NCT01602224,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,54917.50,03/10/2014,Cash or cash equivalent,144076752,HUMALOG,,AN INDIVIDUALIZED TREATMENT APPROACH FOR OLDER PATIENTS - A RANDOMIZED CONTROLLED STUDY IN TYPE 2 DIABETES MELLITUS -IMPERIUM,http://clinicaltrials.gov/ct2/show/NCT02072096,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,845.82,02/04/2014,In-kind items and services,144076724,HUMALOG,,AN INDIVIDUALIZED TREATMENT APPROACH FOR OLDER PATIENTS - A RANDOMIZED CONTROLLED STUDY IN TYPE 2 DIABETES MELLITUS -IMPERIUM,http://clinicaltrials.gov/ct2/show/NCT02072096,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,6543.00,01/29/2014,Cash or cash equivalent,144070630,,,A MULTICENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED 24 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB - LY2439821- IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS,http://clinicaltrials.gov/ct2/show/NCT01695239,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE STE 285,,CEDAR RAPIDS,52403,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2798.00,01/21/2014,Cash or cash equivalent,144075774,CYRAMZA,,A RANDOMIZED DOUBLE BLIND PHASE 3 STUDY OF DOCETAXEL AND RAMUCIRUMAB VERSUS DOCETAXEL AND PLACEBO IN THE TREATMENT OF STAGE IV NON SMALL CELL LUNG CANCER FOLLOWING DISEASE PROGRESSION AFTER ONE PRIOR PLATINUM BASED THERAPY,http://clinicaltrials.gov/ct2/show/NCT01168973,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,8595.00,01/21/2014,Cash or cash equivalent,144075870,,,A COMPARISON OF LY2605541 VERSUS HUMAN INSULIN NPH AS BASAL INSULIN TREATMENT IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS NOT ADEQUATELY CONTROLLED WITH 2 OR MORE ORAL ANTIHYPERGLYCEMIC MEDICATIONS - AN OPEN LABEL RANDOMIZED STUDY,http://clinicaltrials.gov/ct2/show/NCT01790438,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2443.03,04/01/2014,In-kind items and services,144088524,,,COMPARISON OF THE OXYNTOMODULIN ANALOG LY2944876 TO ONCE WEEKLY EXENATIDE AND TO PLACEBO IN PATIENTS WITH TYPE 2 DIABETES,https://clinicaltrials.gov/ct2/show/NCT02119819,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,36668.00,04/07/2014,Cash or cash equivalent,144088442,,,ASSESSMENT OF CLINICAL EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION WITH EVACETRAPIB IN PATIENTS AT A HIGH RISK FOR VASCULAR OUTCOMES,http://clinicaltrials.gov/ct2/show/NCT01687998,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,677.96,04/24/2014,In-kind items and services,130059905,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,745.00,07/15/2014,In-kind items and services,130059911,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,159.92,04/24/2014,In-kind items and services,130070089,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6122.17,01/24/2014,In-kind items and services,130069529,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 E. 10TH ST. SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,179.21,01/28/2014,In-kind items and services,130069531,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,5002.17,02/20/2014,In-kind items and services,130069527,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,200.00,01/02/2014,In-kind items and services,130061281,Neulasta,,Bone Pain Management US NOLAN study,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6353.20,01/14/2014,Cash or cash equivalent,130061279,Neulasta,,Bone Pain Management US NOLAN study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL STE 100,,COUNCIL BLUFFS,51503,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2990.00,06/19/2014,Cash or cash equivalent,130068943,XGEVA,,Osteonecrosis of the Jaw ONJ Case Registry,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,E325 GH,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1785.00,01/20/2014,In-kind items and services,130066937,Aranesp,,NSCLC,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,266.10,09/25/2014,In-kind items and services,130070755,Sensipar,,"Pediatric 26week, Time until Transplant",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3489.06,08/25/2014,In-kind items and services,130070757,Sensipar,,"Pediatric 26week, Time until Transplant",,
Non-covered Recipient Entity,,,,,,,202 10TH ST S E,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,4703.60,01/24/2014,Cash or cash equivalent,130069295,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1934.88,01/01/2014,In-kind items and services,130059907,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,257.28,06/06/2014,In-kind items and services,130059909,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,10/09/2014,Cash or cash equivalent,120600765,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,07/25/2014,Cash or cash equivalent,120599505,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/06/2014,Cash or cash equivalent,120599509,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,06/30/2014,Cash or cash equivalent,120599519,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,694.00,07/02/2014,Cash or cash equivalent,120603655,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,450.00,05/19/2014,Cash or cash equivalent,120602241,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2496.00,06/03/2014,Cash or cash equivalent,120608169,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/06/2014,Cash or cash equivalent,120599507,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,500.00,09/10/2014,Cash or cash equivalent,120602547,,,Sure Scan PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,500.00,01/07/2014,Cash or cash equivalent,120602545,,,Sure Scan PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,400.00,11/18/2014,Cash or cash equivalent,120602001,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2964.00,04/14/2014,Cash or cash equivalent,120608791,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2964.00,04/14/2014,Cash or cash equivalent,120608793,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,02/06/2014,Cash or cash equivalent,120599647,,,ICY AVNRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3219.00,10/23/2014,Cash or cash equivalent,120609101,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,750.00,10/07/2014,Cash or cash equivalent,120603869,,,PainFree SST Protecta,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,321.00,08/06/2014,Cash or cash equivalent,120601443,,,Educate,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1222.00,10/29/2014,Cash or cash equivalent,120605745,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3982.00,08/19/2014,Cash or cash equivalent,120609823,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2750.00,02/06/2014,Cash or cash equivalent,120608561,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1250.00,11/24/2014,Cash or cash equivalent,120605793,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,11725.00,08/14/2014,Cash or cash equivalent,120612445,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,17310.00,09/30/2014,Cash or cash equivalent,120613067,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard ST,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1673.00,07/10/2014,Cash or cash equivalent,120606861,,,Miracle Mid EF,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/30/2014,Cash or cash equivalent,120600939,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,12/24/2014,Cash or cash equivalent,120600941,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,104.00,12/03/2014,Cash or cash equivalent,120599377,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4436.00,08/14/2014,Cash or cash equivalent,120610201,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,6820.00,03/06/2014,Cash or cash equivalent,120611327,,,Sure Scan PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/25/2014,Cash or cash equivalent,120600611,,,Educate,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/10/2014,Cash or cash equivalent,120599521,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1832.50,10/15/2014,Cash or cash equivalent,120607105,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,30.00,01/06/2014,Cash or cash equivalent,120598551,,,PainFree SST Protecta,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,10272.00,04/25/2014,Cash or cash equivalent,120612239,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,9075.00,02/06/2014,Cash or cash equivalent,120611997,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1426.00,07/10/2014,Cash or cash equivalent,120606263,,,Miracle Mid EF,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2375.00,10/20/2014,Cash or cash equivalent,120608027,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/26/2014,Cash or cash equivalent,120600951,,,ICY AVNRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/10/2014,Cash or cash equivalent,120599551,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,5000.00,02/13/2014,In-kind items and services,120610529,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,18964.50,08/06/2014,Cash or cash equivalent,120613193,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,04/28/2014,Cash or cash equivalent,120600649,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,330.00,04/03/2014,Cash or cash equivalent,120601513,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4400.00,03/18/2014,Cash or cash equivalent,120610177,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2375.00,10/20/2014,Cash or cash equivalent,120608029,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,06/30/2014,Cash or cash equivalent,120599499,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,07/25/2014,Cash or cash equivalent,120599503,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2833.00,10/02/2014,Cash or cash equivalent,120608683,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1.00,02/18/2014,In-kind items and services,120598329,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,18964.50,08/06/2014,Cash or cash equivalent,120613195,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,33797.00,02/14/2014,Cash or cash equivalent,120613811,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,10272.00,04/25/2014,Cash or cash equivalent,120612241,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,7771.00,06/03/2014,Cash or cash equivalent,120611615,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,10540.00,02/05/2014,Cash or cash equivalent,120612305,,,Sure Scan PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/10/2014,Cash or cash equivalent,120599549,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,06/30/2014,Cash or cash equivalent,120599501,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,06/30/2014,Cash or cash equivalent,120599517,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme ST,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2500.00,04/14/2014,Cash or cash equivalent,120608207,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,07/10/2014,Cash or cash equivalent,120600801,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,11725.00,03/19/2014,Cash or cash equivalent,120612447,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,364.00,05/29/2014,Cash or cash equivalent,120601755,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,67209.50,05/27/2014,Cash or cash equivalent,120614195,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,67209.50,05/27/2014,Cash or cash equivalent,120614197,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,09/17/2014,Cash or cash equivalent,120600723,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,09/17/2014,Cash or cash equivalent,120600725,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3219.00,10/23/2014,Cash or cash equivalent,120609103,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1222.00,10/29/2014,Cash or cash equivalent,120605747,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,13771.00,01/09/2014,Cash or cash equivalent,120612717,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard ST,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1600.00,06/25/2014,Cash or cash equivalent,120606699,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,33797.00,02/14/2014,Cash or cash equivalent,120613809,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2500.00,05/09/2014,Cash or cash equivalent,120608257,,,ICY AVNRT,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard ST,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1650.00,10/07/2014,Cash or cash equivalent,120606833,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,PO Box 65433,,West Des Moines,50265,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,745.00,03/12/2014,Cash or cash equivalent,120603835,,,CRYSTAL AF,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard ST,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2710.00,01/23/2014,Cash or cash equivalent,120608531,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,750.00,02/25/2014,Cash or cash equivalent,120603849,,,Educate,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3982.00,08/19/2014,Cash or cash equivalent,120609821,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,17310.00,09/30/2014,Cash or cash equivalent,120613065,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4436.00,08/14/2014,Cash or cash equivalent,120610199,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,7771.00,06/03/2014,Cash or cash equivalent,120611617,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,5289.00,02/10/2014,Cash or cash equivalent,120610693,,,Educate,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4404.00,03/24/2014,Cash or cash equivalent,120610179,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,5440.00,01/06/2014,Cash or cash equivalent,120610781,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1832.50,10/15/2014,Cash or cash equivalent,120607107,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2330.00,01/23/2014,Cash or cash equivalent,120607955,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,6950.00,10/07/2014,Cash or cash equivalent,120611365,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,9075.00,02/06/2014,Cash or cash equivalent,120611999,,,CoreValve U S IDE,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard ST,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1050.00,01/21/2014,Cash or cash equivalent,120605303,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/10/2014,Cash or cash equivalent,120599523,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,1854.17,07/15/2014,Cash or cash equivalent,120568075,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,3330.00,05/21/2014,Cash or cash equivalent,120684499,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,1365.00,10/28/2014,Cash or cash equivalent,120567935,,,ISPR SNS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,125.00,01/30/2014,Cash or cash equivalent,120567261,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,682.50,04/08/2014,Cash or cash equivalent,120567641,,,ISPR Infusion,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,9480.00,01/16/2014,Cash or cash equivalent,120612099,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,1371.48,01/16/2014,Cash or cash equivalent,120683869,,,P03 03 PRESTIGE LP,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,11974.00,02/11/2014,Cash or cash equivalent,120568777,,,ISPR SNS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,187.50,02/06/2014,Cash or cash equivalent,120567303,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,144.00,11/12/2014,Cash or cash equivalent,120567277,,,ISPR SCS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,185.00,08/14/2014,Cash or cash equivalent,120567299,,,ISPR SNS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,2000.00,12/02/2014,Cash or cash equivalent,120568123,,,InterStim Cycling,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,341.25,08/12/2014,Cash or cash equivalent,120682855,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,6573.00,02/11/2014,Cash or cash equivalent,120568587,,,ISPR SCS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,780.00,08/12/2014,Cash or cash equivalent,120683337,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,"Onyx Pharmaceuticals, Inc., an Amgen subsidiary",100000000276,"Onyx Pharmaceuticals, Inc., an Amgen subsidiary",CA,62316.00,11/05/2014,In-kind items and services,132195280,Kyprolis,,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,195.00,09/10/2014,Cash or cash equivalent,120682409,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,618.00,05/15/2014,Cash or cash equivalent,120567613,,,ISPR SCS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,1000.01,01/30/2014,Cash or cash equivalent,120567791,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,12800.00,05/12/2014,Cash or cash equivalent,120568795,,,ISPR SNS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,625.00,01/30/2014,Cash or cash equivalent,120567617,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,4375.00,08/14/2014,Cash or cash equivalent,120568421,,,InterStim Cycling,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,62.50,01/30/2014,Cash or cash equivalent,120567193,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,750.00,03/03/2014,Cash or cash equivalent,120567665,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,805.00,06/12/2014,Cash or cash equivalent,120567689,,,ISPR SNS,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,125.00,04/08/2014,Cash or cash equivalent,120567263,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,1350 Beardshear Hall,,Ames,50011,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,390.00,09/10/2014,Cash or cash equivalent,120682903,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2000.00,08/27/2014,Cash or cash equivalent,120607437,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3300.00,10/29/2014,Cash or cash equivalent,164126812,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,West Des Moines,50266,,,Astellas Pharma Global Development,100000005406,Astellas Pharma Global Development,IL,22562.00,02/13/2014,Cash or cash equivalent,172024014,Xtandi,,A Randomized Double Blind Phase II Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,300.00,04/16/2014,Cash or cash equivalent,164126780,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,7180.00,05/07/2014,Cash or cash equivalent,164126820,,,SCORE,,
Non-covered Recipient Entity,,,,,,,450 Laurel St Ste A,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,3750.00,02/06/2014,Cash or cash equivalent,173835914,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Non-covered Recipient Entity,,,,,,,1301 PENNSYLVANIA AVE STE 411,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,350.00,11/12/2014,Cash or cash equivalent,164131880,,,OPTIMUM - LEAD REGISTRY,,
Non-covered Recipient Entity,,,,,,,1301 PENNSYLVANIA AVE STE 411,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,600.00,01/15/2014,Cash or cash equivalent,164131872,,,OPTIMUM - LEAD REGISTRY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,300.00,07/23/2014,Cash or cash equivalent,164126804,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,8950.00,01/29/2014,Cash or cash equivalent,164126816,,,SCORE,,
Non-covered Recipient Entity,,,,,,,450 Laurel St Ste A,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,2500.00,10/09/2014,Cash or cash equivalent,173841186,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3860.00,07/16/2014,Cash or cash equivalent,164126800,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,4160.00,08/06/2014,Cash or cash equivalent,164126824,,,SCORE,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,7260.00,12/03/2014,Cash or cash equivalent,164126828,,,SCORE,,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3730.00,01/22/2014,Cash or cash equivalent,164126792,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2850.00,04/23/2014,Cash or cash equivalent,164126788,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,300.00,10/22/2014,Cash or cash equivalent,164126808,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,490.50,10/03/2014,In-kind items and services,175618232,,,A Phase I Study of MLN6907 in Patients With Metastatic Colorectal,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,150.00,01/22/2014,Cash or cash equivalent,164126796,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,1002 4TH AVE SE,,CEDAR RAPIDS,52403,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,200.00,08/06/2014,Cash or cash equivalent,164124756,,,QUADRIPOLAR PACING PAS,,
Non-covered Recipient Entity,,,,,,,202 10TH ST S E,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,5141.24,03/24/2014,Cash or cash equivalent,130060861,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,9090.00,08/01/2014,Cash or cash equivalent,130062283,Neulasta,,FN Prophylaxis in breast cancer and NHL Cabs,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,SUITE 165,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1370.00,03/25/2014,In-kind items and services,130060961,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,12875.00,02/21/2014,Cash or cash equivalent,175618234,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,202 10TH ST S E,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,508.82,01/02/2014,Cash or cash equivalent,130060859,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,"200 HAWKINS DR, SE 313 GH",,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,85.83,02/25/2014,In-kind items and services,130066939,Aranesp,,NSCLC,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,9928.00,02/03/2014,Cash or cash equivalent,175618236,VELCADE,,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,678.00,01/06/2014,Cash or cash equivalent,130059913,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,117.00,03/31/2014,Cash or cash equivalent,178511254,,,HYD3003,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,20348.92,05/12/2014,Cash or cash equivalent,178511260,,,HYD3003,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,36.00,03/31/2014,Cash or cash equivalent,178511252,,,HYD3003,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702-5014,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,43089.53,01/01/2014,In-kind items and services,174359700,ILARIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,3530 W 4TH ST,,WATERLOO,50701-4503,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1856.77,03/03/2014,Cash or cash equivalent,174394750,ZOMETA,,A PROSPECTIVE RANDOMIZED DOUBLE BLIND MULTI CENTER COMPARATIVE 3 ARM TRIAL EFFICACY AND SAFETY OF ZOLEDRONIC ACID 4MG MONTHLY VS 3 MONTHLY VS PLACEBO AFTER UP TO 12 MONTHS OF TREATMENT WITH ZOLEDRONIC ACID IN PATIENTS WITH BONE LESIONS FROM MULTIPLE MYELOMA OR BREAST CANCER,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE CC10,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,51186.10,01/01/2014,In-kind items and services,174358124,TOBI PODHALER,,A 24 WEEK OPEN LABEL PARALLEL GROUP INTERVENTIONAL PHASE IV STUDY COMPARING TOBRAMYCIN INHALATION POWDER TIP ADMINISTERED ONCE DAILY CONTINUOUSLY VERSUS TIP ADMINISTERED BID IN 28 DAY ON AND OR 28 DAY OFF CYCLES FOR THE TREATMENT OF PULMONARY PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR CANCER CENTER RESEARCH 11510,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,13323.97,07/30/2014,In-kind items and services,174372123,TASIGNA,,PHASE II STUDY OF MMR RATES FOLLOWING NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR FOUR AND A HALF FOR 1 VERSUS 2 YEARS,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE CC10,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,154.50,01/01/2014,In-kind items and services,174411485,ZYKADIA,,A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB,,
Non-covered Recipient Entity,,,,,,,11196 I PFP,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,NOVARTIS PHARMACEUTICALS CORPORATION,NJ,695.25,03/01/2014,In-kind items and services,189667270,ZYKADIA,,A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB,,
Non-covered Recipient Entity,,,,,,,210 E IOWA AVE,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,NOVARTIS PHARMACEUTICALS CORPORATION,NJ,321376.25,01/01/2014,In-kind items and services,189667124,FARYDAK,,EPIGENETIC MODIFICATION OF CHEMOSENSITIVITY AND APOPTOSIS IN METASTATIC MELANOMATREATMENT OF A RESISTANT DISEASE USING DECITABINE TEMOZOLOMIDE AND AND PANOBINOSTAT,,
Non-covered Recipient Entity,,,,,,,250 CEF,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,NOVARTIS PHARMACEUTICALS CORPORATION,NJ,22875.00,01/16/2014,Cash or cash equivalent,189667106,ZYKADIA,,A PHASE II MULTICENTER SINGLE ARM STUDY OF ORAL LDK378 IN CRIZOTINIB NAIVE ADULT PATIENTS WITH ALK ACTIVATED NON SMALL CELL LUNG CANCER,,
Non-covered Recipient Entity,,,,,,,11196 I PFP,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,NOVARTIS PHARMACEUTICALS CORPORATION,NJ,16931.95,02/14/2014,Cash or cash equivalent,189667268,ZYKADIA,,A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE A100,DES MOINES,50314-2610,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,13124.65,10/16/2014,Cash or cash equivalent,174372296,GILENYA,,A TWELVE MONTH PROSPECTIVE RANDOMIZED ACTIVE CONTROLLED OPEN LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,FL 2,AMES,50010-5400,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,5259.69,01/01/2014,In-kind items and services,174384776,ILARIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,Iowa City,52242-1009,,,"KCI USA, Inc",100000010396,"KCI USA, Inc",TX,800.00,08/06/2014,Cash or cash equivalent,188321186,,,Negative Pressure Wound Therapy to Prevent Post Operative Wound Complications Following Cesarean Delivery,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,3750.65,03/03/2014,Cash or cash equivalent,174388763,ZOMETA,,A PROSPECTIVE RANDOMIZED DOUBLE BLIND MULTI CENTER COMPARATIVE 3 ARM TRIAL EFFICACY AND SAFETY OF ZOLEDRONIC ACID 4MG MONTHLY VS 3 MONTHLY VS PLACEBO AFTER UP TO 12 MONTHS OF TREATMENT WITH ZOLEDRONIC ACID IN PATIENTS WITH BONE LESIONS FROM MULTIPLE MYELOMA OR BREAST CANCER,,
Non-covered Recipient Entity,,,,,,,1500 ASSOCIATES DR,,DUBUQUE,52002-2260,,,Novartis Pharmaceuticals Corporation,100000000228,NOVARTIS PHARMACEUTICALS CORPORATION,NJ,2149.93,01/15/2014,Cash or cash equivalent,189667250,ZOMETA,,A PROSPECTIVE RANDOMIZED DOUBLE BLIND MULTI CENTER COMPARATIVE 3 ARM TRIAL EFFICACY AND SAFETY OF ZOLEDRONIC ACID 4MG MONTHLY VS 3 MONTHLY VS PLACEBO AFTER UP TO 12 MONTHS OF TREATMENT WITH ZOLEDRONIC ACID IN PATIENTS WITH BONE LESIONS FROM MULTIPLE MYELOMA OR BREAST CANCER,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,3250.00,11/20/2014,Cash or cash equivalent,195453488,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,3800.00,03/12/2014,Cash or cash equivalent,195453496,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,100.00,08/06/2014,Cash or cash equivalent,195453492,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,4711.13,02/19/2014,Cash or cash equivalent,195453498,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,West Des Moines,50266,,,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,1626.00,01/16/2014,Cash or cash equivalent,173819425,Vesicare,,A Randomized Double Blind Parallel Placebo Controlled Phase 4 Multicenter Study to Assess Efficacy and Safety of VESIcare Solifenacin Succinate to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,7429.93,12/10/2014,Cash or cash equivalent,195453490,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010-3014,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,1102.88,02/19/2014,Cash or cash equivalent,195451780,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,300.00,07/30/2014,Cash or cash equivalent,195453494,Cometriq,,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib -XL184- Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,West Des Moines,50266,,,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,37453.00,11/20/2014,Cash or cash equivalent,173819572,Myrbetriq,,A Prospective Double Blind Randomized Two Period Crossover Multi Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects with Overactive Bladder OAB,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,3477.00,07/31/2014,Cash or cash equivalent,182068498,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Atrium Medical Corporation,100000010784,Atrium Medical Corporation,NH,495.00,01/08/2014,Cash or cash equivalent,189075304,,,ICARUS TRIAL,http://www.clinicaltrials.gov/ct2/show/NCT00593385?term=icarus&rank=4,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,376.56,06/18/2014,In-kind items and services,182068694,TUDORZA,,"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,3391.50,04/09/2014,Cash or cash equivalent,182068496,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,,CEDAR RAPIDS,52403-2414,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,5668.20,04/04/2014,Cash or cash equivalent,174383861,COSENTYX,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER STUDY OF SECUKINUMAB TO DEMONSTRATE THE EFFICACY AT 16 WEEKS AND TO ASSESS THE LONG TERM SAFETY TOLERABILITY AND EFFICACY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265-0433,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,14199.78,04/16/2014,Cash or cash equivalent,174371312,GILENYA,,LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,2034.96,03/18/2014,In-kind items and services,182068490,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,2048.16,01/22/2014,In-kind items and services,182068492,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,3306.00,05/30/2014,Cash or cash equivalent,182068494,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,9215.00,01/31/2014,Cash or cash equivalent,182068502,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,3195.25,03/20/2014,Cash or cash equivalent,174390252,EXJADE,,A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO,,
Non-covered Recipient Entity,,,,,,,1600 DIAMOND ST,,ONAWA,51040-1548,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,231.75,01/01/2014,In-kind items and services,174409458,EXJADE,,A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO,,
Non-covered Recipient Entity,,,,,,,3400 DEXTER CT,,DAVENPORT,52807,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,6000.00,05/29/2014,Cash or cash equivalent,182066188,LINZESS,,"PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH CHRONICCONSTIPATION AND PROMINENT ABDOMINAL BLOATING AT BASELINE",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,4539.68,04/28/2014,In-kind items and services,182068500,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1650.00,04/17/2014,Cash or cash equivalent,188213716,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1650.00,04/17/2014,Cash or cash equivalent,188213719,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,07/16/2014,Cash or cash equivalent,188216984,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1504.98,04/08/2014,In-kind items and services,188219726,LANTUS,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,911.90,06/18/2014,In-kind items and services,188204366,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.93,11/06/2014,In-kind items and services,188300884,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10.55,11/06/2014,In-kind items and services,188300888,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,99.62,11/20/2014,In-kind items and services,188301120,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1857.07,11/20/2014,In-kind items and services,188301122,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2810.00,05/22/2014,Cash or cash equivalent,188268548,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.90,02/25/2014,In-kind items and services,188241352,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,87.78,05/27/2014,In-kind items and services,188274766,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5400.00,03/26/2014,Cash or cash equivalent,188229854,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.95,08/26/2014,In-kind items and services,188293128,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6.24,04/24/2014,In-kind items and services,188238680,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST STE 201,,COUNCIL BLUFFS,51503,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,715.00,08/28/2014,Cash or cash equivalent,182044788,,,GRC55 Annual Adult Fluzone Study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,480.70,12/26/2014,In-kind items and services,188315250,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2600.00,06/30/2014,Cash or cash equivalent,188234900,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,30.00,06/17/2014,Cash or cash equivalent,188214382,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.07,11/20/2014,In-kind items and services,188301192,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.54,08/26/2014,In-kind items and services,188293808,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,89.25,04/24/2014,In-kind items and services,188285482,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,239.70,04/24/2014,In-kind items and services,188285486,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17.07,06/09/2014,In-kind items and services,188272918,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,09/25/2014,In-kind items and services,188290574,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.08,06/25/2014,In-kind items and services,188294166,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17.28,04/24/2014,In-kind items and services,188282520,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.15,07/28/2014,In-kind items and services,188287858,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1875.00,09/24/2014,Cash or cash equivalent,188308714,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3175.00,10/20/2014,Cash or cash equivalent,188308716,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4795.00,06/12/2014,Cash or cash equivalent,188268972,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,110.75,12/02/2014,In-kind items and services,188301270,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.50,09/25/2014,In-kind items and services,188290536,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.90,08/26/2014,In-kind items and services,188288956,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST STE 201,,COUNCIL BLUFFS,51503,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,75.00,09/24/2014,Cash or cash equivalent,182045166,,,GRC55 Annual Adult Fluzone Study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,200.00,04/17/2014,Cash or cash equivalent,188269520,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.75,11/22/2014,In-kind items and services,188307010,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,119.85,11/22/2014,In-kind items and services,188307016,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.17,01/28/2014,In-kind items and services,188275312,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8080.00,06/30/2014,Cash or cash equivalent,188237862,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,258.00,03/26/2014,In-kind items and services,188262706,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,174.80,04/24/2014,In-kind items and services,188285484,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6614.00,11/25/2014,Cash or cash equivalent,188264014,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.62,04/24/2014,In-kind items and services,188239366,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,443.40,01/28/2014,In-kind items and services,188288504,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3622.23,12/03/2014,In-kind items and services,188314728,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7500.00,10/20/2014,Cash or cash equivalent,188314008,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2859.00,12/11/2014,Cash or cash equivalent,188261274,,,Eff-Humalog vs U100 in Insulin Glargine T1DM patients-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.09,12/02/2014,In-kind items and services,188301258,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,32.75,12/02/2014,In-kind items and services,188301260,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,100.32,04/24/2014,In-kind items and services,188239222,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.25,12/02/2014,In-kind items and services,188301338,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.07,11/20/2014,In-kind items and services,188301194,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.20,07/28/2014,In-kind items and services,188283444,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37.62,10/28/2014,In-kind items and services,188309790,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,44.46,07/28/2014,In-kind items and services,188296714,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.30,09/25/2014,In-kind items and services,188290602,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.32,12/26/2014,In-kind items and services,188302238,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.54,07/28/2014,In-kind items and services,188296718,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.16,02/25/2014,In-kind items and services,188241350,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,40.56,10/28/2014,In-kind items and services,188311538,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1050.00,01/17/2014,Cash or cash equivalent,188208180,LANTUS,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.50,10/28/2014,In-kind items and services,188301956,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,19.25,12/02/2014,In-kind items and services,188301264,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,63.90,12/02/2014,In-kind items and services,188301266,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,131.58,04/24/2014,In-kind items and services,188282526,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,43.00,04/24/2014,In-kind items and services,188238684,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,152.95,09/25/2014,In-kind items and services,188290558,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2500.00,08/25/2014,Cash or cash equivalent,188314004,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,225.72,08/26/2014,In-kind items and services,188289338,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.90,12/26/2014,In-kind items and services,188315256,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1500.00,01/03/2014,Cash or cash equivalent,188230554,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.16,03/26/2014,In-kind items and services,188259736,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.80,05/27/2014,In-kind items and services,188251710,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,417 S EAST ST,,CORYDON,50060,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10564.00,08/20/2014,Cash or cash equivalent,188216745,LANTUS,,Diabetes FORWARD,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1685.55,02/25/2014,In-kind items and services,188205152,APIDRA,,A randomized  open-label  active-controlled  3-arm parallel-group  26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2888.00,03/13/2014,Cash or cash equivalent,188249946,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,41.08,02/25/2014,In-kind items and services,188243742,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1400.00,04/22/2014,Cash or cash equivalent,188260766,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3600.00,06/30/2014,Cash or cash equivalent,188260768,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,06/19/2014,Cash or cash equivalent,188226782,,,LT Safety-Treatment Extension Protocol-IV,,
Non-covered Recipient Entity,,,,,,,100 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,36546.90,02/04/2014,In-kind items and services,188221214,LANTUS,,Epidemiology of Diabetes Interventions and Complications,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,399.50,03/26/2014,In-kind items and services,188277192,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12137.00,07/01/2014,Cash or cash equivalent,188268544,,,Diabetes Lixisenatide LYXUMIA,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1010.00,01/28/2014,Cash or cash equivalent,188271720,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,149.03,04/22/2014,In-kind items and services,188250713,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,64.50,06/25/2014,In-kind items and services,188255872,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,62.70,02/25/2014,In-kind items and services,188224200,RENVELA,,A 2-Week  Randomized  Placebo-Controlled  Fixed Dose Period Followed by a 6-Month  Single-Arm  Open-Label  Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidne,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3074.00,10/21/2014,Cash or cash equivalent,188264286,,,AN EXTENSION PROTOCOL FOR MULTIPLE SCLEROSIS PATIENTS WHO PARTICIPATED IN GENZYME SPONSORED STUDIES OF ALEMTUZUMAB  E.G. CAMMS223  CAMMS323 OR CAMMS32400507,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,26.00,08/26/2014,In-kind items and services,188288942,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.50,03/26/2014,In-kind items and services,188277188,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.62,02/25/2014,In-kind items and services,188278458,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9.36,06/25/2014,In-kind items and services,188255868,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6910.00,10/02/2014,Cash or cash equivalent,188234170,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,64.50,02/25/2014,In-kind items and services,188240024,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3398.00,12/02/2014,Cash or cash equivalent,188260478,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37.50,05/27/2014,In-kind items and services,188270926,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10.00,06/03/2014,Cash or cash equivalent,188268632,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,81.30,06/25/2014,In-kind items and services,188256634,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,470.00,04/17/2014,Cash or cash equivalent,188213724,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2008.00,01/28/2014,Cash or cash equivalent,188298920,,,CAMMS Extension study3,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,117.96,06/25/2014,In-kind items and services,188256314,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.23,03/26/2014,In-kind items and services,188260064,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,62.70,01/28/2014,In-kind items and services,188274860,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,357.35,08/20/2014,In-kind items and services,188204554,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,417 S EAST ST,,CORYDON,50060,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,14256.00,03/05/2014,Cash or cash equivalent,188207480,LANTUS,,Longitudinal  Non-Interventional Study in Primary Care Settings to Assess Practice Patterns  Patient Experiences  and Outcomes in the Management of Type 2 Diabetes Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,64.75,01/28/2014,In-kind items and services,188275310,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.00,03/26/2014,In-kind items and services,188266412,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.56,06/25/2014,In-kind items and services,188255874,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,81.30,04/24/2014,In-kind items and services,188239362,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,401.28,02/25/2014,In-kind items and services,188243744,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,393.20,02/25/2014,In-kind items and services,188243748,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.98,02/25/2014,In-kind items and services,188243750,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,56.75,01/28/2014,In-kind items and services,188244004,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.30,03/26/2014,In-kind items and services,188277194,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.27,03/26/2014,In-kind items and services,188260132,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,81.30,03/26/2014,In-kind items and services,188277482,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.20,02/25/2014,In-kind items and services,188243740,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,107.50,08/26/2014,In-kind items and services,188288950,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,119.85,10/28/2014,In-kind items and services,188312618,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,393.20,10/28/2014,In-kind items and services,188313180,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.75,08/26/2014,In-kind items and services,188293126,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5125.00,12/23/2014,Cash or cash equivalent,188309250,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.90,07/28/2014,In-kind items and services,188294824,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5375.00,11/24/2014,Cash or cash equivalent,188314086,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,38.25,05/27/2014,In-kind items and services,188292076,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.30,11/22/2014,In-kind items and services,188309538,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,23.40,03/26/2014,In-kind items and services,188262704,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.90,07/28/2014,In-kind items and services,188296442,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,86.00,10/28/2014,In-kind items and services,188309794,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,196.60,11/22/2014,In-kind items and services,188307644,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.25,12/02/2014,In-kind items and services,188301334,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.30,11/22/2014,In-kind items and services,188307022,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,162.24,11/22/2014,In-kind items and services,188307036,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,18.20,04/24/2014,In-kind items and services,188282106,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.20,02/25/2014,In-kind items and services,188241344,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,41.60,02/25/2014,In-kind items and services,188241346,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.60,02/25/2014,In-kind items and services,188297490,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1050.00,01/17/2014,Cash or cash equivalent,188208182,LANTUS,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.80,04/24/2014,In-kind items and services,188282004,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.65,04/24/2014,In-kind items and services,188282006,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.81,01/28/2014,In-kind items and services,188288256,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.23,08/26/2014,In-kind items and services,188289792,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5100.00,08/04/2014,Cash or cash equivalent,188314002,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2.34,03/26/2014,In-kind items and services,188262710,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,50.16,04/24/2014,In-kind items and services,188238682,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,542.20,09/15/2014,In-kind items and services,188204446,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,86.00,06/25/2014,In-kind items and services,188256312,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2325.00,12/16/2014,In-kind items and services,188300422,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,133.70,02/25/2014,In-kind items and services,188297434,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6.97,11/20/2014,In-kind items and services,188301108,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,40.86,11/20/2014,In-kind items and services,188301112,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,53.07,11/20/2014,In-kind items and services,188301124,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.00,12/18/2014,In-kind items and services,188300494,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,700.00,11/25/2014,Cash or cash equivalent,188217760,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,700.00,11/25/2014,Cash or cash equivalent,188217764,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,112.86,04/24/2014,In-kind items and services,188282108,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,107.50,04/24/2014,In-kind items and services,188282110,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,40.65,07/28/2014,In-kind items and services,188296716,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,42.80,04/24/2014,In-kind items and services,188237532,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.50,11/22/2014,In-kind items and services,188310576,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1050.00,01/17/2014,Cash or cash equivalent,188208184,LANTUS,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1650.00,04/17/2014,Cash or cash equivalent,188213714,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,470.00,04/17/2014,Cash or cash equivalent,188213727,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,470.00,04/17/2014,Cash or cash equivalent,188213730,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6335.00,02/11/2014,Cash or cash equivalent,188249394,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.82,04/24/2014,In-kind items and services,188282114,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11420.00,04/09/2014,Cash or cash equivalent,188235938,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.30,12/26/2014,In-kind items and services,188304230,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.64,08/26/2014,In-kind items and services,188289346,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,131.10,11/22/2014,In-kind items and services,188307494,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.25,12/02/2014,In-kind items and services,188301336,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD STE 100,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,150.00,06/04/2014,Cash or cash equivalent,188206500,DOCETAXEL,,A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide  TAC  versus Doxorubicin and Cyclophosphamide Followed by Docetaxel  AC- T  as Adjuvant Treatment of Operable Breast Cancer HER2NEU Negative Patients with Positive Axillary Lymph Nodes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,500.00,11/24/2014,Cash or cash equivalent,188308718,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,121.95,01/28/2014,In-kind items and services,188288188,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,67.57,12/02/2014,In-kind items and services,188301262,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5210.00,04/08/2014,Cash or cash equivalent,188248760,,,6 month Lantus U100 vs U300 in T2DM patients on Basal-Bolus,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13575.00,09/24/2014,Cash or cash equivalent,188314006,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.30,08/26/2014,In-kind items and services,188293124,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.32,11/22/2014,In-kind items and services,188301472,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,144.92,11/20/2014,In-kind items and services,188301118,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,125.40,10/28/2014,In-kind items and services,188313136,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.30,12/26/2014,In-kind items and services,188315314,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,505.62,06/11/2014,In-kind items and services,188219174,LANTUS,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,417 S EAST ST,,CORYDON,50060,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,08/08/2014,Cash or cash equivalent,188216348,LANTUS,,Diabetes FORWARD,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,01/17/2014,Cash or cash equivalent,188208188,LANTUS,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.08,12/26/2014,In-kind items and services,188304588,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7300.00,03/03/2014,Cash or cash equivalent,188229852,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,133.38,08/26/2014,In-kind items and services,188289538,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.27,07/28/2014,In-kind items and services,188296440,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.65,12/26/2014,In-kind items and services,188315240,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,911.90,06/18/2014,In-kind items and services,188204394,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.35,10/28/2014,In-kind items and services,188312068,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,43.00,08/26/2014,In-kind items and services,188293810,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,275.24,08/26/2014,In-kind items and services,188293812,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,224.00,12/16/2014,In-kind items and services,188300420,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,3616 ADMINISTRATIVE SERVICES BLDG,,AMES,50011,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,14491.00,04/15/2014,Cash or cash equivalent,188300638,,,Eliglustat ENCORE GZGD02607,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,44.46,04/24/2014,In-kind items and services,188282522,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2.16,04/24/2014,In-kind items and services,188282528,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1415 WOODLAND AVE STE 218,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.70,07/28/2014,In-kind items and services,188276566,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.54,03/26/2014,In-kind items and services,188277484,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.55,01/28/2014,In-kind items and services,188275770,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,56.75,06/25/2014,In-kind items and services,188258748,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,65.79,01/28/2014,In-kind items and services,188244494,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2250.00,06/02/2014,Cash or cash equivalent,188214294,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.08,03/26/2014,In-kind items and services,188260062,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,77.60,06/09/2014,In-kind items and services,188273338,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7032.00,09/02/2014,Cash or cash equivalent,188233792,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12900.00,04/22/2014,Cash or cash equivalent,188234870,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,07/16/2014,Cash or cash equivalent,188216980,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,07/16/2014,Cash or cash equivalent,188216982,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.45,06/25/2014,In-kind items and services,188256636,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,319.00,06/06/2014,In-kind items and services,188265086,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,42.80,03/26/2014,In-kind items and services,188266414,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6.48,02/25/2014,In-kind items and services,188278454,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,133.38,02/25/2014,In-kind items and services,188278456,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,14.52,08/26/2014,In-kind items and services,188288944,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2.60,08/26/2014,In-kind items and services,188288954,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.40,10/28/2014,In-kind items and services,188312608,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.07,11/20/2014,In-kind items and services,188301200,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,417 S EAST ST,,CORYDON,50060,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,08/08/2014,Cash or cash equivalent,188216342,LANTUS,,Diabetes FORWARD,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2652.65,12/02/2014,In-kind items and services,188220614,LANTUS,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,235.92,01/28/2014,In-kind items and services,188275768,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.90,01/28/2014,In-kind items and services,188275774,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.50,02/25/2014,In-kind items and services,188224202,RENVELA,,A 2-Week  Randomized  Placebo-Controlled  Fixed Dose Period Followed by a 6-Month  Single-Arm  Open-Label  Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidne,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,64.20,05/27/2014,In-kind items and services,188270928,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9930.00,09/22/2014,Cash or cash equivalent,188303960,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,07/28/2014,In-kind items and services,188283446,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.52,07/28/2014,In-kind items and services,188283448,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.65,01/28/2014,In-kind items and services,188275776,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,41.60,03/26/2014,In-kind items and services,188259796,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.90,09/25/2014,In-kind items and services,188290580,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,34.05,07/28/2014,In-kind items and services,188276306,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,107.00,02/25/2014,In-kind items and services,188244706,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8125.00,09/02/2014,Cash or cash equivalent,188233432,,,Diabetes Lixisenatide LYXUMIA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.96,06/25/2014,In-kind items and services,188256308,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,75.24,06/25/2014,In-kind items and services,188256310,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.54,01/28/2014,In-kind items and services,188244496,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.52,01/28/2014,In-kind items and services,188275772,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.41,06/09/2014,In-kind items and services,188272388,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,486.72,01/28/2014,In-kind items and services,188275314,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.45,01/28/2014,In-kind items and services,188275316,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.87,11/20/2014,In-kind items and services,188301114,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,27.92,11/20/2014,In-kind items and services,188301116,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.20,01/28/2014,In-kind items and services,188275762,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1832.78,12/02/2014,In-kind items and services,188314702,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,15.12,04/24/2014,In-kind items and services,188239360,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,07/08/2014,Cash or cash equivalent,188268682,,,Diabetes Lixisenatide LYXUMIA,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.85,03/26/2014,In-kind items and services,188277190,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,45.40,03/26/2014,In-kind items and services,188257564,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,125.40,08/26/2014,In-kind items and services,188288948,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,86.00,03/26/2014,In-kind items and services,188259732,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,36957.00,07/03/2014,Cash or cash equivalent,188268330,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,336.90,12/02/2014,In-kind items and services,188301268,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.08,01/28/2014,In-kind items and services,188275764,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9000.00,05/23/2014,Cash or cash equivalent,188234898,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,275.24,03/26/2014,In-kind items and services,188262708,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,155.00,08/19/2014,Cash or cash equivalent,188216080,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2760.00,08/05/2014,Cash or cash equivalent,188298928,,,CAMMS Extension study3,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,23.92,08/26/2014,In-kind items and services,188289336,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,08/26/2014,In-kind items and services,188289342,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.32,10/28/2014,In-kind items and services,188309798,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.24,07/28/2014,In-kind items and services,188296436,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,218.50,11/22/2014,In-kind items and services,188302246,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.32,07/28/2014,In-kind items and services,188296712,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,786.40,02/25/2014,In-kind items and services,188241348,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.96,06/25/2014,In-kind items and services,188294162,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,162.60,06/25/2014,In-kind items and services,188294164,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10950.00,12/23/2014,Cash or cash equivalent,188309058,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,127.50,02/25/2014,In-kind items and services,188297492,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,109.25,02/25/2014,In-kind items and services,188297494,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9.72,01/28/2014,In-kind items and services,188288186,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,18.26,11/06/2014,In-kind items and services,188300886,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM  LixiLan-O,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,600.00,03/26/2014,Cash or cash equivalent,188230558,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.50,12/26/2014,In-kind items and services,188304512,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,45.40,08/26/2014,In-kind items and services,188298044,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.82,06/25/2014,In-kind items and services,188256316,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,471.00,05/06/2014,Cash or cash equivalent,188268496,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,28.07,11/20/2014,In-kind items and services,188301110,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,70.00,12/18/2014,In-kind items and services,188300492,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.00,12/18/2014,In-kind items and services,188300496,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37.62,06/25/2014,In-kind items and services,188255870,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,357.35,08/20/2014,In-kind items and services,188204560,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,01/17/2014,Cash or cash equivalent,188208190,LANTUS,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3600.00,02/04/2014,Cash or cash equivalent,188226448,,,LT Safety-Treatment Extension Protocol-IV,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7498.53,12/03/2014,In-kind items and services,188220676,LANTUS,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1907.25,04/09/2014,Cash or cash equivalent,192034426,,,,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,24.00,05/20/2014,Cash or cash equivalent,192134560,,,,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.00,04/24/2014,In-kind items and services,188237530,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.30,04/24/2014,In-kind items and services,188237534,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.17,05/27/2014,In-kind items and services,188251714,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,01/17/2014,Cash or cash equivalent,188208186,LANTUS,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3658.00,03/04/2014,Cash or cash equivalent,188250050,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,600.00,10/16/2014,Cash or cash equivalent,188226240,,,LT Safety-Treatment Extension Protocol-IV,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,357.35,05/27/2014,In-kind items and services,188204322,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5300.00,03/03/2014,Cash or cash equivalent,188230556,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.04,04/24/2014,In-kind items and services,188238686,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,244.75,12/16/2014,In-kind items and services,188300418,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,700.00,11/25/2014,Cash or cash equivalent,188217762,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8142.00,05/15/2014,Cash or cash equivalent,188298924,,,CAMMS Extension study3,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,357.35,04/15/2014,In-kind items and services,188204266,APIDRA,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients  GetGoal Duo-2,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2290.77,02/25/2014,In-kind items and services,188205054,APIDRA,,A randomized  open-label  active-controlled  3-arm parallel-group  26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2035.00,04/03/2014,Cash or cash equivalent,192034458,,,,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4000.00,05/13/2014,Cash or cash equivalent,188248494,,,Diabetes Lixisenatide LYXUMIA,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2610.00,02/25/2014,Cash or cash equivalent,192034450,,,,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,675.00,03/13/2014,Cash or cash equivalent,192034442,,,,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2500.00,05/01/2014,Cash or cash equivalent,192034466,,,,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4175.00,11/04/2014,Cash or cash equivalent,188262150,,,Eff-SC-Combo Lixi U100 vs Lixi vs Lantus-on top of metformin,,
Non-covered Recipient Entity,,,,,,,100 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22360.98,02/04/2014,In-kind items and services,188221512,LANTUS,,Epidemiology of Diabetes Interventions and Complications,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,64.75,03/26/2014,In-kind items and services,188263844,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,301.00,02/25/2014,In-kind items and services,188243746,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,675.00,03/13/2014,Cash or cash equivalent,192034432,,,,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,4102.00,10/30/2014,Cash or cash equivalent,192117249,,,,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6.48,03/26/2014,In-kind items and services,188277480,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2500.00,05/01/2014,Cash or cash equivalent,192034474,,,,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,550.48,03/26/2014,In-kind items and services,188259734,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.32,01/28/2014,In-kind items and services,188244492,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,FAX,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,117.45,05/27/2014,In-kind items and services,188270930,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2785.25,12/02/2014,In-kind items and services,188301272,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.00,11/22/2014,In-kind items and services,188307428,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.07,11/20/2014,In-kind items and services,188301196,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.07,11/20/2014,In-kind items and services,188301198,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,63.75,12/26/2014,In-kind items and services,188315244,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,131.58,04/24/2014,In-kind items and services,188239364,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,06/17/2014,Cash or cash equivalent,188214428,LANTUS,,Compaison of New Formulation of Insulin Glargine with Lantus in Paitent with Type 2 Diabestes on Non-insulin Antidiabetic Therapy  Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,44.34,06/25/2014,In-kind items and services,188259064,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,258.00,08/26/2014,In-kind items and services,188289340,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.00,06/25/2014,In-kind items and services,188294758,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,417 S EAST ST,,CORYDON,50060,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,700.00,08/27/2014,Cash or cash equivalent,188216236,LANTUS,,Diabetes FORWARD,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.90,08/26/2014,In-kind items and services,188293818,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.08,09/25/2014,In-kind items and services,188287382,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,203.25,07/28/2014,In-kind items and services,188296438,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.60,11/22/2014,In-kind items and services,188307008,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,133.70,11/22/2014,In-kind items and services,188307018,,,Efficacy and Safety of Insulin Glargine  Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1.25,12/02/2014,In-kind items and services,188301340,,,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.90,02/25/2014,In-kind items and services,188242032,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,990.00,05/06/2014,Cash or cash equivalent,188269392,,,Eff-SC-Efficacy safety in Elderly,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,511.16,08/26/2014,In-kind items and services,188288952,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,103.10,09/25/2014,In-kind items and services,188290576,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,81.30,04/24/2014,In-kind items and services,188282524,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,275.24,04/24/2014,In-kind items and services,188282112,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.96,08/26/2014,In-kind items and services,188289722,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,"5880 University Ave, 208",,West Des Moines,50266,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,500.00,08/19/2014,Cash or cash equivalent,197002876,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions ORBIT II. This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,9431.35,05/16/2014,Cash or cash equivalent,197003902,,,CLARITY,,"Complete Lesion Assessment With ffR and IVUS TechnologY CLARITY I. CLARITY I is a pilot study to identify the clinically appropriate endpoints of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia CLI."
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,9629.10,02/11/2014,Cash or cash equivalent,197003298,,,CLARITY,,"Complete Lesion Assessment With ffR and IVUS TechnologY CLARITY I. CLARITY I is a pilot study to identify the clinically appropriate endpoints of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia CLI."
Non-covered Recipient Entity,,,,,,,1111 6th Avenue East Tower Suite A100,,Des Moines,50314,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1131.00,06/10/2014,Cash or cash equivalent,192136234,,,,,
Non-covered Recipient Entity,,,,,,,"5880 UNIVERSITY AVE, 208",,WEST DES MOINES,50266,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,1500.00,01/14/2014,Cash or cash equivalent,197003754,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions ORBIT II. This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Non-covered Recipient Entity,,,,,,,1622 East Lomard Street,,Davenport,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,2500.00,09/04/2014,Cash or cash equivalent,197003906,,,LIBERTY 360,,"LIBERTY 360 Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease PAD.  The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease PAD."
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,2829.65,11/25/2014,Cash or cash equivalent,197003910,,,CLARITY,,"Complete Lesion Assessment With ffR and IVUS TechnologY CLARITY I. CLARITY I is a pilot study to identify the clinically appropriate endpoints of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia CLI."
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,25.00,07/25/2014,Cash or cash equivalent,192134566,,,,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,23.00,02/07/2014,Cash or cash equivalent,192134552,,,,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,300.00,11/21/2014,Cash or cash equivalent,192368344,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,100.00,10/10/2014,Cash or cash equivalent,192368378,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,3000.00,12/05/2014,Cash or cash equivalent,192369056,,,ORTHOGHK3 SOW 3 Mallory Head Revision Stem,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,200.00,04/18/2014,Cash or cash equivalent,192368046,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,400.00,10/24/2014,Cash or cash equivalent,192368112,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,300.00,11/21/2014,Cash or cash equivalent,192368100,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,400.00,12/19/2014,Cash or cash equivalent,192368352,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,2000.00,05/01/2014,Cash or cash equivalent,192369048,,,ORTHOGHK3 SOW 3 Mallory Head Revision Stem,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,5000.00,05/22/2014,Cash or cash equivalent,192369058,,,ORTHOGHK3 SOW5 Vanguard Long Term 7 10 Year Follow Up,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,600.00,06/20/2014,Cash or cash equivalent,192368052,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,500.00,08/26/2014,Cash or cash equivalent,192368056,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,300.00,07/18/2014,Cash or cash equivalent,192368062,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,500.00,04/18/2014,Cash or cash equivalent,192368356,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,769.23,06/13/2014,In-kind items and services,196746084,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,769.23,05/28/2014,In-kind items and services,196748684,Aptiom,,Efficacy and Safety of Eslicarbazepine Acetate BIA 2 093 as Adjunctive Therapy for Refractory Partial Seizures in a Double Blind Randomised Placebo Controlled Parallel-Group Multicentre Clinical Trial,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,3104.64,02/28/2014,Cash or cash equivalent,196748502,Aptiom,,Efficacy and Safety of Eslicarbazepine Acetate BIA 2 093 as Adjunctive Therapy for Refractory Partial Seizures in a Double Blind Randomised Placebo Controlled Parallel-Group Multicentre Clinical Trial,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,769.23,12/05/2014,In-kind items and services,196747752,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,3252.48,05/28/2014,Cash or cash equivalent,196748682,Aptiom,,Efficacy and Safety of Eslicarbazepine Acetate BIA 2 093 as Adjunctive Therapy for Refractory Partial Seizures in a Double Blind Randomised Placebo Controlled Parallel-Group Multicentre Clinical Trial,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,769.23,04/04/2014,In-kind items and services,196745854,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,100.00,07/18/2014,Cash or cash equivalent,192368360,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,400.00,08/26/2014,Cash or cash equivalent,192368365,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,7500.00,05/01/2014,Cash or cash equivalent,192369064,,,ORTHOGHK3 Vanguard Midterm Publication and Echo Hip System White Paper,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,800.00,05/05/2014,Cash or cash equivalent,192368041,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,300.00,09/12/2014,Cash or cash equivalent,192368106,,,ORTHOCRK005 Vanguard Total Knee Mutli Center Data Collection,,
Non-covered Recipient Entity,,,,,,,701 10th Street SE,,CEDAR RAPIDS,52403,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,500.00,09/12/2014,Cash or cash equivalent,192368370,,,ORTHOCRROWG2 Regenerex Tibial Tray Multi Center Study,,
Non-covered Recipient Entity,,,,,,,8101 Birchwood Ct,Ste N,Johnston,50131,,,"Merz North America, Inc.",100000005377,"Merz Pharmaceuticals, LLC",NC,41565.00,01/15/2014,Cash or cash equivalent,198599206,Xeomin,,CD FLEX,,
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,8417.00,05/08/2014,Cash or cash equivalent,187570752,,,DU176b-E-U210,,
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,10930.50,08/14/2014,Cash or cash equivalent,187572044,,,DU176b-E-U210,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,03/26/2014,Cash or cash equivalent,163696022,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,450.00,04/16/2014,Cash or cash equivalent,163693424,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,150.00,03/11/2014,Cash or cash equivalent,163690518,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,04/17/2014,Cash or cash equivalent,163693446,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,324.66,04/18/2014,Cash or cash equivalent,163693458,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,439.60,04/07/2014,Cash or cash equivalent,163695302,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,425.46,01/24/2014,Cash or cash equivalent,163691902,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,04/04/2014,Cash or cash equivalent,163693734,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3405.00,05/26/2014,Cash or cash equivalent,163682150,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,125.00,03/17/2014,Cash or cash equivalent,163691636,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,75.00,02/06/2014,Cash or cash equivalent,163692692,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,380.38,05/12/2014,Cash or cash equivalent,163737974,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/22/2014,Cash or cash equivalent,163730002,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,278.92,01/30/2014,Cash or cash equivalent,163687786,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,515.60,07/16/2014,Cash or cash equivalent,163701960,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,5462.40,07/24/2014,Cash or cash equivalent,163682450,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,12/15/2014,Cash or cash equivalent,163710024,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,07/14/2014,Cash or cash equivalent,163736514,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,08/11/2014,Cash or cash equivalent,163705190,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,433.72,06/03/2014,Cash or cash equivalent,163696410,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,02/04/2014,Cash or cash equivalent,163692496,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,09/25/2014,Cash or cash equivalent,163733772,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,57.91,10/01/2014,Cash or cash equivalent,163684402,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,426.86,05/27/2014,Cash or cash equivalent,163697296,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/04/2014,Cash or cash equivalent,163710732,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,210.00,07/23/2014,Cash or cash equivalent,163703790,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,04/03/2014,Cash or cash equivalent,163694915,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,750.00,11/07/2014,Cash or cash equivalent,163733178,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1058.12,03/07/2014,Cash or cash equivalent,163692812,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,110.00,12/11/2014,Cash or cash equivalent,163711615,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,483.06,07/17/2014,Cash or cash equivalent,163681280,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,09/20/2014,Cash or cash equivalent,163703620,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,52.62,11/25/2014,Cash or cash equivalent,163688224,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,09/15/2014,Cash or cash equivalent,163705548,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,132.43,07/18/2014,Cash or cash equivalent,163681318,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,10/21/2014,Cash or cash equivalent,163707360,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,54.62,01/15/2014,Cash or cash equivalent,163729316,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/09/2014,Cash or cash equivalent,163683418,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/04/2014,Cash or cash equivalent,163707614,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,156.86,12/23/2014,Cash or cash equivalent,163709296,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3.30,05/20/2014,Cash or cash equivalent,163738924,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,BOSTON SCIENTIFIC CORPORATION,100000010636,"Atritech, Inc.",MN,600.00,01/13/2014,Cash or cash equivalent,131475986,,,PROSPECTIVE RANDOMIZED EVALUATION OF THE WATCHMAN LAA CLOSUR,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,945.00,06/13/2014,Cash or cash equivalent,196746082,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,BOSTON SCIENTIFIC CORPORATION,100000010636,"Atritech, Inc.",MN,7356.00,12/05/2014,Cash or cash equivalent,131475982,,,PROSPECTIVE RANDOMIZED EVALUATION OF THE WATCHMAN LAA CLOSUR,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,BOSTON SCIENTIFIC CORPORATION,100000010636,"Atritech, Inc.",MN,21904.00,01/13/2014,Cash or cash equivalent,131475984,,,PROSPECTIVE RANDOMIZED EVALUATION OF THE WATCHMAN LAA CLOSUR,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,06/27/2014,Cash or cash equivalent,163681852,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,462.97,02/26/2014,Cash or cash equivalent,163690850,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,150.00,12/30/2014,Cash or cash equivalent,163709856,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,75.00,02/21/2014,Cash or cash equivalent,163692744,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,154.03,11/24/2014,Cash or cash equivalent,163706852,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/01/2014,Cash or cash equivalent,163733478,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2702.70,04/16/2014,Cash or cash equivalent,163732008,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,17010.40,11/11/2014,Cash or cash equivalent,163705480,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,05/02/2014,Cash or cash equivalent,163731428,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,02/10/2014,Cash or cash equivalent,163739780,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,08/19/2014,Cash or cash equivalent,163709200,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,05/21/2014,Cash or cash equivalent,163739016,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,7.17,10/29/2014,Cash or cash equivalent,163684420,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,06/26/2014,Cash or cash equivalent,163738258,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,05/28/2014,Cash or cash equivalent,163697726,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1370.40,08/12/2014,Cash or cash equivalent,163742728,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,743.47,04/24/2014,Cash or cash equivalent,163681592,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/04/2014,Cash or cash equivalent,163711116,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,250.00,04/28/2014,Cash or cash equivalent,163694060,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,07/11/2014,Cash or cash equivalent,163742208,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,19329.60,08/18/2014,Cash or cash equivalent,163702906,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,65.08,09/18/2014,Cash or cash equivalent,163686080,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,200.00,04/08/2014,Cash or cash equivalent,163693578,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,12/08/2014,Cash or cash equivalent,163708020,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1907.90,08/22/2014,Cash or cash equivalent,163736918,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,05/28/2014,Cash or cash equivalent,163737914,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,207.27,06/19/2014,Cash or cash equivalent,163739180,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/23/2014,Cash or cash equivalent,163682064,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,07/07/2014,Cash or cash equivalent,163699672,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,2127.60,04/04/2014,Cash or cash equivalent,196745852,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,2835.00,12/05/2014,Cash or cash equivalent,196747750,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,769.23,02/28/2014,In-kind items and services,196748504,Aptiom,,Efficacy and Safety of Eslicarbazepine Acetate BIA 2 093 as Adjunctive Therapy for Refractory Partial Seizures in a Double Blind Randomised Placebo Controlled Parallel-Group Multicentre Clinical Trial,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,06/06/2014,Cash or cash equivalent,163739370,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/11/2014,Cash or cash equivalent,163706102,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,07/14/2014,Cash or cash equivalent,163680896,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,04/21/2014,Cash or cash equivalent,163694416,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,59.00,07/18/2014,Cash or cash equivalent,163699318,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,15545.70,09/25/2014,Cash or cash equivalent,163733666,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,09/03/2014,Cash or cash equivalent,163737418,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,06/24/2014,Cash or cash equivalent,163681834,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1000.00,07/23/2014,Cash or cash equivalent,163681888,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,306.86,06/24/2014,Cash or cash equivalent,163700942,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,270.00,09/03/2014,Cash or cash equivalent,163702430,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1567.70,10/08/2014,Cash or cash equivalent,163706590,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,500.00,06/11/2014,Cash or cash equivalent,163700141,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,14.34,02/24/2014,Cash or cash equivalent,163690070,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,06/05/2014,Cash or cash equivalent,163697376,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,06/10/2014,Cash or cash equivalent,163701460,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3.30,05/20/2014,Cash or cash equivalent,163710416,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,52.62,10/16/2014,Cash or cash equivalent,163686318,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,06/12/2014,Cash or cash equivalent,163738244,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/25/2014,Cash or cash equivalent,163680770,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,130.43,08/20/2014,Cash or cash equivalent,163685248,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,05/12/2014,Cash or cash equivalent,163741366,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,269.43,09/12/2014,Cash or cash equivalent,163684110,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,999.52,06/02/2014,Cash or cash equivalent,163682358,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,01/06/2014,Cash or cash equivalent,163729526,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,06/04/2014,Cash or cash equivalent,163701864,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,07/03/2014,Cash or cash equivalent,163701933,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,7519.20,09/18/2014,Cash or cash equivalent,163685888,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,996.45,03/24/2014,Cash or cash equivalent,163731558,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,7.17,10/15/2014,Cash or cash equivalent,163685558,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,05/13/2014,Cash or cash equivalent,163698576,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,74.70,02/28/2014,Cash or cash equivalent,163739798,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,11/03/2014,Cash or cash equivalent,163705426,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,04/15/2014,Cash or cash equivalent,163694960,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,08/18/2014,Cash or cash equivalent,163736594,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,156.44,10/07/2014,Cash or cash equivalent,163706370,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,08/19/2014,Cash or cash equivalent,163703500,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,590.00,05/29/2014,Cash or cash equivalent,163698292,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,02/18/2014,Cash or cash equivalent,163691772,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,500.00,12/12/2014,Cash or cash equivalent,163730708,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,250.00,01/14/2014,Cash or cash equivalent,163689120,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,42.50,09/02/2014,Cash or cash equivalent,163734032,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,156.86,09/30/2014,Cash or cash equivalent,163705754,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,125.00,04/30/2014,Cash or cash equivalent,163698726,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/03/2014,Cash or cash equivalent,163710554,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,270.00,08/11/2014,Cash or cash equivalent,163710622,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/15/2014,Cash or cash equivalent,163711852,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,57.91,08/21/2014,Cash or cash equivalent,163684332,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,102.15,09/26/2014,Cash or cash equivalent,163733240,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,07/16/2014,Cash or cash equivalent,163681124,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,08/22/2014,Cash or cash equivalent,163708736,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,240.00,05/14/2014,Cash or cash equivalent,163698586,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,240.00,09/25/2014,Cash or cash equivalent,163707695,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,08/13/2014,Cash or cash equivalent,163704990,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,720.00,07/04/2014,Cash or cash equivalent,163701944,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,244.08,08/28/2014,Cash or cash equivalent,163702980,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,156.86,09/29/2014,Cash or cash equivalent,163705344,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,64.34,03/24/2014,Cash or cash equivalent,163690326,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,175.00,03/31/2014,Cash or cash equivalent,163695444,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,08/25/2014,Cash or cash equivalent,163704284,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,118.00,10/10/2014,Cash or cash equivalent,163706934,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,402.83,07/24/2014,Cash or cash equivalent,163737258,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,52.62,11/12/2014,Cash or cash equivalent,163686180,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,253.72,08/01/2014,Cash or cash equivalent,163703632,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,295.40,01/29/2014,Cash or cash equivalent,163687424,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2000.00,05/26/2014,Cash or cash equivalent,163682770,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1593.60,09/29/2014,Cash or cash equivalent,163741492,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,03/27/2014,Cash or cash equivalent,163731776,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,246.86,05/22/2014,Cash or cash equivalent,163696888,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,200.00,03/04/2014,Cash or cash equivalent,163691980,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,03/07/2014,Cash or cash equivalent,163740744,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,06/20/2014,Cash or cash equivalent,163700353,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,09/10/2014,Cash or cash equivalent,163705064,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/02/2014,Cash or cash equivalent,163734000,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,09/30/2014,Cash or cash equivalent,163733992,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,68.08,07/14/2014,Cash or cash equivalent,163700438,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,07/11/2014,Cash or cash equivalent,163680706,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,09/20/2014,Cash or cash equivalent,163709242,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,13.42,11/26/2014,Cash or cash equivalent,163688786,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,02/19/2014,Cash or cash equivalent,163740812,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,06/11/2014,Cash or cash equivalent,163702210,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,250.00,05/11/2014,Cash or cash equivalent,163698760,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,461.72,06/17/2014,Cash or cash equivalent,163701118,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,04/24/2014,Cash or cash equivalent,163693312,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,09/12/2014,Cash or cash equivalent,163733548,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,253.72,05/06/2014,Cash or cash equivalent,163696646,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,63.00,07/03/2014,Cash or cash equivalent,163737646,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,04/16/2014,Cash or cash equivalent,163742376,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,04/18/2014,Cash or cash equivalent,163742384,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,04/22/2014,Cash or cash equivalent,163694612,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,04/14/2014,Cash or cash equivalent,163694378,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4801.60,11/05/2014,Cash or cash equivalent,163685016,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,13.42,12/29/2014,Cash or cash equivalent,163713838,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,180.00,07/31/2014,Cash or cash equivalent,163703440,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,12/02/2014,Cash or cash equivalent,163705728,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,09/04/2014,Cash or cash equivalent,163704120,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,283.72,08/29/2014,Cash or cash equivalent,163703366,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/30/2014,Cash or cash equivalent,163708770,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,06/27/2014,Cash or cash equivalent,163700587,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,09/22/2014,Cash or cash equivalent,163734276,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,06/30/2014,Cash or cash equivalent,163701164,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,30.00,09/08/2014,Cash or cash equivalent,163704500,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,34908.00,05/29/2014,Cash or cash equivalent,163698288,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,08/18/2014,Cash or cash equivalent,163704818,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,90.00,12/01/2014,Cash or cash equivalent,163705508,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1000.00,04/09/2014,Cash or cash equivalent,163693586,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,98.36,02/25/2014,Cash or cash equivalent,163690820,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4170.20,02/25/2014,Cash or cash equivalent,163690828,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,60.00,08/22/2014,Cash or cash equivalent,163705220,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,125.00,03/18/2014,Cash or cash equivalent,163691675,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,24.24,10/24/2014,Cash or cash equivalent,163707730,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,123.60,04/30/2014,Cash or cash equivalent,163732446,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,111.96,06/04/2014,Cash or cash equivalent,163738840,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,11/12/2014,Cash or cash equivalent,163705654,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,02/13/2014,Cash or cash equivalent,163741342,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,05/30/2014,Cash or cash equivalent,163741608,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/10/2014,Cash or cash equivalent,163733616,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,304.92,04/29/2014,Cash or cash equivalent,163694064,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,8.12,11/04/2014,Cash or cash equivalent,163705802,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,251.86,03/25/2014,Cash or cash equivalent,163690724,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,80.00,04/04/2014,Cash or cash equivalent,163742178,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,276.86,07/08/2014,Cash or cash equivalent,163700036,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,07/15/2014,Cash or cash equivalent,163701977,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,04/28/2014,Cash or cash equivalent,163742802,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,08/27/2014,Cash or cash equivalent,163730238,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,120.00,08/05/2014,Cash or cash equivalent,163702282,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,186.86,12/22/2014,Cash or cash equivalent,163708900,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,246.86,06/19/2014,Cash or cash equivalent,163699398,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,05/12/2014,Cash or cash equivalent,163698977,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,08/20/2014,Cash or cash equivalent,163736718,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,03/20/2014,Cash or cash equivalent,163742068,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,02/20/2014,Cash or cash equivalent,163739766,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,40.00,06/16/2014,Cash or cash equivalent,163738460,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/26/2014,Cash or cash equivalent,163712886,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,120.00,09/17/2014,Cash or cash equivalent,163710706,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,160.00,08/05/2014,Cash or cash equivalent,163680960,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2321.60,11/27/2014,Cash or cash equivalent,163688802,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,6.00,05/16/2014,Cash or cash equivalent,163710064,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,27.77,04/29/2014,Cash or cash equivalent,163732848,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,80.00,05/02/2014,Cash or cash equivalent,163742588,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,130.43,08/06/2014,Cash or cash equivalent,163680972,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,226.86,02/17/2014,Cash or cash equivalent,163690610,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,225.00,03/06/2014,Cash or cash equivalent,163692784,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,126.86,05/19/2014,Cash or cash equivalent,163698246,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1630.40,11/10/2014,Cash or cash equivalent,163729124,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4302.90,12/23/2014,Cash or cash equivalent,163731118,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2588.00,02/24/2014,Cash or cash equivalent,163741854,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,160.00,06/19/2014,Cash or cash equivalent,163681072,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,99.75,09/25/2014,In-kind items and services,210218490,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,11323.80,10/26/2014,Cash or cash equivalent,210218496,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,330.00,09/29/2014,In-kind items and services,210215442,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,1459.35,06/24/2014,In-kind items and services,210218478,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,608.92,06/29/2014,In-kind items and services,210218480,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,353.85,03/31/2014,In-kind items and services,210218482,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,1154.91,07/28/2014,In-kind items and services,210218486,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,252.90,07/10/2014,In-kind items and services,210215440,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,252.90,03/10/2014,In-kind items and services,210218492,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,255.00,01/01/2014,In-kind items and services,210215012,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,24238.80,07/27/2014,Cash or cash equivalent,210218484,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,322.00,08/14/2014,In-kind items and services,210218488,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,173.98,03/10/2014,In-kind items and services,210218494,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,717.54,11/24/2014,In-kind items and services,210218498,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3275,DES MOINES,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim b.v.,,7747.00,04/21/2014,Cash or cash equivalent,210218476,Tradjenta,,"CARMELINA. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1252.00,04/18/2014,Cash or cash equivalent,198280866,TECFIDERA,,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,310.00,12/01/2014,Cash or cash equivalent,198280906,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1000.00,12/04/2014,Cash or cash equivalent,198280917,TYSABRI,,TYSABRI Global Observational Program in Safety,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,2050.00,06/06/2014,Cash or cash equivalent,198280934,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,2250.00,09/30/2014,Cash or cash equivalent,198280846,TECFIDERA,,Dimethyl Fumarate DMF Observational Study,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,600.00,07/31/2014,Cash or cash equivalent,198280890,TYSABRI,,TYSABRI Global Observational Program in Safety,,
Non-covered Recipient Entity,,,,,,,1440 PLEASANT ST STE 1,,DES MOINES,50314-1728,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,423.00,12/19/2014,Cash or cash equivalent,198266792,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,4TH FL,CEDAR RAPIDS,52401,,,Stryker Corporation,100000010503,Stryker Corporation,MI,3665.00,07/09/2014,Cash or cash equivalent,204908074,,,Triathlon Cruciate Retaining CR Total Knee System Outcomes Study,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,635.00,07/28/2014,Cash or cash equivalent,198280832,TECFIDERA,,Dimethyl Fumarate DMF Observational Study,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,626.00,07/18/2014,Cash or cash equivalent,198280856,TECFIDERA,,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,3375.00,10/02/2014,Cash or cash equivalent,198280896,TYSABRI,,John Cunningham Virus JCV Antibody Study of Multiple Sclerosis MS Patients With Relapsing Forms of MS Receiving Treatment With Tysabri,,
Non-covered Recipient Entity,,,,,,,111 6TH AVE  Suite A100,,DES MOINES,50314,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1950.00,04/22/2014,Cash or cash equivalent,198280924,TYSABRI,,TYSABRI Global Observational Program in Safety,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,900.00,01/16/2014,Cash or cash equivalent,207669432,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,230 NE STREET,NULL,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,750.00,07/16/2014,Cash or cash equivalent,207753156,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,07/07/2014,Cash or cash equivalent,207791994,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,82.00,07/16/2014,Cash or cash equivalent,207774342,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,736.25,01/23/2014,Cash or cash equivalent,207669558,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1953.44,01/23/2014,Cash or cash equivalent,207574464,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,04/25/2014,Cash or cash equivalent,207578516,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,06/25/2014,Cash or cash equivalent,207745054,,,BIOTX RUN STUDY OPEN LABEL EXTENSION STUDY FOR PF00547659  OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,77.55,07/23/2014,In-kind items and services,207787788,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,18.00,02/19/2014,Cash or cash equivalent,207570298,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,07/23/2014,In-kind items and services,207753438,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2937.00,07/16/2014,Cash or cash equivalent,207797812,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,06/11/2014,Cash or cash equivalent,207731528,XELJANZ,,A LONG TERM OPEN LABEL FOLLOW UP STUDY OF TOFACITINIB  CP 690550  FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,04/30/2014,Cash or cash equivalent,207813638,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,04/30/2014,Cash or cash equivalent,207833252,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,300.00,01/15/2014,Cash or cash equivalent,207848590,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,04/30/2014,Cash or cash equivalent,207813670,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6057.05,12/17/2014,Cash or cash equivalent,208046084,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,500.00,12/04/2014,Cash or cash equivalent,208050168,BOSULIF,,A PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5326.00,08/21/2014,Cash or cash equivalent,207872944,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,11/13/2014,Cash or cash equivalent,207972122,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,938.13,11/13/2014,Cash or cash equivalent,207972144,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,11/03/2014,In-kind items and services,208020584,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,12/11/2014,Cash or cash equivalent,208018052,XELJANZ,,A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP MULTICENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP690550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHNS DISEASE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,11510 PRP  RESEARCH,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,11/01/2014,In-kind items and services,208048594,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Non-covered Recipient Entity,,,,,,,TIFFANY NEMECEK STE201,201 RIDGE STREET COUNCIL,BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,53.46,09/09/2014,In-kind items and services,207931944,PREVNAR  13,,Concomitant Administration of 13valent Pneumococcal Conjugate Vaccine 13vPnC With Influenza Vaccine in 23valent Pneumococcal Polysaccharide 23vPS Prevaccinated Adults,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1276.56,07/17/2014,Cash or cash equivalent,207759994,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,09/23/2014,Cash or cash equivalent,207919652,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF 04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207495030,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,Suite 201 201 Ridge Street,,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,05/21/2014,In-kind items and services,207956266,CELEBREX,,A Randomized Double Blind Parallel Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,06/27/2014,In-kind items and services,208013735,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,510.00,08/21/2014,Cash or cash equivalent,207887018,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1436.88,01/23/2014,Cash or cash equivalent,207613662,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,01/08/2014,Cash or cash equivalent,207495304,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,01/08/2014,Cash or cash equivalent,207491670,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,01/27/2014,Cash or cash equivalent,207499596,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,05/01/2014,In-kind items and services,208013752,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,10/01/2014,Cash or cash equivalent,207957500,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3600.00,01/16/2014,Cash or cash equivalent,207509460,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1347.81,04/03/2014,Cash or cash equivalent,207531470,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5278.00,02/19/2014,Cash or cash equivalent,207607151,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,Research Foundation1622 East Lombard Street,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,107.20,03/19/2014,In-kind items and services,207539629,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,798.00,03/13/2014,Cash or cash equivalent,207531768,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,350.00,05/28/2014,Cash or cash equivalent,207707572,CELEBREX,,CV SAFETY STUDY COMPARING CELECOXIB  100200 MG QD  WITH IBUPROFEN AND NAPORXEN IN OA AND RA PATIENTS WITH CVD OR HIGH RISK FOR CVD,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207554544,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26.00,02/19/2014,Cash or cash equivalent,207519470,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,15.00,07/16/2014,Cash or cash equivalent,207755426,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,07/03/2014,Cash or cash equivalent,207761764,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,07/25/2014,Cash or cash equivalent,207784578,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1276.56,07/17/2014,Cash or cash equivalent,207789634,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4000.00,07/17/2014,Cash or cash equivalent,207793514,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,15.00,07/16/2014,Cash or cash equivalent,207755488,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,06/02/2014,In-kind items and services,208035246,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,539.00,08/21/2014,Cash or cash equivalent,207873195,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1276.56,10/01/2014,Cash or cash equivalent,207935676,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5066.25,08/21/2014,Cash or cash equivalent,207873147,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,DR ISAM MARAR,1701 W BROADWAY,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,114.67,01/30/2014,In-kind items and services,207956748,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3000.00,12/11/2014,Cash or cash equivalent,208018122,XELJANZ,,A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP MULTICENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP690550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHNS DISEASE,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,308.00,07/16/2014,Cash or cash equivalent,207755458,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,03/26/2014,Cash or cash equivalent,207625700,CELEBREX,,A Randomized Double Blind ParallelGroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,350.00,07/07/2014,Cash or cash equivalent,207756316,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3000.00,01/15/2014,Cash or cash equivalent,207813196,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2723.00,08/14/2014,Cash or cash equivalent,207872997,,,A Study To Monitor Long Term Treatment With PF 00547659,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4053.00,08/21/2014,Cash or cash equivalent,207906874,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7101.80,12/30/2014,In-kind items and services,208055308,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,12/11/2014,In-kind items and services,208011803,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,300 Locust Street,Suite 350,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1250.00,11/19/2014,Cash or cash equivalent,207986712,INLYTA,,MaRCC Registry  Metastatic advanced Renal Cell Cancer Registry,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,08/27/2014,Cash or cash equivalent,207904444,XELJANZ,,Long Term Effectiveness And Safety Of CP 690 550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,07/29/2014,In-kind items and services,208054086,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,12/11/2014,Cash or cash equivalent,208052024,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5681.44,09/17/2014,In-kind items and services,208025716,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,06/19/2014,In-kind items and services,208013828,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,58736.25,10/02/2014,In-kind items and services,208047912,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4261.08,07/11/2014,In-kind items and services,208041846,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,01/08/2014,Cash or cash equivalent,207576154,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,95.00,02/20/2014,Cash or cash equivalent,207548219,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1650.63,01/23/2014,Cash or cash equivalent,207575556,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,800.00,10/23/2014,Cash or cash equivalent,207967788,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26.00,02/19/2014,Cash or cash equivalent,207587342,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,01/08/2014,Cash or cash equivalent,207497831,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,284.86,07/23/2014,In-kind items and services,207771312,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26.00,02/19/2014,Cash or cash equivalent,207546282,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1500.00,05/01/2014,Cash or cash equivalent,207704908,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,593.75,05/14/2014,Cash or cash equivalent,207725472,BOSULIF,,AN OPEN LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA  CML  WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,06/11/2014,Cash or cash equivalent,207722544,XELJANZ,,A LONG TERM OPEN LABEL FOLLOW UP STUDY OF TOFACITINIB  CP 690550  FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,798.00,03/13/2014,Cash or cash equivalent,207542018,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,19.69,01/16/2014,Cash or cash equivalent,207510142,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1347.81,06/25/2014,Cash or cash equivalent,207746838,,,BIOTX RUN STUDY OPEN LABEL EXTENSION STUDY FOR PF00547659  OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,05/29/2014,Cash or cash equivalent,207731738,,,BIOTX RUN STUDY OPEN LABEL EXTENSION STUDY FOR PF00547659  OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,938.13,08/27/2014,Cash or cash equivalent,207898318,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,07/03/2014,Cash or cash equivalent,207759982,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,06/11/2014,Cash or cash equivalent,207741734,XELJANZ,,A LONG TERM OPEN LABEL FOLLOW UP STUDY OF TOFACITINIB  CP 690550  FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,44.00,07/16/2014,Cash or cash equivalent,207755442,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,44.00,07/16/2014,Cash or cash equivalent,207755462,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,07/07/2014,Cash or cash equivalent,207756300,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,32.00,02/19/2014,Cash or cash equivalent,207655104,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave,,AMES,50010,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,60.00,06/03/2014,In-kind items and services,207716278,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835 and PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,57.00,07/16/2014,Cash or cash equivalent,207775342,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,08/27/2014,Cash or cash equivalent,207888602,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,240.00,08/21/2014,Cash or cash equivalent,207872934,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,TIFFANY NEMECEK STE201,201 RIDGE STREET COUNCIL,BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,175.00,09/09/2014,In-kind items and services,207931928,PREVNAR  13,,Concomitant Administration of 13valent Pneumococcal Conjugate Vaccine 13vPnC With Influenza Vaccine in 23valent Pneumococcal Polysaccharide 23vPS Prevaccinated Adults,,
Non-covered Recipient Entity,,,,,,,DR JENNIFER SUE KAY,201 RIDGE STREET,COUNCIL BUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,74.60,03/28/2014,In-kind items and services,207931958,,,Duration of Immunity Study,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,08/27/2014,Cash or cash equivalent,207914544,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,185.00,08/21/2014,Cash or cash equivalent,207915198,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,991.50,11/13/2014,Cash or cash equivalent,208001430,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,353.00,08/21/2014,Cash or cash equivalent,207904940,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,01/27/2014,Cash or cash equivalent,207495436,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2723.00,12/17/2014,Cash or cash equivalent,208038972,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7101.80,12/31/2014,In-kind items and services,208047878,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/01/2014,Cash or cash equivalent,207929188,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5681.44,09/18/2014,In-kind items and services,208011996,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,125.00,08/21/2014,Cash or cash equivalent,207919372,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,201 Ridge Street Suite 201,,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,606.00,09/16/2014,In-kind items and services,207958530,PREVNAR  13,,A Phase 4 Randomized Doubleblind Trial To Evaluate The Immunogenicity And Safety Of A 13valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine In Adults 50 Years And Older Who Received 1,,Study Drug
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,666.00,02/19/2014,Cash or cash equivalent,207660580,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,500.00,06/19/2014,Cash or cash equivalent,207712000,,,BIOTX RUN STUDY A PHASE 2B EFFICACY AND SAFETY STUDY OF PF00547659 IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,450.00,06/19/2014,Cash or cash equivalent,207736706,,,BIOTX RUN STUDY A PHASE 2B EFFICACY AND SAFETY STUDY OF PF00547659 IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,917.94,01/23/2014,Cash or cash equivalent,207545735,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207496010,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,06/11/2014,Cash or cash equivalent,207725346,XELJANZ,,A LONG TERM OPEN LABEL FOLLOW UP STUDY OF TOFACITINIB  CP 690550  FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,01/08/2014,Cash or cash equivalent,207593106,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207586110,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,07/22/2014,Cash or cash equivalent,207768722,XELJANZ,,A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB CP690550 FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,04/25/2014,Cash or cash equivalent,207566904,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,05/08/2014,Cash or cash equivalent,207725938,,,BIOTX RUN STUDY OPEN LABEL EXTENSION STUDY FOR PF00547659  OPERA II,,
Non-covered Recipient Entity,,,,,,,Research Foundation1622 East Lombard Street,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,60.00,03/19/2014,In-kind items and services,207568612,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1436.88,03/27/2014,Cash or cash equivalent,207693681,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207683764,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3.00,07/16/2014,Cash or cash equivalent,207755420,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26.00,07/16/2014,Cash or cash equivalent,207755438,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,500.00,05/01/2014,Cash or cash equivalent,207729738,CELEBREX,,CV SAFETY STUDY COMPARING CELECOXIB  100200 MG QD  WITH IBUPROFEN AND NAPORXEN IN OA AND RA PATIENTS WITH CVD OR HIGH RISK FOR CVD,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,350.00,07/07/2014,Cash or cash equivalent,207783718,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2350.00,01/15/2014,Cash or cash equivalent,207836632,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4.00,07/16/2014,Cash or cash equivalent,207791934,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,04/30/2014,Cash or cash equivalent,207813644,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,04/30/2014,Cash or cash equivalent,207831735,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,02/10/2014,In-kind items and services,208055920,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,02/07/2014,In-kind items and services,208024534,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/01/2014,Cash or cash equivalent,207959120,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,11/13/2014,Cash or cash equivalent,207995620,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,09/23/2014,Cash or cash equivalent,207856331,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF 04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluff,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,118.00,08/11/2014,In-kind items and services,207914623,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1420.36,06/25/2014,In-kind items and services,208054094,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,11/13/2014,Cash or cash equivalent,207972168,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,02/07/2014,In-kind items and services,208048418,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 321,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6560.00,12/29/2014,Cash or cash equivalent,208017354,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND GREATER THAN 25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,10/01/2014,Cash or cash equivalent,207943126,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,900.00,12/04/2014,Cash or cash equivalent,208034119,BOSULIF,,A PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,344.00,08/21/2014,Cash or cash equivalent,207910164,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,09/23/2014,Cash or cash equivalent,207879658,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF 04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,08/27/2014,Cash or cash equivalent,207919882,XELJANZ,,Long Term Effectiveness And Safety Of CP 690 550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,439.38,10/01/2014,Cash or cash equivalent,207939550,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/01/2014,Cash or cash equivalent,207929153,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,201 Ridge Street,Suite 201,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,198.80,09/30/2014,In-kind items and services,208042996,PREVNAR  13,,A Phase 4 Randomized Doubleblind Trial To Evaluate The Immunogenicity And Safety Of A 13valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine In Adults 50 Years And Older Who Received 1,,Study Drug
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,950.00,10/22/2014,Cash or cash equivalent,207922754,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,09/24/2014,Cash or cash equivalent,207858894,XELJANZ,,Long Term Effectiveness And Safety Of CP 690 550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,03/26/2014,Cash or cash equivalent,207495948,CELEBREX,,A Randomized Double Blind ParallelGroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,04/03/2014,Cash or cash equivalent,207551808,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,01/01/2014,In-kind items and services,207575629,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,08/27/2014,Cash or cash equivalent,207886226,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,1500 ASSOCIATES DR,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,576.00,03/14/2014,Cash or cash equivalent,207940232,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,95.00,01/23/2014,Cash or cash equivalent,207509868,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,525.00,02/25/2014,Cash or cash equivalent,207641713,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,WEST BROADWAY CLINIC,1701 W BROADWAY,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,59.25,04/01/2014,In-kind items and services,207929140,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1500.00,10/01/2014,Cash or cash equivalent,207940348,,,The Evaluation of Bococizumab PF04950615 in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects SPIRE2,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,04/03/2014,Cash or cash equivalent,207575579,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,01/08/2014,Cash or cash equivalent,207496181,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,01/08/2014,Cash or cash equivalent,207494314,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1704.06,01/16/2014,Cash or cash equivalent,207531548,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,974 73RD ST 23,,WINDSOR HEIGHTS,50324,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1280.00,04/08/2014,Cash or cash equivalent,207534910,INLYTA,,Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1347.81,06/25/2014,Cash or cash equivalent,207725996,,,BIOTX RUN STUDY OPEN LABEL EXTENSION STUDY FOR PF00547659  OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1704.06,04/03/2014,Cash or cash equivalent,207539516,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1650.63,01/23/2014,Cash or cash equivalent,207568476,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,01/08/2014,Cash or cash equivalent,207559790,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1500.00,07/17/2014,Cash or cash equivalent,207753100,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,800.00,01/16/2014,Cash or cash equivalent,207653819,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,18.00,02/19/2014,Cash or cash equivalent,207603078,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4000.00,06/19/2014,Cash or cash equivalent,207736092,,,BIOTX RUN STUDY A PHASE 2B EFFICACY AND SAFETY STUDY OF PF00547659 IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave,,AMES,50010,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,284.86,06/03/2014,In-kind items and services,207734330,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835 and PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,06/02/2014,In-kind items and services,208031672,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,12/17/2014,Cash or cash equivalent,208018054,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,09/23/2014,Cash or cash equivalent,207879424,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF 04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,533.00,07/16/2014,Cash or cash equivalent,207797538,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,01/08/2014,Cash or cash equivalent,207600824,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26.00,07/16/2014,Cash or cash equivalent,207761962,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,07/25/2014,Cash or cash equivalent,207756432,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,10/01/2014,Cash or cash equivalent,207952278,,,The Evaluation of Bococizumab PF04950615 in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects SPIRE2,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,550.00,11/13/2014,Cash or cash equivalent,207995178,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,800.00,12/04/2014,Cash or cash equivalent,208022856,BOSULIF,,A PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,10/01/2014,Cash or cash equivalent,207925294,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3025.00,12/17/2014,Cash or cash equivalent,208030756,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,09/30/2014,In-kind items and services,208012070,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2700.00,10/02/2014,Cash or cash equivalent,207954834,CELEBREX,,A Randomized Double Blind Parallelgroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4.00,02/19/2014,Cash or cash equivalent,207520074,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,300 Locust Street,Suite 350,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,425.00,03/28/2014,Cash or cash equivalent,207554172,INLYTA,,MaRCC Registry  Metastatic advanced Renal Cell Cancer Registry,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207578492,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,06/11/2014,Cash or cash equivalent,207740232,XELJANZ,,A LONG TERM OPEN LABEL FOLLOW UP STUDY OF TOFACITINIB  CP 690550  FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4000.00,10/01/2014,Cash or cash equivalent,207958360,,,The Evaluation of Bococizumab PF04950615 in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects SPIRE2,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1466.56,05/08/2014,Cash or cash equivalent,207743036,,,BIOTX RUN STUDY OPEN LABEL EXTENSION STUDY FOR PF00547659  OPERA II,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,95.00,01/23/2014,Cash or cash equivalent,207673746,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,03/26/2014,Cash or cash equivalent,207569262,CELEBREX,,A Randomized Double Blind ParallelGroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1347.81,04/03/2014,Cash or cash equivalent,207585272,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHN S DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,920.00,02/14/2014,Cash or cash equivalent,207531658,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,1500 Associates Drive,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,70.00,02/19/2014,Cash or cash equivalent,207577390,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207676324,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,01/27/2014,Cash or cash equivalent,207619632,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35.00,07/16/2014,Cash or cash equivalent,207771606,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,300 Locust Street,Suite 350,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,395.00,04/11/2014,Cash or cash equivalent,207539444,INLYTA,,NONINTERVENTIONAL LONGITUDINAL COHORT STUDY OF ADVANCED RCC PATIENTS,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,NULL,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3288.31,01/16/2014,Cash or cash equivalent,207677704,BOSULIF,,A Phase 3 Randomized OpenLabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,02/25/2014,Cash or cash equivalent,207690932,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,07/25/2014,Cash or cash equivalent,207774436,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4000.00,05/01/2014,Cash or cash equivalent,207722592,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Pf04950615 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,938.13,08/27/2014,Cash or cash equivalent,207916562,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,09/23/2014,Cash or cash equivalent,207854420,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF 04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,296.88,10/22/2014,Cash or cash equivalent,207938390,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,439.38,11/13/2014,Cash or cash equivalent,207971965,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,230 NE STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,300.00,07/16/2014,Cash or cash equivalent,207795480,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,09/23/2014,Cash or cash equivalent,207855118,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF 04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,05/28/2014,Cash or cash equivalent,207698246,CELEBREX,,CV SAFETY STUDY COMPARING CELECOXIB  100200 MG QD  WITH IBUPROFEN AND NAPORXEN IN OA AND RA PATIENTS WITH CVD OR HIGH RISK FOR CVD,,
Non-covered Recipient Entity,,,,,,,Research Foundation1622 East Lombard Street,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,50.00,03/19/2014,In-kind items and services,207675740,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,06/19/2014,Cash or cash equivalent,207742578,,,BIOTX RUN STUDY A PHASE 2B EFFICACY AND SAFETY STUDY OF PF00547659 IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3750.00,12/04/2014,Cash or cash equivalent,208046848,BOSULIF,,A PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1276.56,10/01/2014,Cash or cash equivalent,207940140,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE STE 100,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3350.00,11/04/2014,Cash or cash equivalent,207998146,,,B5371002  Infliximab RA Biosimilar,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,23494.50,05/05/2014,In-kind items and services,207951210,BOSULIF,,An Open Label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia  CML  Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,Study Drug
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,296.88,10/22/2014,Cash or cash equivalent,207937767,BOSULIF,,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia CML Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3000.00,12/11/2014,Cash or cash equivalent,208032072,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1514.06,12/17/2014,Cash or cash equivalent,208018110,,,A MULTICENTER OPENLABEL EXTENSION STUDY TO ASSESS LONGTERM SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA II,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,11510 PRP  RESEARCH,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,12/01/2014,In-kind items and services,208020682,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6338.75,12/04/2014,Cash or cash equivalent,208046854,BOSULIF,,A PHASE 3 RANDOMIZED OPENLABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA,,
Non-covered Recipient Entity,,,,,,,TIFFANY NEMECEK STE201,201 RIDGE STREET COUNCIL,BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,677.16,09/09/2014,In-kind items and services,207931954,PREVNAR  13,,Concomitant Administration of 13valent Pneumococcal Conjugate Vaccine 13vPnC With Influenza Vaccine in 23valent Pneumococcal Polysaccharide 23vPS Prevaccinated Adults,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,79.80,08/21/2014,Cash or cash equivalent,207882662,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,11510 PRP  RESEARCH,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,10/01/2014,In-kind items and services,208025826,,,A Study Of Inotuzumab Ozogamicin Versus Investigators Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,12/11/2014,Cash or cash equivalent,208051430,XELJANZ,,A OPENLABEL EXTENSION STUDY OF CP690550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHNS DISEASE,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,600.00,09/02/2014,Cash or cash equivalent,207890893,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Avenue,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,975.43,10/02/2014,Cash or cash equivalent,207965226,CELEBREX,,A Randomized Double Blind Parallelgroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/01/2014,Cash or cash equivalent,207929204,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events SPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,11/13/2014,Cash or cash equivalent,207979910,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1006.00,08/21/2014,Cash or cash equivalent,207895962,,,Study To Test Whether PF 00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn s Disease,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2840.72,08/25/2014,In-kind items and services,208011860,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,12/08/2014,In-kind items and services,208011936,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3000.00,12/11/2014,Cash or cash equivalent,208024192,XELJANZ,,A OPENLABEL EXTENSION STUDY OF CP690550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHNS DISEASE,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,01/23/2014,Cash or cash equivalent,207566144,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,03/26/2014,Cash or cash equivalent,207571338,CELEBREX,,A Randomized Double Blind ParallelGroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,350.00,01/27/2014,Cash or cash equivalent,207537820,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave,,AMES,50010,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,77.55,06/03/2014,In-kind items and services,207717964,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835 and PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,NULL,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,01/08/2014,Cash or cash equivalent,207491764,XELJANZ,,LongTerm Effectiveness And Safety Of CP690550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,05/14/2014,Cash or cash equivalent,207704776,BOSULIF,,AN OPEN LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA  CML  WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD CT,,JOHNSTON,50131,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,31806.90,01/03/2014,Cash or cash equivalent,192939218,Neupro,,"A multi-center, multinational, double-blind, placebo-controlled, three-arm, Phase 4 study to evaluate the efficacy of Rotigotine on Parkinson?s disease associated apathy, motor symptoms and mood",,
Non-covered Recipient Entity,,,,,,,600 7th St SE,,CEDAR RAPIDS,52401,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,5449.00,02/03/2014,Cash or cash equivalent,192944332,,,"A phase 2 Multicenter, open-label, follow up study to assess the long term safety and efficacy of CDP6038 administered subcutaneously to subjects with active rheumatoid arthritis who completed study RA0056.",,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,3178.90,02/17/2014,Cash or cash equivalent,192943968,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (>=16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,AMES,50010,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,90.00,01/10/2014,Cash or cash equivalent,192939412,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Non-covered Recipient Entity,,,,,,,600 7th St SE,,CEDAR RAPIDS,52401,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,16527.00,01/30/2014,Cash or cash equivalent,192944330,,,"A phase 2 Multicenter, open-label, follow up study to assess the long term safety and efficacy of CDP6038 administered subcutaneously to subjects with active rheumatoid arthritis who completed study RA0056.",,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,2604.70,08/08/2014,Cash or cash equivalent,192944040,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,2400.00,01/24/2014,Cash or cash equivalent,192941512,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD CT,,JOHNSTON,50131,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,7377.30,04/11/2014,Cash or cash equivalent,192943204,Neupro,,"A multi-center, multinational, double-blind, placebo-controlled, three-arm, Phase 4 study to evaluate the efficacy of Rotigotine on Parkinson?s disease associated apathy, motor symptoms and mood",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1400.00,07/25/2014,Cash or cash equivalent,192941852,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,600 7th St SE,,CEDAR RAPIDS,52401,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,17505.90,04/10/2014,Cash or cash equivalent,192941774,Cimzia,,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE FOR INDUCING AND SUSTAINING CLINICAL RESPONSE IN THE TREATMENT OF DMARD-NA?VE ADULTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS PHASE 3",,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,3447.00,05/02/2014,Cash or cash equivalent,192945770,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (>=16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES",,
Non-covered Recipient Entity,,,,,,,600 7th St SE,,CEDAR RAPIDS,52401,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,134.00,03/05/2014,Cash or cash equivalent,192941704,Cimzia,,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE FOR INDUCING AND SUSTAINING CLINICAL RESPONSE IN THE TREATMENT OF DMARD-NA?VE ADULTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS PHASE 3",,
Non-covered Recipient Entity,,,,,,,600 7th St SE,,CEDAR RAPIDS,52401,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,9936.00,03/05/2014,Cash or cash equivalent,192941844,Cimzia,,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE FOR INDUCING AND SUSTAINING CLINICAL RESPONSE IN THE TREATMENT OF DMARD-NA?VE ADULTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS PHASE 3",,4 payments of 2484.00 consolidated together
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1200.00,04/21/2014,Cash or cash equivalent,192941604,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,2002 Holcombe Blvd  Building 122,,West De Moines,50266,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,12665.00,08/13/2014,Cash or cash equivalent,204139476,,,COMMENCE 2012 02,,
Non-covered Recipient Entity,,,,,,,600 7th St SE,,CEDAR RAPIDS,52401,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,2726.00,03/05/2014,Cash or cash equivalent,192941712,Cimzia,,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE FOR INDUCING AND SUSTAINING CLINICAL RESPONSE IN THE TREATMENT OF DMARD-NA?VE ADULTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS PHASE 3",,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Arbor Pharmaceuticals, Inc.",100000005507,"Arbor Pharmaceuticals, Inc.",GA,5331.60,04/15/2014,Cash or cash equivalent,212109806,None,,None,,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Arbor Pharmaceuticals, Inc.",100000005507,"Arbor Pharmaceuticals, Inc.",GA,1000.00,05/28/2014,Cash or cash equivalent,212109810,None,,None,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1375.00,05/02/2014,Cash or cash equivalent,192945764,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (>=16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES",,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Arbor Pharmaceuticals, Inc.",100000005507,"Arbor Pharmaceuticals, Inc.",GA,1184.80,07/16/2014,Cash or cash equivalent,212109812,None,,None,,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Arbor Pharmaceuticals, Inc.",100000005507,"Arbor Pharmaceuticals, Inc.",GA,5331.60,03/12/2014,Cash or cash equivalent,212109804,None,,None,,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Arbor Pharmaceuticals, Inc.",100000005507,"Arbor Pharmaceuticals, Inc.",GA,2500.00,05/28/2014,Cash or cash equivalent,212109808,None,,None,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,353.85,10/01/2014,In-kind items and services,210978752,,,"CARMELINA- A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3550.90,04/07/2014,In-kind items and services,208053502,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,11/13/2014,Cash or cash equivalent,207981328,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,09/24/2014,Cash or cash equivalent,207859092,XELJANZ,,Long Term Effectiveness And Safety Of CP 690 550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,353.85,10/01/2014,In-kind items and services,210979672,,,"CARMELINA- A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,4476.25,02/01/2014,Cash or cash equivalent,196514112,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,411 Laurel St Ste 3262,,Des Moines,50314,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,2500.00,05/09/2014,Cash or cash equivalent,196521940,,,Ph III min. 52-wk extension trial,,
Non-covered Recipient Entity,,,,,,,5950 University Ave Ste 321,,West Des Moines,50266,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,1099.20,07/01/2014,Cash or cash equivalent,196522358,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St Ste 501,,Council Bluffs,51503,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,3000.00,10/31/2014,Cash or cash equivalent,196521374,,,Effect BIBF 1120 on FVC  pivotal,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,332.69,10/01/2014,Cash or cash equivalent,196522402,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,5950 University Ave Ste 321,,West Des Moines,50266,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,2666.40,02/01/2014,Cash or cash equivalent,196513898,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,University Of Iowa   B5,,Iowa City,52242,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,3000.00,08/01/2014,Cash or cash equivalent,196512328,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4947.30,06/24/2014,Cash or cash equivalent,207442578,NonCovered Product,,"PHASE III, OPEN LABEL, RANDOMIZED, IN PATS W NSCL",,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,2681.00,11/12/2014,Cash or cash equivalent,194978194,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Non-covered Recipient Entity,,,,,,,540 E JEFFERSON ST STE 400,,IOWA CITY,52245-2479,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,6963.00,11/12/2014,Cash or cash equivalent,194978432,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Non-covered Recipient Entity,,,,,,,540 E JEFFERSON ST STE 400,,IOWA CITY,52245-2479,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,4403.71,12/03/2014,Cash or cash equivalent,194978436,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Non-covered Recipient Entity,,,,,,,3530 W 4TH ST,,WATERLOO,50701,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,01/27/2014,Cash or cash equivalent,207414056,NonCovered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,01/22/2014,Cash or cash equivalent,207413866,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,342.57,05/01/2014,Cash or cash equivalent,207419822,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,09/23/2014,Cash or cash equivalent,207435732,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,09/23/2014,Cash or cash equivalent,207435736,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1382.63,11/06/2014,Cash or cash equivalent,207443442,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,01/22/2014,Cash or cash equivalent,207413868,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,250.00,09/03/2014,Cash or cash equivalent,194978190,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,3201.00,07/24/2014,Cash or cash equivalent,194978186,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Non-covered Recipient Entity,,,,,,,3530 WEST 4TH STREET,,WATERLOO,33331,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,2250.00,02/05/2014,Cash or cash equivalent,189695422,Revlimid,,Celgene - CONNECT MM,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,6300.00,03/17/2014,Cash or cash equivalent,189690638,Revlimid,,Celgene - Connect MDSAML,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,342.57,02/03/2014,Cash or cash equivalent,207414504,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,09/23/2014,Cash or cash equivalent,207435730,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,855 A Ave NE,,Cedar Rapids,52402,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,100.00,08/27/2014,In-kind items and services,189687876,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,202 TENTH STREET SE SUITE 285,,Cedar Rapids,52403,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,1500.00,04/09/2014,Cash or cash equivalent,189688154,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,3530 WEST 4TH STREET,,WATERLOO,33331,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,110.00,04/17/2014,In-kind items and services,189688178,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,01/22/2014,Cash or cash equivalent,207413864,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,P O BOX 3014,1215 DUFF AVENUE,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,375.00,10/02/2014,Cash or cash equivalent,189690682,Revlimid,,Celgene - Connect MDSAML,,
Non-covered Recipient Entity,,,,,,,8421 PLUM DR,,URBANDALE,50322,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2788.00,05/23/2014,Cash or cash equivalent,207425388,NonCovered Product,,SUNDIAL,,
Non-covered Recipient Entity,,,,,,,855 A Ave NE,,Cedar Rapids,52402,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,3375.00,07/30/2014,Cash or cash equivalent,189688150,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,966.00,01/03/2014,Cash or cash equivalent,207430960,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,200.00,04/30/2014,In-kind items and services,189693882,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,3699 Epworth Road,,Newburgh,47630,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,9795.00,01/29/2014,Cash or cash equivalent,189695806,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,966.00,01/03/2014,Cash or cash equivalent,207430958,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,16210.00,01/29/2014,Cash or cash equivalent,189695998,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,300.00,04/30/2014,In-kind items and services,189691972,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,01/22/2014,Cash or cash equivalent,207413870,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,09/23/2014,Cash or cash equivalent,207435734,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2898.00,01/03/2014,Cash or cash equivalent,207430956,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,10350.00,09/12/2014,Cash or cash equivalent,207432584,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1500.00,05/27/2014,Cash or cash equivalent,207420830,NonCovered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,1351 EAST KIMBERLY ROAD SUITE 100,,BETTENDORF,52722,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,1500.00,01/29/2014,Cash or cash equivalent,189687822,Revlimid,,Celgene - CONNECT MM,,
Non-covered Recipient Entity,,,,,,,4150 KIMBALL AVE,,WATERLOO,50701,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,401.00,02/25/2014,Cash or cash equivalent,207424112,Avastin,,AVASTIN AS ADJUVANT TREATMENT IN BC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,3650.00,03/20/2014,Cash or cash equivalent,207412830,NonCovered Product,,CV OUTCOME TRIAL 2,,
Non-covered Recipient Entity,,,,,,,4150 KIMBALL AVE,,WATERLOO,50701,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,2753.00,12/18/2014,Cash or cash equivalent,207444902,Avastin,,AVASTIN AS ADJUVANT TREATMENT IN BC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,340.00,02/26/2014,In-kind items and services,189696106,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,4150 KIMBALL AVE,,WATERLOO,50701,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,463.00,05/15/2014,Cash or cash equivalent,207426414,Avastin,,AVASTIN AS ADJUVANT TREATMENT IN BC PATIENTS,,
Non-covered Recipient Entity,,,,,,,300 East Locus,,Des Moines,50309,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,131.42,03/05/2014,In-kind items and services,189693766,Revlimid,,CC-5013-NHL-007,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,12750.00,02/05/2014,Cash or cash equivalent,189689896,Revlimid,,Celgene - CONNECT MM,,
Non-covered Recipient Entity,,,,,,,855 A Ave NE,,Cedar Rapids,52402,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,3375.00,07/30/2014,Cash or cash equivalent,189688146,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,5625.00,02/05/2014,Cash or cash equivalent,189689886,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,855 A Ave NE,,Cedar Rapids,52402,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,200.00,05/21/2014,In-kind items and services,189687852,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,3699 Epworth Road,,Newburgh,47630,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,300.00,03/06/2014,In-kind items and services,189691072,Revlimid,,Celgene - CONNECT MM,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,13840.00,07/23/2014,Cash or cash equivalent,212932702,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,5334.00,10/06/2014,Cash or cash equivalent,212913436,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,STE 300,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,83.58,07/21/2014,In-kind items and services,212913952,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,University of Iowa Hospitals Cancer Center Researc,200 Hawkins Drive,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,46.04,06/13/2014,In-kind items and services,212908838,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2055.00,09/08/2014,Cash or cash equivalent,212922430,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate,Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma Protocol No. P06241 also known as P202",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1921.60,03/31/2014,Cash or cash equivalent,212920654,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,9088.00,01/24/2014,Cash or cash equivalent,212917985,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,STE 300,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,596.40,07/15/2014,In-kind items and services,212901562,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1419.72,01/09/2014,In-kind items and services,212930128,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1640.00,07/31/2014,Cash or cash equivalent,212918714,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,7325.00,04/18/2014,Cash or cash equivalent,212937840,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,345.00,10/23/2014,Cash or cash equivalent,212935462,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,Vaccine Trials Office,University of Iowa Hospital 358 MRF,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,7.36,02/06/2014,In-kind items and services,212903204,GARDASIL9,,"A Randomized, International, Double-Blinded With In-House Blinding, Controlled With GARDASILTM, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine Administered to 16- to 26-Year-Old Women",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,14329.00,06/30/2014,Cash or cash equivalent,212919542,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,300 east locust st,suite 350,Des moines,50309,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,166304.00,01/27/2014,In-kind items and services,185198262,ERBITUX,,Erbitux-Comparing Carboplat Paclitax W WO Concur Cetux-BMSSP,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,Ste 3262,Des Moines,50314,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,405.69,12/04/2014,In-kind items and services,185190671,FARXIGA,,Phase III T1D - Initial,,
Non-covered Recipient Entity,,,,,,,701 10th St SE,,Cedar Rapids,52403,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,31182.00,01/16/2014,In-kind items and services,185199108,ERBITUX,,Erbitux-Comparing Carboplat Paclitax W WO Concur Cetux-BMSSP,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,100.13,10/09/2014,Cash or cash equivalent,207439348,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,5970 JPP,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,1951.26,02/03/2014,Cash or cash equivalent,185200154,OPDIVO,,Phase III RCC Monotherapy vs  everolimus  ONO 4538 03,,
Non-covered Recipient Entity,,,,,,,Dept Of Pediatrics,Division Of Pediatric Cardiology,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,112.05,08/25/2014,In-kind items and services,185173644,NULOJIX,,Phase IIIB CNI to bela Switch Study,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,912.50,02/24/2014,Cash or cash equivalent,185195379,,,Prospective Research Assessment in Multiple Myeloma  An Observational Evaluation  PREAMBLE,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,5970 JPP,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,2079.21,09/18/2014,In-kind items and services,185199262,OPDIVO,,Phase III RCC 1L,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST  STE 3262,,DES MOINES,50314,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,117525.00,01/29/2014,Cash or cash equivalent,185190678,BYDUREON,,Exenatide Study of Cardiovascular Event Lowering Trial  EXSCEL   A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,5970 JPP,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,387.21,02/03/2014,Cash or cash equivalent,185186581,SPRYCEL,,DASCERN.  Dasatinib Early Switch,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,966.00,04/21/2014,Cash or cash equivalent,207412968,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5750.00,03/10/2014,Cash or cash equivalent,207431834,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1500.00,01/27/2014,Cash or cash equivalent,207414224,NonCovered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,3530 W 4TH ST,,WATERLOO,50701,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,05/27/2014,Cash or cash equivalent,207420706,NonCovered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6900.00,01/03/2014,Cash or cash equivalent,207430954,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC  PATIENTS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,370.69,07/24/2014,Cash or cash equivalent,207434156,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,200.25,03/28/2014,Cash or cash equivalent,207415898,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,1126.75,05/19/2014,Cash or cash equivalent,174183376,Humira,,P11 282,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,87.94,11/14/2014,Cash or cash equivalent,174183442,Humira,,P11 282,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,2451.00,04/25/2014,Cash or cash equivalent,214363574,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,97239,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,185.00,06/06/2014,Cash or cash equivalent,214363582,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,600.00,08/06/2014,Cash or cash equivalent,214363604,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,20398.60,10/20/2014,Cash or cash equivalent,212935042,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2868.00,09/08/2014,Cash or cash equivalent,212913290,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 W,151,IOWA CITY,52246,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3710.40,11/03/2014,Cash or cash equivalent,212932226,VICTRELIS,,"Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C.",,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,825.00,10/08/2014,Cash or cash equivalent,214363608,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,STE 300,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,185.83,08/22/2014,In-kind items and services,212902002,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,212.50,10/08/2014,Cash or cash equivalent,214363616,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,STE 300,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,91.72,10/23/2014,In-kind items and services,212936278,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,15338.00,07/03/2014,Cash or cash equivalent,212905838,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,1053.00,03/24/2014,Cash or cash equivalent,174183414,Humira,,P11 282,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,337.45,10/08/2014,Cash or cash equivalent,214363618,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,663.00,10/15/2014,Cash or cash equivalent,214363620,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,8976.00,01/09/2014,Cash or cash equivalent,214363566,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,375.00,06/11/2014,Cash or cash equivalent,214363586,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,663.00,07/16/2014,Cash or cash equivalent,214363594,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,212.50,10/08/2014,Cash or cash equivalent,214363612,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,663.00,12/17/2014,Cash or cash equivalent,214363622,SGN35,,SG0350014,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2781.36,10/14/2014,Cash or cash equivalent,212908874,GARDASIL9,,"A Randomized, International, Double-Blinded With In-House Blinding, Controlled With GARDASILTM, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine Administered to 16- to 26-Year-Old Women",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,10785.60,12/15/2014,Cash or cash equivalent,212939208,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,STE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,8660.00,03/19/2014,Cash or cash equivalent,212937038,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy",,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,,CEDAR RAPIDS,52403,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,176.46,01/24/2014,In-kind items and services,212912734,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,13321.40,02/03/2014,Cash or cash equivalent,212909978,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate,Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma Protocol No. P06241 also known as P202",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,43786.00,01/29/2014,Cash or cash equivalent,212925648,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,20165.00,06/12/2014,Cash or cash equivalent,212904700,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,STE 300,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,514.92,06/16/2014,In-kind items and services,212923726,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3255.30,04/16/2014,Cash or cash equivalent,212903378,VICTRELIS,,"Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C.",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,14236.48,05/01/2014,Cash or cash equivalent,212926364,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,3500.00,05/20/2014,Cash or cash equivalent,187093580,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,10255.00,01/30/2014,Cash or cash equivalent,207850160,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,10852.05,01/22/2014,Cash or cash equivalent,207850242,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,8943.25,02/28/2014,Cash or cash equivalent,207850252,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,3807.75,03/12/2014,Cash or cash equivalent,207850258,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,10827.95,08/25/2014,Cash or cash equivalent,207850276,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,3198.20,10/07/2014,Cash or cash equivalent,207850288,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,281.64,02/15/2014,In-kind items and services,207850308,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,11323.53,08/12/2014,Cash or cash equivalent,187093588,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,14730.10,06/10/2014,Cash or cash equivalent,207850234,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,14032.11,05/15/2014,In-kind items and services,207850326,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,8241.80,11/19/2014,Cash or cash equivalent,207850294,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,3978.00,05/21/2014,Cash or cash equivalent,207850176,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,2374.06,01/22/2014,Cash or cash equivalent,207850182,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,1340.94,02/21/2014,Cash or cash equivalent,207850188,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,993.75,10/03/2014,Cash or cash equivalent,207850216,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,1740.00,05/08/2014,Cash or cash equivalent,207850170,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,4204.85,09/05/2014,Cash or cash equivalent,207850282,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,3617.75,12/05/2014,Cash or cash equivalent,207850302,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,305.10,02/15/2014,In-kind items and services,207850314,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,5310.00,03/21/2014,Cash or cash equivalent,207850164,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,7002.50,04/10/2014,Cash or cash equivalent,207850194,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,5036.35,04/25/2014,Cash or cash equivalent,207850222,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,483.44,05/12/2014,Cash or cash equivalent,207850200,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,1352.81,06/17/2014,Cash or cash equivalent,207850208,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,12527.50,05/16/2014,Cash or cash equivalent,207850228,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,11417.70,07/18/2014,Cash or cash equivalent,187093584,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,310.62,05/15/2014,In-kind items and services,187093706,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,2498.12,10/24/2014,Cash or cash equivalent,187093602,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,3597.00,10/02/2014,Cash or cash equivalent,195282134,,,MA-209,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,11080.65,07/11/2014,Cash or cash equivalent,207850264,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,459.80,08/22/2014,Cash or cash equivalent,207850269,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,178.65,09/10/2014,Cash or cash equivalent,195282295,,,MA-209,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,7303.56,02/15/2014,In-kind items and services,207850320,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,3290.50,08/18/2014,Cash or cash equivalent,174183392,Humira,,P11 282,,
Non-covered Recipient Entity,,,,,,,1378 Nw 124th St,Suite 200,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,3088.00,12/01/2014,Cash or cash equivalent,215275836,,,MA-209,,Products Given
Non-covered Recipient Entity,,,,,,,411 Laurel,Suite 2250,Des Moines,50314,,,Mallinckrodt LLC,100000005571,"Cadence Pharmaceuticals, Inc.",CA,966.66,07/10/2014,Cash or cash equivalent,209576428,OFIRMEV,,Reduce Post Operative Nausea Vomiting and Pain in Outpatient Setting,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,4306.60,07/02/2014,Cash or cash equivalent,195282308,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,450.00,11/19/2014,Cash or cash equivalent,195281824,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,47.50,12/30/2014,Cash or cash equivalent,195281972,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Northwest 92nd Court,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,400.00,12/04/2014,Cash or cash equivalent,195282146,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,Suite 8,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,3772.00,11/19/2014,Cash or cash equivalent,195281181,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,47.50,11/13/2014,Cash or cash equivalent,195281351,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,6851.60,06/26/2014,Cash or cash equivalent,195281620,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,47.00,10/02/2014,Cash or cash equivalent,195281504,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,187.00,12/18/2014,Cash or cash equivalent,195282282,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,10224.00,12/04/2014,Cash or cash equivalent,195281633,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct, Suite Suite 8",,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,1097.50,07/10/2014,Cash or cash equivalent,195281834,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,59.00,09/04/2014,Cash or cash equivalent,195281362,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,,Dallas,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,1035.00,08/08/2014,Cash or cash equivalent,195281842,,,MA-209,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,7917.55,08/19/2014,Cash or cash equivalent,208691152,BIO HPV,,"A phase III, double blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals  HPV 16 18 L1 AS04 vaccine administered intramuscularly according to a three dose schedule  0, 1, 6 month  in health",,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,7054.87,05/08/2014,Cash or cash equivalent,208641780,ADVAIR,ADVAIR,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,4878.00,07/22/2014,Cash or cash equivalent,208670236,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,365.00,01/31/2014,Cash or cash equivalent,208633488,POTIGA,POTIGA,"A multicenter, open label, long term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial onset seizures  Extension of Study VRX RET E22 301",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3057.75,12/01/2014,Cash or cash equivalent,208646860,ADVAIR,ADVAIR,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,690.00,09/03/2014,Cash or cash equivalent,208644740,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3647.70,11/11/2014,Cash or cash equivalent,208692872,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1418.75,09/23/2014,Cash or cash equivalent,208691544,BIO HPV,,"A phase IIIb, open, multi centre gynaecological extension study for the follow up of a subset of HPV 015 study subjects",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3221.10,10/28/2014,Cash or cash equivalent,208692068,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,2000.00,02/10/2014,Cash or cash equivalent,217550484,Kuvan,,"PKU Demographics, Outcomes, and Safety Registry",,PKUDOS
Non-covered Recipient Entity,,,,,,,1111 6th Ave A100,,Des Moines,50314,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,17972.28,04/29/2014,Cash or cash equivalent,216054240,Gilenya,,CFTY720D2312,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,1000.00,08/14/2014,Cash or cash equivalent,217550488,Kuvan,,"PKU Demographics, Outcomes, and Safety Registry",,PKUDOS
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1618.20,05/01/2014,Cash or cash equivalent,208654066,VOTRIENT,,"A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave A100,,Des Moines,50314,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,8557.65,02/05/2014,Cash or cash equivalent,216054238,Gilenya,,CFTY720D2312,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,3250.00,05/13/2014,Cash or cash equivalent,217550486,Kuvan,,"PKU Demographics, Outcomes, and Safety Registry",,PKUDOS
Non-covered Recipient Entity,,,,,,,1111 6th Ave A100,,Des Moines,50314,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,14378.31,08/01/2014,Cash or cash equivalent,216054242,Gilenya,,CFTY720D2312,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2314.80,10/02/2014,Cash or cash equivalent,208692028,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1462.50,03/18/2014,Cash or cash equivalent,208666910,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,647.00,04/10/2014,Cash or cash equivalent,208674878,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Acute Coronary Syndrome  ACS  to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,16087.50,04/10/2014,Cash or cash equivalent,208674882,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Acute Coronary Syndrome  ACS  to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,6718.85,01/21/2014,Cash or cash equivalent,208684256,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1341.25,07/21/2014,Cash or cash equivalent,208643156,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,7154.37,09/16/2014,Cash or cash equivalent,187093592,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,1593.91,10/14/2014,Cash or cash equivalent,187093598,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE SUITE 341,,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,12423.39,06/13/2014,Cash or cash equivalent,187093582,ACZONE,,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1187.50,01/23/2014,Cash or cash equivalent,208639312,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3069.90,09/02/2014,Cash or cash equivalent,208691286,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,4270.00,01/31/2014,Cash or cash equivalent,208686192,TYKERB,TYKERB,"A Randomized, Double blind, Multicenter, Placebo controlled Study of Adjuvant Lapatinib in Women with Early Stage ErbB2 Overexpressing Breast Cancer",,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2296.66,01/21/2014,Cash or cash equivalent,208664914,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1265.63,03/04/2014,Cash or cash equivalent,208666742,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1500.00,08/19/2014,Cash or cash equivalent,208691182,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,4384.13,07/21/2014,Cash or cash equivalent,208643484,ADVAIR,ADVAIR,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,52996.06,03/04/2014,Cash or cash equivalent,208680864,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2179.80,07/08/2014,Cash or cash equivalent,208660164,BIO MMR  RIT,,"A phase IIIA, randomized, observer blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals  MMR vaccine  209762   Priorix   compared to Merck   Co., Inc. s MMR vaccine  M M R II , as a first dose, bo",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1397.25,08/05/2014,Cash or cash equivalent,208644208,ADVAIR,ADVAIR,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,42230.50,03/26/2014,Cash or cash equivalent,208631476,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,664.00,01/31/2014,Cash or cash equivalent,208633496,POTIGA,POTIGA,"A multicenter, open label, long term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial onset seizures  Extension of Study VRX RET E22 301",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,362.50,03/04/2014,Cash or cash equivalent,208627336,TANZEUM,,"A Randomized, Open Label, Parallel Group, Multicenter Study to Determine the Efficacy and Long Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,845.75,09/23/2014,Cash or cash equivalent,208691410,BIO HPV,,"A phase IIIb, open, multi centre gynaecological extension study for follow up of a subset of 580299 008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant at their final 580299 008 study visit  Visit 10 at Mon",,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2296.66,05/06/2014,Cash or cash equivalent,208667910,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1250.00,11/25/2014,Cash or cash equivalent,208673406,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,17685.00,01/21/2014,Cash or cash equivalent,208638810,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2817.00,08/19/2014,Cash or cash equivalent,208690948,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1431.00,12/02/2014,Cash or cash equivalent,208673884,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,9067.73,07/21/2014,Cash or cash equivalent,208690180,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,7435.50,10/07/2014,Cash or cash equivalent,208691836,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2000.00,12/09/2014,Cash or cash equivalent,208631472,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,25843.75,04/10/2014,Cash or cash equivalent,208631474,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Acute Coronary Syndrome  ACS  to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,326.00,01/28/2014,Cash or cash equivalent,208684556,ADVAIR,ADVAIR,"A Randomized, Double Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate Salmeterol Combination Product 250 50mcg BID  ADVAIR DISKUS   in Comparison to Salmeterol 50mcg BID  SEREVENT DISKUS   on the Rate of Exacerbations of C",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2564.10,09/16/2014,Cash or cash equivalent,208691272,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1218.50,05/06/2014,Cash or cash equivalent,208641534,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,500.00,10/07/2014,Cash or cash equivalent,208645518,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1372.25,11/19/2014,Cash or cash equivalent,208646542,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,500.00,05/09/2014,Cash or cash equivalent,208641804,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3239.10,10/02/2014,Cash or cash equivalent,208691862,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3051.90,05/06/2014,Cash or cash equivalent,208658336,BIO MMR  RIT,,"A phase IIIA, randomized, observer blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals  MMR vaccine  209762   Priorix   compared to Merck   Co., Inc. s MMR vaccine  M M R II , as a first dose, bo",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,362.50,03/04/2014,Cash or cash equivalent,208627334,TANZEUM,,"A Randomized, Open Label, Parallel Group, Multicenter Study to Determine the Efficacy and Long Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,5780.25,02/25/2014,Cash or cash equivalent,208639380,ADVAIR,ADVAIR,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1982.12,02/25/2014,Cash or cash equivalent,208680868,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1399.50,05/13/2014,Cash or cash equivalent,208668050,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,11502.18,05/06/2014,Cash or cash equivalent,208688138,VERAMYST,VERAMYST,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1456.20,04/08/2014,Cash or cash equivalent,208687746,ARZERRA,,"Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B Cell Non Hodgkin Lymphoma Relapsed After Rituximab Containining Therapy",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2964.60,10/21/2014,Cash or cash equivalent,208692082,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2643.30,10/28/2014,Cash or cash equivalent,208692006,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3145.50,12/02/2014,Cash or cash equivalent,208693122,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2567.70,10/07/2014,Cash or cash equivalent,208692182,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,8435.53,04/25/2014,Cash or cash equivalent,208654354,,,An exploratory study to assess two doses of GSK2402968 in the Treatment of Ambulant boys with Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3294.00,01/08/2014,Cash or cash equivalent,208664788,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2239.20,09/09/2014,Cash or cash equivalent,208691288,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,
Non-covered Recipient Entity,,,,,,,201 Ridge Suite 201,,Council Bluffs,51503,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1755.60,10/28/2014,In-kind items and services,211633880,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,2055 Kimball AveAttn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1919.00,01/29/2014,Cash or cash equivalent,211608914,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1015 Duff Avenue,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,877.80,10/27/2014,In-kind items and services,211636564,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave Jeb Lee Administration,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2240.20,11/19/2014,Cash or cash equivalent,211624852,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,IOWA CITY VA HEALTH CARE SYSTEM 601 HIGHWAY 6 WEST 151,,IOWA CITY,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2025.00,05/15/2014,Cash or cash equivalent,211606402,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,900.00,05/21/2014,Cash or cash equivalent,211623548,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,500.00,03/14/2014,Cash or cash equivalent,211623570,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2500.00,03/14/2014,Cash or cash equivalent,211623578,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,1215 Duff AveJeb Lee Administration,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2201.40,01/30/2014,Cash or cash equivalent,211624328,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,IOWA CITY VA HEALTH CARE SYSTEM 601 HIGHWAY 6 WEST 151,,IOWA CITY,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2200.00,05/15/2014,Cash or cash equivalent,211606356,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST 151,,IOWA CITY,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4456.40,02/17/2014,Cash or cash equivalent,211606390,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1185.30,06/18/2014,Cash or cash equivalent,211623528,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2500.00,03/13/2014,Cash or cash equivalent,211623584,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,904.50,03/27/2014,Cash or cash equivalent,211623588,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,500.00,03/27/2014,Cash or cash equivalent,211623634,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,966.00,11/18/2014,Cash or cash equivalent,211623610,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2081.40,12/12/2014,Cash or cash equivalent,211623602,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave Attn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6284.90,05/23/2014,Cash or cash equivalent,211608930,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr C44PGH,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,18.75,07/28/2014,In-kind items and services,211649586,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2500.00,03/27/2014,Cash or cash equivalent,211623466,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,10.95,05/27/2014,In-kind items and services,211647544,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,35.25,01/04/2014,In-kind items and services,211663566,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave Attn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3748.00,03/21/2014,Cash or cash equivalent,211608936,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,100.00,05/23/2014,Cash or cash equivalent,211622448,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,131.70,10/17/2014,Cash or cash equivalent,211623614,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,1701 W BroadwayAttn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1451.70,01/21/2014,Cash or cash equivalent,211623520,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave Attn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,919.80,04/29/2014,Cash or cash equivalent,211608942,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,73.05,12/01/2014,In-kind items and services,213435374,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,DES MOINES,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,500.00,07/10/2014,Cash or cash equivalent,213430042,,,INTEGRATED CLINICAL TRIAL SERVICES INC,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,2000.00,02/21/2014,Cash or cash equivalent,213433140,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,IOWA CITY VA HEALTH CARE SYSTEM 601 HIGHWAY 6 WEST 151,,IOWA CITY,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2000.00,05/15/2014,Cash or cash equivalent,211606398,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,74.25,01/06/2014,In-kind items and services,211649114,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,601 Highway 6 West 151 Attn Sarah Else,,Iowa City,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3677.20,10/09/2014,Cash or cash equivalent,211609080,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave Attn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,23731.20,03/21/2014,Cash or cash equivalent,211608966,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave Attn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,9199.50,11/19/2014,Cash or cash equivalent,211608934,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave Jeb Lee Administration,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2905.20,03/27/2014,Cash or cash equivalent,211624858,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W BroadwayAttn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1608.30,02/25/2014,Cash or cash equivalent,211623498,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1701 W BroadwayAttn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3610.80,01/21/2014,Cash or cash equivalent,211623522,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1198.80,04/22/2014,Cash or cash equivalent,211623544,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,IOWA CITY VA HEALTH CARE SYSTEM 601 HIGHWAY 6 WEST 151,,IOWA CITY,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,625.00,05/15/2014,Cash or cash equivalent,211606438,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street Suite 3262,,Des. Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4827.90,10/20/2014,In-kind items and services,211634866,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2500.00,03/19/2014,Cash or cash equivalent,211623598,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,35.25,01/02/2014,In-kind items and services,211663560,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W BroadwayAttn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2997.00,02/25/2014,Cash or cash equivalent,211623510,Januvia,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,601 Highway 6 West 151 Attn Sarah Else,,Iowa City,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1228.20,10/16/2014,Cash or cash equivalent,211609076,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr C44PGH,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,10.95,07/28/2014,In-kind items and services,211649594,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,2055 Kimball AveAttn Angie BixbyEllermann,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4089.60,01/23/2014,Cash or cash equivalent,211608950,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50.00,06/09/2014,Cash or cash equivalent,211623532,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway Attn Jan Patterson,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,500.00,03/19/2014,Cash or cash equivalent,211623592,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,74.25,01/02/2014,In-kind items and services,211649214,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,701 10TH ST SE,,CEDAR RAPIDS,52403-1251,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,311.40,05/22/2014,Cash or cash equivalent,205815076,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,697.50,02/21/2014,Cash or cash equivalent,205816663,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2496.60,08/27/2014,Cash or cash equivalent,205809394,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,23.10,12/01/2014,In-kind items and services,213435606,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,62.40,12/01/2014,In-kind items and services,213436224,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2092.50,05/22/2014,Cash or cash equivalent,205813986,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,73.05,12/01/2014,In-kind items and services,213433494,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,4405 Hamilton Boulevard,,Sioux City,51104,,,"Transcend Medical, Inc.",100000061364,"Transcend Medical, Inc.",CA,8800.00,01/22/2014,Cash or cash equivalent,221496102,,,COMPASS,,
Non-covered Recipient Entity,,,,,,,201 GILMORE HALL,,IOWA CITY,52242-1320,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,47.25,05/16/2014,Cash or cash equivalent,220629256,Kogenate FS,,Randomized Trial on Secondary Prophylaxis in Adults,,
Non-covered Recipient Entity,,,,,,,201 GILMORE HALL,,IOWA CITY,52242-1320,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1106.50,05/16/2014,Cash or cash equivalent,220629176,Kogenate FS,,Randomized Trial on Secondary Prophylaxis in Adults,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,DES MOINES,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,1113.75,12/15/2014,Cash or cash equivalent,213431322,,,INTEGRATED CLINICAL TRIAL SERVICES INC,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,DES MOINES,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,2500.00,10/20/2014,Cash or cash equivalent,213429360,,,INTEGRATED CLINICAL TRIAL SERVICES INC,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,73.05,12/01/2014,In-kind items and services,213433496,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,77537.56,02/06/2014,Cash or cash equivalent,213428826,Other,,Iowa City VA Medical Research Foundation,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,635.00,02/28/2014,Cash or cash equivalent,213432648,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,73.05,12/01/2014,In-kind items and services,213434468,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,35.55,12/01/2014,In-kind items and services,213435918,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,97.05,12/01/2014,In-kind items and services,213435044,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,62.40,12/01/2014,In-kind items and services,213437004,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,250.00,11/14/2014,Cash or cash equivalent,213432646,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,2035.00,02/28/2014,Cash or cash equivalent,213433028,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,142.20,12/01/2014,In-kind items and services,213435458,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,DES MOINES,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,1583.48,03/31/2014,Cash or cash equivalent,213431912,,,INTEGRATED CLINICAL TRIAL SERVICES INC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,3500.00,12/19/2014,Cash or cash equivalent,213429058,,,THE IOWA CLINIC PC,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,51.20,12/01/2014,In-kind items and services,213436272,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,DES MOINES,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,500.00,12/15/2014,Cash or cash equivalent,213432278,,,INTEGRATED CLINICAL TRIAL SERVICES INC,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,DES MOINES,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,3037.52,07/10/2014,Cash or cash equivalent,213431324,,,INTEGRATED CLINICAL TRIAL SERVICES INC,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,35.00,12/01/2014,In-kind items and services,213435982,,,IOWA CITY VA MEDICAL RESEARCH FND,,
Non-covered Recipient Entity,,,,,,,5500 Lakeview Parkway,,Davenport,52807,,,"Roche Molecular Systems, Inc.",100000005630,"Roche Molecular Systems, Inc.",CA,220085.17,12/12/2014,Cash or cash equivalent,220543306,,,Bloodscreening,,
Non-covered Recipient Entity,,,,,,,1622E.LombardStreet,,Davenport,52803,,,Covidien LP,100000000083,Covidien LP,MA,1040.00,04/30/2014,Cash or cash equivalent,215239416,,,VISIBILITY ILIAC,,
Non-covered Recipient Entity,,,,,,,1622 E. Lombard Street,,Davenport,52803,,,Covidien LP,100000000083,Covidien LP,MA,1365.00,10/22/2014,Cash or cash equivalent,215239772,,,DURABILITY ILIAC,,
Non-covered Recipient Entity,,,,,,,400 NORTHWESTERN BELL BLDG,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,676.88,05/20/2014,Cash or cash equivalent,195291488,SELZENTRY,,"A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY OF MARAVIROC IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN HIV 1 INFECTED SUBJECTS CO INFECTED WITH HEPATITIS C AND OR HEPATITIS B VIRUS",,
Non-covered Recipient Entity,,,,,,,400 NORTHWESTERN BELL BLDG,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,587.81,07/28/2014,Cash or cash equivalent,195291492,SELZENTRY,,"A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY OF MARAVIROC IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN HIV 1 INFECTED SUBJECTS CO INFECTED WITH HEPATITIS C AND OR HEPATITIS B VIRUS",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1896.30,01/08/2014,Cash or cash equivalent,195291444,TIVICAY,,"A Phase 3, randomized, double blind study of the safety and efficacy of GSK1349572 plus abacavir lamivudine fixed dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV 1 infected antiretroviral therapy naive adult subjects.",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,3125.00,03/04/2014,Cash or cash equivalent,195291451,TRELAVUE,,"A Phase IIIb, randomized, open label study of the safety and efficacy of dolutegravir abacavir lamivudine once daily compared to atazanavir and ritonavir plus tenofovir emtricitabine once daily in HIV 1 infected antiretroviral therapy na ve women",,
Non-covered Recipient Entity,,,,,,,400 NORTHWESTERN BELL BLDG,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,587.81,02/13/2014,Cash or cash equivalent,195291478,SELZENTRY,,"A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY OF MARAVIROC IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN HIV 1 INFECTED SUBJECTS CO INFECTED WITH HEPATITIS C AND OR HEPATITIS B VIRUS",,
Non-covered Recipient Entity,,,,,,,400 NORTHWESTERN BELL BLDG,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,587.81,10/27/2014,Cash or cash equivalent,195271816,SELZENTRY,,"A Multicenter, Randomized, Blinded, Placebo controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv 1 infected Subjects Co infected With Hepatitis C And or Hepatitis B Virus",,
Non-covered Recipient Entity,,,,,,,400 NORTHWESTERN BELL BLDG,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,437.50,09/15/2014,Cash or cash equivalent,195291500,SELZENTRY,,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC   DARUNAVIR RITONAVIR VERSUS EMTRICITABINE TENOFOVIR   DARUNAVIR RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NA VE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1165.50,01/08/2014,Cash or cash equivalent,195291434,TIVICAY,,"A Phase 3, randomized, double blind study of the safety and efficacy of GSK1349572 plus abacavir lamivudine fixed dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV 1 infected antiretroviral therapy naive adult subjects.",,
